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Summary 
T cells directed against brain antigens are generally held to play a crucial role in the 
initiation of multiple sclerosis (MS). This was deduced from experimental autoimmune 
encephalomyelitis (EAE). In this model for MS, T cells reactive for myelin antigens 
induced a severe paralytic disease upon transfer to healthy syngeneic recipients. 
Intriguingly, the disease does not start immediately upon transfer of the pathogenic 
effector T cells. Instead, as earlier studies have shown, the effector T cells attack their 
target organ only after having migrated in the periphery through secondary lymphoid 
organs. The aim of the project was to characterize the functional properties of these 
migrating encephalitogenic T cells during the course of EAE and to identify biological 
pathways which determine their migratory behaviour and pathogenic potential. To this 
end, average linkage hierarchical clustering, pathway and gene ontology (GO) analyses 
of transcriptomes from cultured and ex vivo-isolated myelin basic protein-reactive T cells 
(TMBP cells) were performed.  
At the time of transfer, encephalitogenic T cells in vitro are maximally activated, 
i.e. they exhibit a prominent upregulation of cell cycle genes such as cyclin A2 (CCNA2) 
and cyclin B2 (CCNB2) among others. In contrast, T cells isolated from spleen 3 days 
post transfer, downregulated activation markers such as interleukin 2 receptor (IL2R) and 
interferon γ (IFNγ), and at the same time upregulated migration specific genes such as 
CC-chemokine receptor 1 (CCR1), CC-chemokine receptor 2 (CCR2) and CC-chemokine 
receptor 5 (CCR5). Hierarchical cluster analysis revealed that several transcription 
regulators known for inhibiting cell cycle progression such as krüppel-like factor 4 
(KLF4), B-cell translocation gene 2 (BTG2) and transducer of ERBB2, 1 (TOB1) were 
clustered together with cell cycle and migration genes. Overexpression of KLF4 in T 
cells not only inhibited G1/S phase progression of the cell cycle but additionally induced 
upregulation of CCR2 and CCR5. A novel tetraspan membrane protein called epithelial 
membrane protein (EMP1), was found to be up regulated in ex vivo-isolated effector T 
cells. Overexpression of EMP1 in encephalitogenic T cells influenced the migratory 
behaviour of effector T cells both in vitro and in vivo. EMP1 enhanced T cell motility 
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within the extracellular matrix milieu in vitro and promoted T cell migration from the 
connective tissue to lymph nodes in vivo resulting in an accelerated onset of EAE.  
In conclusion, gene expression profiling of encephalitogenic T cells revealed 
interesting genome wide transcriptomic changes and established a correlation between 
cell cycle progression and cell migration. As a result, in silico analysis put forth several 
interesting candidate genes that hold promise as potential targets for therapeutic 
intervention. 
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1. Introduction 
Our organism is constantly exposed to a wide variety of microbial pathogens. The system 
that comes into play to protect us from these everyday invaders is a complicated and 
highly precise mechanism called the immune system. The adaptive immune system 
consists of antigen presenting cells (APCs) and lymphocytes which together coordinate 
the recognition and elimination of any invading pathogen. In most cases this system is 
highly effective i.e., the pathogen is eliminated without any lasting damage to host 
tissues. But there are circumstances, as in the case of autoimmune diseases, when T cells 
can mount an immune response directed against self-tissues with detrimental 
consequences. Autoimmune diseases affect approximately 5% of the population in 
western countries. The exact cause of autoimmune diseases is largely unknown. 
However, several environmental and genetic factors are known to contribute to the 
triggering of an autoimmune reaction. Autoimmune disorders are divided into two 
categories: systemic and localized. Systemic autoimmune disorders, such as rheumatoid 
arthritis or lupus, affect many organs of the body simultaneously, while localized 
disorders, such as type I diabetes, Crohn’s disease or multiple sclerosis, afflict only one 
organ.  
1.1 Multiple sclerosis 
Multiple sclerosis is a chronic inflammatory disease with multiple dispersed lesions, 
called plaques, within the central nervous system (CNS). These defects result in a diverse 
spectrum of neurological symptoms such as numbness, impaired vision, loss of balance, 
paresis, bladder dysfunction and psychological changes. Women are afflicted twice as 
frequently as men and the disease usually starts between the ages of 20 to 40. One of the 
salient features of this disease is an inflammatory lesion consisting of T lymphocytes and 
other mononuclear immune cells. 
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1.2  Clinical course 
In 1996 the United States National Multiple Sclerosis Society standardized four subtype 
definitions (1). These are termed as the primary-progressive (PP)-, secondary-progressive 
(SP)-, relapsing-remitting (RR)- and progressive-relapsing (PR)-MS (Figure 1. 1).  
 
Figure 1. 1 Schematic representation of different clinical forms of MS.  
Image adapted from Kieseier et al (2). 
1.2.1 Relapsing-remitting MS  
Approximately 85% of MS patients present RRMS, which is characterized by disease 
relapses with full recovery 
1.2.2 Secondary progressive MS  
SPMS is characterized by disease progression with or without occasional relapses. At 
least 50% of patients with RRMS will transition into SPMS. 
1.2.3 Primary progressive MS  
Approximately 10% of MS patients present a disease progression with occasional 
plateaus from the onset of the disease. 
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1.2.4 Progressive relapsing MS  
This is the least common form presenting a progressive course with acute relapses with or 
without full recovery.  
1.3 Diagnosis 
According to the McDonald criteria, magnetic resonance imaging (MRI) evidence of 
CNS lesions disseminated in time and space is sufficient for a diagnosis of MS even 
before clinical symptoms have occurred. The McDonald criteria define the Barkhof-
Tintore MRI criteria requiring 3 of the following 4 elements: (i) at least one gadolinium-
enhancing lesion or 9 T2 hyper intense lesions; (ii) at least one infractentorial lesion; (iii) 
at least one juxtacortical lesion; and (iv) at least 3 periventricular lesions. 
1.4 Pathogenesis 
The aetiology of MS is still unclear but recent data point to a combination of genetic and 
environmental factors. Evidence for the role of genetic factors comes from the MS 
susceptibility gene localized to the major histocompatibility complex (MHC). The 
proportion of the total genetic susceptibility explained by the MHC locus is estimated to 
range between 20% and 50% (3). According to the knowledge obtained from 
experimental autoimmune encephalomyelitis (EAE) studies, peripherally activated 
autoreactive CD4+ T cells enter the CNS and recognize auto-antigens, thereby releasing 
proinflammatory cytokines. Cytokines such as IFNγ and tumour necrosis factor-α (TNF-
α) and chemokines recruit additional inflammatory cells and antimyelin antibody forming 
B cells that amplify tissue injury (4). CD8+ T cells are thought to play a prominent role in 
MS, because CD8+ T cells were found to be clonally expanded within MS plaques and 
their numbers correlated with the extent of acute axonal injury. Demyelination is brought 
about by various contributing factors such as antimyelin antibodies, activated 
macrophages, microglial cells, complement factors and TNF-α (4,5). Chronic 
inflammation of the CNS subsequently leads to structural damage including 
axonal/neuronal degeneration and astrogliosis (6)  
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1.5 Experimental autoimmune encephalomyelitis  
Experimental autoimmune encephalomyelitis is one of the well characterized animal 
models of human MS. Since its first description in primates (7), EAE has been replicated 
in a wide range of species including guinea pigs (8), rabbits (9), goats (10), mice (11), 
rats (12), hamsters (13), dogs (14), sheep (15), marmosets (16) and chickens (17). Studies 
from animal models have provided strong evidence for brain antigen specific T 
lymphocytes being the pathogenic mediators of EAE. 
1.6 EAE in Lewis rats 
1.6.1 Active EAE in Lewis rats 
EAE is an acute monophasic paralytic disease in Lewis rats. It can be induced after 
immunization with either homogenized CNS tissue or isolated myelin basic protein 
(MBP) emulsified in complete Freund’s adjuvant (CFA). About 9-10 days post 
immunization (p.i.), T cells and a large number of macrophages infiltrate the CNS, 
forming large perivascular inflammatory lesions (18). Subsequently, paresis and paralysis 
of the tail and limbs occur owing to oedema and moderate demyelination caused by 
inflammation in the CNS. In addition to neurological deficits, EAE is also accompanied 
by a profound loss in body weight (18). The development of clinical and pathological 
signs of CNS dysfunction in EAE is known to correlate with leukocyte infiltration of the 
brain (19). Resting lymphocytes commonly do not breach the blood-brain barrier (BBB). 
However, activated lymphocytes can cross the BBB regardless of their antigen (Ag) 
specificity, but it is only T cells that recognize their cognate Ag and can recruit other 
inflammatory cells (20,21).  
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1.6.2 Adoptive transfer EAE in Lewis rats 
Adoptive-transfer EAE (AT-EAE) is an important experimental tool for the investigation 
of T cell function and regulation in neuroinflammation and autoimmune diseases. AT-
EAE in Lewis rat is induced by injection of 5 to 10 million freshly activated TMBP cells. 
The animals are monitored daily for neurological signs and weight change. Clinical EAE 
is graded in five scores: 0.5, loss of tail tonus; 1, tail paralysis; 2, gait disturbance; 3, hind 
limb paralysis; 4, tetraparesis; and 5, death. The disease is highly predictable and is 
typically monophasic and self-limited (Figure 1. 2). One of the consistent feature of this 
disease model is that, irrespective of the number of cells injected, clinical and histological 
changes do not develop in the CNS immediately upon cell transfer but only after a 
preclinical latency period of at least 3 days (22). Studies using AT-EAE in experimental 
animals has provided many insights into the behaviour of pathogenic T cells culminating 
in the design of T cell directed therapies (23). 
 
Figure 1. 2 Clinical course of AT-EAE in Lewis rats. 
(Image adapted from Odoardi et al. (24). 
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1.7 T lymphocyte migration to the CNS in AT-EAE 
The concept of the BBB was originally introduced by the German bacteriologist, Paul 
Ehrlich during the late 1800s. He found that intravenous injection of dyes into the 
bloodstream stained all tissues in most organs except the brain.  
The BBB is formed by highly specialized endothelial cells, which inhibit 
transcellular passage of molecules across the barrier by an extremely low pinocytic 
activity (39). The endothelial cells of the brain are different in many ways from those 
found in the peripheral tissues. Brain endothelial cells are joined by tight junctions of 
high electrical resistance providing an effective barrier against molecules. Only 
molecules that have a molecular weight less than 500 Daltons can reliably pass through 
the BBB (40).  
The CNS is generally considered as an immunologically privileged site owing to 
the presence of the BBB, its lack of lymphatic vessels and the absence of classical MHC-
positive antigen presenting cells. However, recent evidence points to immunosurveillance 
of the CNS taking place and that only freshly activated T cells and not resting T cells can 
enter the CNS. Adoptive transfer experiments using TMBP cells indicate that instead of 
immediately infiltrating the CNS after activation, they undergo a functional tuning 
process, which enable them to cross the blood-brain barrier. This preclinical phase 
normally lasts for 3 to 4 days, during which TMBP cells are distributed in the peripheral 
lymphoid organs. 
The exact molecular and cellular mechanisms guiding activated encephalitogenic T 
cells into the CNS during this early preclinical phase are not clearly understood. 
However, according to the traditional view the T cell infiltration into the CNS follows a 
biphasic course in EAE (20,41). The first phase consists of ‘pioneer T cells’, that 
infiltrate within a few hours after transfer and encounter their antigen presented by local 
antigen-presenting cells (42). This first entry of TMBP effector cells supposedly converts 
the CNS from an immune hostile environment to an immune friendly environment 
facilitating inflammation. Subsequently, after an interval of 3-4 days, a second wave 
composed of millions of effector TMBP cells enters the CNS, marking the onset of 
inflammatory disease. Disease activity reaches a maximum, after which it declines 
rapidly, resulting in a complete clinical remission within a few days. This clinical 
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recovery is considered to be due to enhanced apoptosis of inflammatory T cells in the 
lesion (43).  
Recent studies using green fluorescent labelled encephalitogenic MBP-specific T 
cells (TMBP-GFP) in vivo imply that a transcriptomic programming in the periphery is 
essential for enabling effector T cell migration into the CNS. (44). Importantly, on their 
way to CNS these TMBP-GFP cells undergo functional changes in peripheral organs, from 
maximal activation to migratory state, characterized by downregulation of activation 
markers, an upregulation of chemokine receptors and an increase of MHC class II 
molecules on their surface. Eventually, upon arrival to the CNS, migratory TMBP-GFP cells 
undergo reactivation as a result of cognate antigen recognition presented by local antigen 
presenting cells and set the stage for inflammatory leukocyte infiltration. Several pieces 
of evidence support this hypothesis. Firstly, retransfer of TMBP-GFP cells from the spleen of 
an EAE rat 3 days post adoptive transfer to naïve syngeneic rats results in TMBP-GFP cell 
infiltration into the CNS within 24 hours (Streyl et al, unpublished). Moreover, surgical 
connection of blood circulation of an EAE animal (3 days post adoptive transfer of TMBP-
GFP cells) to naïve rat also results in early infiltration of TMBP-GFP cells. In order to migrate 
to the CNS TMBP-GFP cells undergo post activation phenotypic changes in the periphery.  
It follows, therefore, that deeper insights into the molecular changes of TMBP-GFP 
cells during their migratory path in the periphery might result in the identification of 
novel targets for interfering with T cell migration to the CNS. 
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1.8 Targeting T cell migration: Therapeutic strategies for multiple 
sclerosis 
Cell motility is crucial for the effective function of T lymphocyte and immune 
homeostasis. Priming of lymphocytes for adaptive immune responses requires their 
migration from the blood stream to lymph nodes to allow their interaction with antigen 
loaded APCs. Distinct lymphocyte subsets use different combinations of cell migration 
factors on their surface to orchestrate effector functions and for general immune 
surveillance. Lymphocyte homing to skin requires the expression of selectin E (SELE)  
and selectin P (SELP) ligands, CC-chemokine receptor 4 (CCR4) and CC-chemokine 
receptor 10 (CCR10) (45). Likewise, lymphocyte tropism for the intestines is controlled 
by expression of the intestine homing receptor α4β7 and CC-chemokine receptor 9 
(CCR9) which binds to mucosal addressin cell adhesion molecule 1 (MAdCAM1) and 
CC-chemokine ligand 25 (CCL25), respectively (46). Up to now, no adhesion molecule 
combination has been defined that specifically target (effector) T cells to the CNS. 
Development of new treatments for MS would require a detailed understanding of 
the molecular mechanisms of autoreactive T cell migration to the brain. In healthy 
condition, only a limited number of T lymphocytes are able to cross the BBB and 
penetrate the CNS. In MS, there is an increased permeability of the BBB leading to an 
increased transmigration of autoreactive T lymphocytes. After activation, they recruit 
lymphocytes, macrophages and B cells which induce damage to the CNS. Blocking the 
migration of T lymphocytes across the BBB has long been considered a promising 
therapeutic approach to autoimmune diseases of the CNS. The first such agent limiting T 
cell migration to CNS and representing a breakthrough for the treatment of MS, is a 
monoclonal antibody (mAb) called natalizumab (Tysabri). Natalizumab is a humanized 
monoclonal antibody to α4β1 integrin. The integrin heterodimer α4β1 has two binding 
domains, one to fibronectin and the other to vascular cell adhesion molecule 1 (VCAM1). 
Studies from both in vitro and in vivo have established that the interaction between α4b1 
integrin and VCAM1 plays an important role in T cell recruitment across the BBB and 
interference with these molecules significantly reduced adhesion of encephalitogenic T 
cell blasts to brain endothelium (39) (Figure 1. 3). Moreover, the targeting of α4β1 
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integrin by natalizumab blocked clinical paralysis in various animal models of MS and 
has also been approved for treatment of MS. 
 
Figure 1. 3 Illustration depicting the mode of action of natalizumab. 
Natalizumab is indicated by stars in the lower panel. Image adapted from Steinmann et al (2007) 
(47) 
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2 Objectives 
Studies using the AT-EAE model for MS have shown that activated encephalitogenic T 
cells undergo functional changes in the peripheral lymphoid organs such as spleen before 
migrating to the CNS. There is a phenotypic change from the activated T cell state to 
migratory T cell state with downregulation of activation markers and upregulation of 
chemokine receptors. However, still lacking was a detailed understanding of the 
transcriptomic changes between these different T cell states. The objectives of this thesis 
were:- 
1. To characterize the genome-wide transcriptomic changes in TMBP-GFP CD4+ T 
cells during the pre-clinical course of AT-EAE. 
2. To identify the molecular link between T cell activation and the T cell migratory 
state. 
3. To identify and test the function of novel membrane molecules implicated in T 
cell migration to CNS. 
 
  14 
Materials 
15 
3. Materials 
3.1 Animals 
Lewis rats aged 6-8 weeks old were obtained from the animal facility of Max Planck 
Institute for Biochemistry (Martinsried, Germany). All animal experiments were 
performed as per the guidelines of the Bavarian state regulations for animal 
experimentation.  
3.2 Cell lines 
Cell Line Description Catalogue 
Number 
Company 
NIH/3T3 
Mouse embryonic fibroblast cell 
line derived from NIH/Swiss strain 
CRL-1658 LGC/ATCC 
RBL1 
Rat basophilic leukaemia cell line 
derived from Wistar rat peripheral 
blood  
CRL-1378 LGC/ATCC 
293T 
Human embryonic kidney cell line 
transformed with adenovirus E1a 
and carrying a temperature sensitive 
T antigen. 
CRL-11268 LGC/ATCC 
Phoenix™-
Eco 
293T cell line carrying genes for 
gag-pol and envelope protein for 
generation of ecotropic retroviruses.  
RVK-10001 Orbigen 
GP+E 86 cell 
line 
NIH/3T3 cell line carrying genes for 
gag-pol and envelope protein for 
generation of ecotropic retroviruses. 
CRL-9642 LGC/ATCC 
Table 3. 1 List of mammalian cell lines used. 
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3.3 Plasmids 
Plasmid Name Use Company 
pMSCVneo 
Mammalian ecotropic retroviral expression 
plasmid DNA 
Clonetech 
pIRES2-EGFP Mammalian expression plasmid DNA Clonetech 
pRNAT-H1.4/Retro 
Mammalian siRNA retroviral expression 
plasmid DNA 
Genscript 
pGEMTEASY TA cloning plasmid DNA Promega 
pGL3basic Luciferase reporter plasmid DNA Promega 
Table 3. 2 List of plasmids used. 
3.4 Antigens 
Myelin basic protein (MBP was prepared from guinea pig brain homogenates as reported 
(48). S100 calcium binding protein β (S100β) and ovalbumin (OVA) were obtained from 
Sigma-Aldrich.  
3.5 Antibodies 
Primary 
Antibodies 
(Clone) 
Isotype Specificity Applications Company 
CD45RC 
(OX22) 
Mouse 
IgG1κ 
Rat  FACS Serotec 
CD4 
(W3/25) 
Mouse 
IgG1κ 
Rat  FACS Serotec 
αβTCR 
(R73) 
Mouse 
IgG1κ 
Rat  FACS Serotec 
MHC-II 
(OX6) 
Mouse 
IgG1κ 
Rat  FACS 
Purified from 
hybridoma culture 
supernatant 
CD11a Mouse Rat  FACS BD 
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(WT.1) IgG1κ 
EMP1 Rabbit IgG 
Mouse, Rat, 
Cow, Dog & 
Human  
WB, IF, IP & 
ELISA 
Santa Cruz 
biotechnology 
KLF4 Rabbit IgG 
Human & 
Rodent  
WB, IC, IH 
 
Affinity BioReagents 
PAN 
ACTIN 
Rabbit IgG 
Human & 
Rodent 
WB, IC 
 
Cell signalling 
technology 
Table 3. 3 List of primary antibodies used. 
FACS-Fluorescence Activated Cell Sorting, ELISA-Enzyme Linked Immunosorbent Assay, IC- 
Immunocytochemistry, IF-Immunofluorescence, IH-Immunohistochem, IP- Immunoprecipitation, 
WB -Western Blot.  
 
Secondary Antibodies Host Conjugation Company 
Anti-mouse Goat Allophycocyanin Invitrogen 
Anti-goat Donkey Allophycocyanin Dianova 
Anti-rabbit Goat Allophycocyanin Jackson ImmunoResearch 
Table 3. 4 List of secondary antibodies used. 
3.6 Buffers and Reagents 
 Cell culture medium and buffers 
Dulbecco’s modified Eagle’s medium (DMEM) for 5 L 
DMEM powder (Gibco)     specified amount 
Sodium bicarbonate (Merck)     18.5 g 
Distilled water quantum sufficit (q.s.) 
to 5 L 
 
T-cell medium (TCM) for 1 L 
Penicillin/Streptomycin (Gibco) (10000 IU/mL)  10 mL 
Sodium pyruvate (100 mM) (Gibco)    10 mL  
Non-essential amino acids (100 ×) (Gibco)   10 mL  
L-Asparagine (0.36% solution) (Gibco)   10 mL  
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Glutamine (200 mM) (Gibco)    10 mL  
β-mercaptoethanol (Merck)     4 μL 
DMEM medium      q.s. to 1000 mL 
 
Re-stimulation medium (RM) for T cells  
Fresh autologous rat serum     1 mL 
TCM        q.s. to 100 mL 
 
T cell culture medium with growth factor (TCGF) 
Supernatant from ConA (Pharmacia Biotech) stimulated mouse splenocytes as a 
source of IL2 and other growth factors   30 mL 
Inactivated horse serum (PAA Lab)    50 mL 
TCM        q.s. to 500 mL 
 
Eagle’s HEPES solution (EH) 
HEPES (Gibco)      125 mL 
DMEM medium      q.s. to 5 L 
 
Freezing medium  
Inactivated horse serum (PAA Lab)    80 mL 
Dimethyl sulfoxide (Sigma)     10 mL 
 TCM        10 mL 
  
Phosphate buffered saline (PBS) 
Sodium chloride (Merck)     137 mM 
Potassium chloride (Merck)     2.7 mM 
Disodium hydrogen phosphate (Merck)   4.3 mM  
Potassium dihydrogen phosphate (Merck)   1.47 mM 
Distilled water      800 mL 
Adjusted pH to 7.4 and volume made up to 1L using distilled water and sterilized 
by filtration 
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Ammonium chloride-potassium (ACK)-erythrocyte lysing buffer 
Ammonium chloride (Merck)     0.15 M 
Potassium bicarbonate (Merck)    10 mM 
Ethylene diamine tetra acetic acid (Merck)   0.1 mM 
Distilled water      800 mL 
Adjusted pH to 7.4 and volume made up to 1 L using distilled water and sterilized 
by filtration 
 
Hypoxanthine-Xanthine-Mycophenolic acid (HXM) medium 
Hypoxanthine (Sigma)     15 μg/mL 
Xanthine (Sigma)      250 μg/mL 
Mycophenolic acid (Sigma)     25 μg/mL 
Inactivated fetal calf serum (PAA Lab)   50 mL 
DMEM medium      q.s. to 500 mL 
 
Reagents for density gradient  
Blood lymphocyte gradient  
Heparin (5000 U/mL) (Sigma)    100 μL 
Optiprep (Nycomed Pharma)     0.63 mL/5 mL blood 
 
CNS lymphocyte gradient 
Percol isotonic solution (1.124 g/mL) (Biochem AG) 10.8 mL 
Percol underlay solution (1.077 g/mL) (Biochem AG) 10 mL 
 
FACS buffers 
FACS buffer for surface staining 
Rat serum       3 mL 
PBS        q.s. to 100 mL 
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FACS buffer for surface staining of EMP1 
Bovine serum albumin (BSA) (Sigma)   1 g 
Sodium azide (Merck)     1 g 
 PBS        q.s. to 100 mL 
  
FACS buffer for intracellular staining 
Fixation solution 
Paraformaldehyde (PFA) (Merck)    4 g 
PBS        q.s. to 100 mL 
Permeabilization solution 
 Triton X 100 (Carl Roth)     1 mL 
 PBS        q.s. to 100 mL 
 or  
 Methanol (Merck)      90% in PBS 
Incubation buffer 
PBS        100 mL 
BSA (Sigma)       0.5 g 
  
 Transfection reagents 
Chloroquine solution 1000× 
Chlroquine diphosphate (Sigma)    100 mM 
 Distilled water      q.s. to 10 mL 
Calcium chloride solution (2 M) 
Calcium chloride (Merck)     29.4 g 
Distilled water      q.s. to 100 mL 
 
HEPES-buffered saline (HBS) 2× 
HEPES (Gibco)      50 mM 
Sodium chloride (Merck)     280 mM 
Disodium hydrogen phosphate (Merck)   1.5 mM 
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Adjusted pH exactly to 6.95 using Hydrochloric acid (HCl) (Merck) followed by 
sterilization by filtration through 0.2 μm filter. Small volume aliquot were stored 
at -20° C 
Western Blot buffers 
2× Sample Buffer 
0.5 M Tris-HCl, pH 6.8     1.25 mL 
Glycerol (Carl Roth)      2.5 mL 
Sodium dodecyl sulphate (SDS) (Carl Roth) 10% (w/v) 2.0 mL 
Bromophenol blue (Sigma) 0.5% (w/v)   0.2 mL 
Deionized water      3.5 mL 
50 μL of β-mercaptoethanol (Merck) added to 950 μL of sample buffer before 
use. 
 
SDS-poly acrylamide gel electrophoresis (PAGE) Running Buffer 10× 
Tris base (Sigma)      30.3 g 
Glycine (Merck)      144.0 g 
SDS (Carl Roth)      10.0 g 
Deionized water      q.s. to 1 L 
 
SDS-PAGE Transfer Buffer 
 Tris base (Sigma)      3.03 g 
Glycine (Merck)      14.4 g 
Methanol (Merck)      200 mL 
Deionized water      q.s. to 1 L 
 
TBS-T (Tris-buffered saline with tween) Wash Buffer 10× 
Tris-base (Sigma)      31.52 g 
Sodium Chloride (Merck)     175.32 g 
Tween-20 (Sigma)      10 mL 
 Deionized water      q.s. to 2 L 
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4. Methods 
4.1 Generation of antigen specific T cells 
Antigen specific T cells were generated using the method of Flügel et al, 1999 (49). 
Lewis rats were immunized by subcutaneous injection of 100 μg of MBP antigen 
emulsified in CFA (Gibco-BRL) containing 4 mg/mL Mycobacterium tuberculosis. Cells 
from the draining lymph nodes were isolated 10 days after immunization and cultured 
with a modified limiting dilution method. Lymph node cells (2×105 cells/well) were 
cultured together with MBP (10 μg/mL) in 96-well plates for 3 days and propagated for 
5-6 days in IL2 conditioned medium. 
4.2 Retroviral transduction of antigen specific T cells 
Retroviral packaging cells were generated using GP+E-86 cell lines (50) by adopting the 
established method of Flügel et al. (49). Phoenix-eco packaging cell lines were 
transfected with retroviral plasmids pMSCVneo-EMP1-IRES2-EGFP and pMSCVneo-
IRES2EGFP (control). Two days after transfection, viral particles containing supernatant 
were passed through a syringe filter of 0.45 μm and were added to sub-confluent grown 
GP+E-86 cell lines. Viral transduced GFP positive GP+E-86 cells (GPE-EMP1 and GPE-
GFP) were selected in HXM medium for several days and subsequently were FACS 
sorted several times to obtain 100% GFP positive GP+E-86 packaging cell lines which 
could produce retroviruses encoding EMP1-IRES2-GFP and GFP respectively. FACS-
based viral titration using 3T3NIH cell lines was also performed to determine efficiency 
of virus production.  
Retroviral mediated transduction of primary T lymphocytes was performed by co-
cultivation with GP+E-86 packaging cells. The packaging cells were seeded in a 96 well 
plate (1.4×106 cells per plate) and then freshly isolated draining lymph node cells 
obtained from 10 days post MBP/CFA immunized animals, were added to the wells at a 
concentration of 2 X 105 cells/well together with MBP (10 μg/mL). Selection with G418 
(0.4 mg/mL) was started after 3 days of culture with IL2 conditioned medium and 
maintained throughout the entire culture period. 
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For the subsequent re-stimulation, T lymphocytes were incubated with 1×106 irradiated 
(5000 rad) syngeneic thymocytes/well in the presence of MBP (10 μg/mL). T lymphocyte 
blasts cells were transferred into IL2 conditioned medium and propagated further. 
4.3 Recombinant DNA cloning  
For construction of a recombinant mammalian retroviral over-expression system, full 
length cDNA for KLF4 and EMP1 were amplified by polymerase chain reaction (PCR) 
from in vitro activated MBP-specific T cells and were cloned between EcoRI (Fermentas) 
and SacII (Fermentas) in pMSCVneoIRES2EGFP plasmid DNA. 
pMSCVneoIRES2EGFP was constructed by sub-cloning IRES2EGFP from 
pIRES2EGFP into pMSCVneo between HpaI (Fermentas) and EcoRI (Fermentas).  
For construction of luciferase assay promoter plasmids, sequences from -1000 to 
+70 upstream of transcription start site of chemokine receptors viz, CCR2, CCR5 and 
CXC-chemokine receptor (CXCR3) were amplified by PCR from rat genomic DNA. 
CCR2 was cloned between XhoI (Fermentas); CCR5 and CXCR3 were cloned between 
SacI (Fermentas) and XhoI (Fermentas) sites in pGL3 basic vector. Full length KLF4 
cDNA for promoter assay was cloned between EcoRI (Fermentas) and SacII (Fermentas) 
in pMSCVneo vector which lacks EGFP. All the constructs were sequence verified for 
mutations. Primers sequences used for cDNA and promoter amplification is shown in 
Table 4. 1. 
Gene Forward (5’---3’) Reverse (5’---3’) 
KLF4 5’-TCTGAATTCTTAATGAGGC 
AGCCACCTGGCGA-3’ 
5’-TCTCCGCGGTGTGGGTCATG 
TCCACGATGTGG-3’ 
EMP1 5’-TCTGAATTCAAGATGTT 
GGTGCTACTGGCC-3’ 
5’-GTCCTGAGGAAGAAATAA 
GCTCGT-3’ 
CCR2 5’-CTCGAGTCTAATTTGGA 
GGCAGGATT-3’ 
5’-CTCGAGGAAATAGAGAA 
TGAGATGTTGATAGTATG-3’ 
CCR5 5’-GAGCTCTCAGAAGTGA 
AGTATCTTGCCA-3’ 
5’-CTCGAGGGAACGGATGTC 
TCACCT-3’ 
CXCR3 5’-CCGTGAACAGAGGAA 
GTGAA-3’ 
5’-GTCCATCGGGAGAGAAGA-3’ 
Table 4. 1 List of primers used for recombinant DNA cloning. 
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4.4 Proliferation assay for T cells 
T cells (5×104 cells/well) were co-cultured with irradiated thymocytes (1.2×106 cells/mL) 
in 100 μL RM per well together with antigens  viz., MBP, 10 μg/mL or OVA (Sigma), 10 
μg/mL or ConA (Pharmacia Biotech) 0.25μg/mL. 48 hrs later, radioactive thymidine 
[3H]dT (Amerscham Biosciences) (2 Ci/mmol) was added to the culture and radioactive 
counts were measured after 16-24 hours using a β counter. 
4.5 Cytofluorometry FACS 
Surface staining 
Cells were washed three times in PBS followed by incubation in PBS+3% Rat serum for 
blocking. Primary antibodies were added in 1:100 dilution in PBS+3% Rat serum for 60 
mins on ice followed by three times washing in same buffer. Allophycocyanin-labelled 
goat anti-mouse was used as secondary antibody. 
 
Intracellular staining 
For intracellular staining, cells were fixed in 2% PFA for 10-15 mins then washed in 
PBS. Permeabilization was carried out using ice cold methanol added slowly to pre-
chilled cells, while gently vortexing, to a final concentration of 90% methanol and 
incubated on ice for 30 mins. Cells were washed in incubation buffer and blocked for 10 
mins in incubation buffer at room temperature. Primary antibodies at the appropriate 
dilutions were added and incubated at room temperature for 30-60 mins. After being 
washed three times in incubation buffer, secondary antibodies were added and incubated 
for 30 mins at room temperature before being washed in PBS. 
4.6 Quantitative polymerase chain reaction  
Total RNA was isolated from cells using Trizol Reagent (Invitrogen) and reverse 
transcribed to cDNA using Revert-Aid M-MuLV Reverse transcriptase (Fermentas) 
according the manufacturer’s protocol. The cDNA was then analyzed for gene expression 
by semi-quantitative real time PCR (qPCR) using the GeneAmp 5700 Detection System 
(Applied Biosystems). β actin gene expression was taken as internal control 
housekeeping gene. Ready-made Taqman primers and probes were ordered from Applied 
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Biosystem where applicable. Custom designed primers and Taqman probes were ordered 
with FAM-TAMRA as fluorophore-quenchers respectively. The list of custom designed 
Taqman primer probes are listed in Table 4. 2. 
 
Gene Forward  Reverse  FAM-Probe-TAMRA  
β-actin 5´-TACAACCTCC TT GCAGCTCCT-3´ 
5´-TTGTCGAGAC 
GAGCGC-3´ 
5´-CGCCACCAGTTC 
GCATGGAT-3´ 
IFNγ 
5´-AACAGTAAAG 
CAAAAAAGGATG
CATT-3´ 
5´-TTCATTGACAG 
CTTTGTGCTGG-3´ 
5´-CGCCAAGTTCGAG 
GTGAACAACCC-3´ 
IL2 5´-CTCCCCATGA TGCTCACGTT-3´ 
5´-TCATTTTCCAGG 
CACTGAAGATG-3´ 
5´-CAATTCTGTGGC 
CTGCTTGGG CAA-3´ 
IL2R 
5´-CACAGTCTGT 
GTACCAGGAGAA
CCT-3´ 
5´-CCACGAAGTG 
GTAGATTCTCTTG
G-3´ 
5´-CAGGTCACTGCAG 
GGAGCCCCC-3´ 
TNFα 5´-TCGAGTGACAA GCCCGTAGC-3´ 
5´-CTCAGCCACTC 
CAGCTGCTC-3´ 
5´-CGTCGTAGCAAAC 
CACCAAGCAGA-3´ 
IL4 
5´-CGGTGAACTGA 
GGAAACTCTGTA
GA-3´ 
5´-TCAGTGTTGTG 
AGCGTGGACTC-3´ 
5´-CGGTCTGAACTCAC 
TGAGAAGCTGCACC-3´ 
IL10 
5´-GAAGACCCTC 
TGGATACAGCTG
C-3´ 
5´-TGCTCCACTGCC 
TTGCTTTT-3´ 
5´-CGCTGTCATCGATT 
TCTCCCCTGTGA-3´ 
IL17 5´-AGTCCCCGG AGAATTCCA-3´ 
5´-GAGTACCGCTG 
CCTTCACTGT-3´ 
5´-ATGTGCCTGATGC 
TGTT-3´ 
CCR2 5´-CACTTAGAC CAGGCCATGCA-3´ 
5´-TGACAGAGAC 
TCTTGGAATGACA
CACTGCTG-3´ 
5´-ACTTCTCACCAACA 
AAGGCATAAAT-3´ 
CCR5 
5´-GTTCTCCTG 
TGGACCGGGTAT
AG-3´ 
5´-ATTGTCAAACG 
CTTCTGCAAAC-3´ 
5´-AGCTTACACGATCA 
GGATTGACTTGC-3´ 
CXCR3 5´-AGCAGCCAAG CCATGTACCTT-3´ 
5´-TAGGGAGATGT 
GCTGTTTTCCA-3´ 
5´-AGGTCAGTGAACGT 
CAAGTGCTAGATGCCT
C-3´ 
EMP1 5´-TCCTCTCGGG ATCCACCAT-3´ 
5´-TCTACACTCAC 
CACTACGCCCA-3´ 
5´-CTGGTGTGCTGGCT 
GTGCAT-3´ 
EMP2 5´-CGTCCTGACG GCCATCAT-3´ 
5´-GACGGAAGCCC 
CGATCA-3´ 
5´-CATGTCCTGTCTG 
TGTGTC-3´ 
EMP3 5´-GGCCTGCAGT AACGTCAGTGA-3´ 
5´-GGATGAGAGAC 
AGCACCATGAG-3´ 
5´-AACGGCTGGCTG 
AAG-3´ 
KLF4 5´-CAGTCGCAA GTCCCCTCTCT-3´ 
5´-TATCAAGAGC 
TCATGCCAC-3´ 
5´-CTCTTTGGCTTGG 
GCTCCT-3´ 
RORγ 5’-GACAGGGCC CCACAG AGA-3’ 
5’-TTTGTGAGGTG 
TGGG TCTTCTTT-3’ 
5’-CGAACATCTCGGG 
AGTTGCTG GCT-3’ 
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T-BET 5’-CCAACAATGTG ACCCAGATGAT-3’ 
5’-CTGGCTCACC 
GTCATTCA-3’ 
5’-TCCTGCAGTCCCTC 
CATAAGT ACCAGCC-3’ 
FOXP3 5’-TGGCAAACGG AAGTCTCAA-3’ 
5’-TCTCATCCAGA 
GGTGATCTGCTT-3’ 
5’-AGCCGGGAGAGTT 
TCTCAAGCACTGC-3’ 
Table 4. 2 List of Taqman primers and probes used for qPCR. 
4.7 EAE induction 
AT-EAE in Lewis rats was induced by intraperitoneal (i.p.) or subcutaneous (s.c.) or 
intravenous (i.v.) injection of 3×106 encephalitogenic T lymphocytes. The animals were 
monitored for weight loss and clinical symptoms. Clinical evaluation was performed by 
grading clinical scores as follows: 0.5, loss of tail tonus; 1, tail paralysis; 2, gait 
disturbance; 3, hind-limb paralysis; 4, tetraparesis; and 5, death. 
4.8 Memory animal generation 
In order to embed CD4+ TMBP-GFP and TMBP-EMP1 in the immune system of syngeneic 
neonatal rats, 2.5×106 cells in 0.5 mL/animal in EH medium were administered by i.p. 
injection into new-borns within 48 hrs after birth under hypothermia. After T cell 
transfer, the new born rats were kept under 30°C humid atmosphere until fully recovered 
and then returned to their mother. T cells were transferred 4-5 days after re-stimulation 
with antigen in vitro.  
4.9 In vitro matrigel motility assay 
Matrigel (BD Biosciences) is a murine tumour extract, rich in extracellular matrix 
components such as laminin, collagen IV, heparan sulfate, proteoglycans and entactin. 
Matrigel (BD Biosciences) was thawed on ice and mixed at a ratio of 1:1 with RM 
containing 5×104-10×104 cells. The mixture was incubated in a custom made cylindrical 
inset in a 35 mm culture dish and imaged after 30 mins incubation at 37° C incubator 
(Figure 4. 1). Time lapse video microscopy was performed at controlled temperature and 
CO2 conditions at 10× objective with a time lapse of 30 secs. 
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Figure 4. 1 Diagrammatic representation of time lapse video microscopy setup for 
matrigel motility assay. 
The setup consists of a small cylindrical polypropylene tube with an inner radius of 5 mm and 
height of 7 mm cut out and attached to the centre of 35mm culture dish using 1% agarose. The 
mixture of matrigel and T cells in a proportion of 1:1 (shown in orange) is then pipetted into the 
lumen of the cylindrical space and incubated in a closed system with controlled temperature and 
pH. After 30 mins of incubation, time lapse video microscopy is performed in intervals of 30 
seconds over 30 minutes. 
4.10 Microarray data analysis 
TMBP-GFP cells were generated as described before in detail (49). Activated T cells (Tblast) 
were obtained 2 days post re-stimulation in vitro using thymocytes and MBP antigen 
followed by FACS sorting. Resting T cells (Tresting) were obtained 7 days post antigen 
exposure followed by FACS sorting. AT-EAE was induced as described before by 
injection of 5 million in vitro activated TMBP-GFP (44). FACS sorting of TMBP-GFP cells 
from spleen (Tspleen) and TMBP-GFP cells from CNS (TCNS) was performed, 3.5 days post 
AT-EAE induction. RNA was isolated and reverted into cDNA followed by cRNA 
synthesis for microarray analysis. Organs were pooled from several animals to obtain 
enough starting material. The pooled RNA was divided into three parts for three 
independent microarray hybridizations and measurements were performed by our 
collaborators at the Max Planck Institute of Molecular Genetics.  
The microarray expression dataset consisted of normalized expression data from 
three measurements. The dataset essentially pertains to T cells from four different milieus 
viz, in vitro activated (Tblast), in vitro resting (Trest), ex vivo spleen (Tspleen) and ex vivo 
spinal cord (TCNS). Comparison analysis was performed to define three T cell state such 
as Tactivated (Tblast versus Tresting), Tmigratory (Tspleen versus Tblast) and Teffector (TCNS versus 
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Tblast). After generating a list of differentially expressed genes in Tactivated, Tmigratory and 
Teffector, all transcripts without annotations were disregarded for further downstream 
analysis. This resulted in an expression dataset consisting of only 17,694 probesets from 
a total of 31,256 probesets in the Affymetrix GeneChip® Rat Expression Set 230. 
 Average linkage hierarchial clustering was performed on the annotated expression 
dataset using GENESIS (http://genome.tugraz.at/genesisclient/genesisclient_description 
.shtml). Further, downstream analyses were carried out only on data pertaining to Tactivated 
and Tmigratory. For GO based analysis affymetrix probesets were downloaded from GO 
consortium database (http://www.geneontology.org/). For pathway based analysis, the 
GenMAPP (Gene Map Annotator and Pathway Profiler) program was used 
(http://www.genmapp.org/).  
4.11 Dual luciferase assay 
One day before transfection, 293T cells (4×104 cells per well) were plated in a 48 well 
plate. 24 hours later, cells were transfected with 0.5 μg each of pGL3 reporter constructs 
(pGL3 basic, pGL3-CCR2, pGL3-CCR5, pGL3-CXCR3), 0.3 μg of pMSCVneo or 
pMSCVneo-KLF4 vector and 10 ng of pTK-renilla. Two days after transfection, cells 
were washed once with ice cold PBS and lysed in 65 μL /well of 1× passive lysis buffer. 
The lysate was clarified by centrifugation and collected in 96 well opaque walled plates. 
Luciferase activity was measured after an addition of 45μL of LARII™ reagent 
(Promega) per well. For internal control, Renilla luciferase activity was measured 
immediately after addition of Stop & Glow™ reagent (Promega) 45 μL per well. Results 
were normalized to empty vector PMSCVneo. 
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4.12 Bioinformatics  
Extraction of promoter sequences 
Chemokine receptor promoter sequences were downloaded using BioMart central portal 
as follows:- http://www.biomart.org/ 
 
Prediction of transcription factor binding site in target DNA sequences 
Potential transcription factor binding sites in chemokine receptor promoter sequences 
CCR1, CCR2, CCR3, CCR4, CCR5 and CXCR3 were predicted using a web based tool 
called Matinspector™ from Genomatix which can be reached at the following website:- 
http://www.genomatix.de/online_help/help_matinspector/matinspector_help.html 
 
Multiple sequence alignment of protein sequences 
Evolutionarily conserved motifs in EMP1 was identified by a multiple sequence 
alignment (MSA) of EMP1 protein sequences from different mammalian species such as 
human, monkey, pig, cattle, rabbit, rat and mouse. PMP22/EMP/MP20 family motifs 
were illustrated by MSA of EMP1, EMP2, EMP3 and PMP22. The ClustalW2 program 
used for MSA is available online at the following portal:- 
http://www.ebi.ac.uk/Tools/clustalw2/index.html 
 
Prediction of transmembrane helices 
EMP1 transmembrane helices were determined and illustrated using SOSUI server as 
reported which is available at the following web portal (51) :-  
http://bp.nuap.nagoya-u.ac.jp/sosui/sosui_submit.html 
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5. Results 
5.1 Microarray analysis of encephalitogenic T cells  
EAE can be induced by adoptive transfer of freshly-activated TMBP cells. In contrast, 
resting T cells are not pathogenic irrespectively of the number of injected cells. 
Intriguingly, the TMBP cell blasts do not immediately migrate into their target organ; 
they rather follow predefined migration paths leading them from peripheral lymph 
nodes to the spleen and finally into the CNS. Moreover, there is a dramatic 
downregulation of activation marker and an upregulation of chemokine receptors in 
the periphery (44). Notably, TMBP cells extracted from the spleen 3.5 days post 
transfer, readily infiltrate the CNS and induce disease as early as 24 hours post transfer 
(p.t.) (Streyl et al, PhD dissertation). 
In order to investigate the gene expression changes in encephalitogenic T cells 
TMBP-GFP cells during the pre-clinical phase of AT-EAE, a genome-wide 
transcriptional profiling of in vitro cultured TMBP-GFP cells (resting cells: Tresting and 
freshly activated blast cells: Tblast) and ex vivo -isolated migratory TMBP-GFP cells (by 
FACS from spleen (Tspleen) and CNS (TCNS) 3.5 days p.t.) (Figure 4. 1) was performed. 
Microarray analysis was carried out using the affymetrix oligonucelotide microarray 
(Gene Chip ® Rat Expression Set 230) expression dataset consisting of 30,248 
transcripts, including over 28,000 well substantiated rat genes. Microarray was 
performed by the automation group (Dr. Wilfried Nietfeld, Max Planck Institute of 
Molecular Genetics, Berlin) and data normalization was executed by the department of 
computational molecular biology (Prof. Dr. Martin Vingron, Max Planck Institute for 
Molecular Genetics, Berlin), the resultant expression values being presented as log to 
the base ‘e’. Thus we started with expression datasets comprising expression values 
pertaining to four different samples of encephalitogenic T cells termed Tblast, Tresting, 
Tspleen and TCNS. Prior to data analysis three different T cell states or transcriptomes 
were defined as follows.  
1. Tactivated state: comparison of Tblast versus Tresting. 
2. Tmigratory state: comparison of Tspleen versus Tblast. 
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3. Teffector state: comparison of TCNS versus Tblast. 
Activated T cell state (Tactivated state) represents the transcriptome of T cell blasts 48 
hrs after re-stimulation in vitro whereas migratory T cell state represents the 
transcriptome of T cell 3.5 days post adoptive transfer in peripheral lymphoid organ, 
spleen. Effector T cell state on the other hand represents the transcriptome of 
reactivated TMBP cells within the target organ, CNS.  
5.2 Cluster analysis of the microarray expression data 
Cluster analysis is the most popular and commonly used method for gene expression 
analysis. One of the primary goals of clustering is to group together objects such as 
genes or transcriptomes with similar expression pattern. When genes with similar 
expression profiles are grouped together they are believed to be co-regulated and 
functionally related. 
 Tspleen vs Tblast TCNS vs Tblast Tblast vs Tresting 
Number of upregulated 
( ≥ 2 fold) transcripts 
587 514 919 
Number of downregulated 
( ≤ 0.5 fold) transcripts 
1027 1149 1791 
Total number of differentially 
regulated transcripts 
1614 1663 2710 
Total number of transcripts 30200 30200 30200 
Table 5. 1 A summary of differentially regulated transcripts from microarray 
dataset. 
A summary of the number of differentially regulated transcripts is given in Table 5. 1. 
A cut off of ≥ 2 fold was chosen for upregulation and ≤ 0.5 fold for downregulation. A 
comparison between Tspleen and Tblast state resulted in 1614 differentially regulated 
transcripts. The number of regulated transcripts in Tblast cells (i.e., after activation with 
specific antigen) compared to Tresting cells was 2710 transcripts. This indicates that 
Tblast cells upon migration to spleen experience a dramatic reorganization of their 
transcriptional program to attain the Tmigratory state in vivo.  
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Average linkage cluster analysis revealed surprisingly diverse gene expression 
patterns. Importantly, out of 30248 transcripts only a fraction (~6%) of them showed a 
differential regulation (Table 5. 1). Moreover, the regulation of genes in Tmigratory and 
Teffector states is very similar, as can been seen from the heat map illustration of cluster 
analysis (Figure 5. 3), implying a similar transcriptome between Tspleen and TCNS. In 
vitro activated T cells undergo transcriptomic changes that imparts them migratory 
phenotype facilitating CNS infiltration. Two interesting clustering pattern could be 
observed from the analysis, namely (i) downregulated in Tactivated and upregulated in 
Tmigratory and Teffector and (ii) upregualted in Tactivated and downregulated in Tmigratory and 
Teffector. Several clustered genes are labelled and depicted in Figure 5. 4. One of the 
prominent features evident from the cluster analysis is the reciprocal regulation of the 
same genes in Tactivated and Tmigratory. Genes that are upregulated in Tactivated state were 
downregulated in Tmigratory state and vice versa (Figure 5. 2, Figure 5. 3 and 
Figure 5. 4). 
 As expected, major differences between Tblast cells and Tresting cells included 
genes responsible for strong immune activation and proliferation, i.e. genes encoding 
cytokines for e.g. interleukin 17f (IL17F), CC-ligand 2 (CCL2); cell cycle-associated 
genes, for e.g. cell division cycle 20 homolog (CDC20), cyclin E1 (CCNE1), 
cytoskeleton associated protein 5 (CKAP5); factors of the DNA replication machinery, 
for e.g. deoxyuridine triphosphatase (DUT), minichromosome maintenance complex 
component 7 (MCM7), replication factor C 3 (RFC3); DNA polymerases, for e.g. 
minichromosome maintenance complex component 4 (MCM4), minichromosome 
maintenance complex component (MCM6) and cell metabolism, for e.g. 3-hydroxy-3-
methylglutaryl-Coenzyme A reductase (HMGCR), cytochrome P450, family 51 
(CYP51), phosphomevalonate kinase (PMVK) (Appendix 1). In striking contrast 
Tmigratory state displayed a completely distinct genotype. The genes regulated in Tspleen 
controlled functions such as cell communication for e.g. Rho GTPase activating 
protein 4 (ARHGAP4), dual specificity phosphatase 5 (DUSP5), dishevelled 
associated activator of morphogenesis 1 (DAAM1), plasminogen activator, urokinase 
receptor (PLAUR); cell adhesion for e.g. CD44 antigen (CD44), epithelial membrane 
protein 1 (EMP1), neuropilin (NRP1), selectin L (SELL); cell migration for e.g. 
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integrin β1 (ITGβ1), integrin β7 (ITGβ7), (CCR5), vinculin (VCL), and immune 
response for e.g. CXC-chemokine ligand 2 (CXCL2), GLI pathogenesis-related 1 
(GLIPR1), immunoglobulin superfamily, member 6 (IGSF6) (Appendix 2). Overall 
cluster analysis revealed a strong association of cell cycle genes in a Tactivated state and 
cell migration related genes with Tmigratory state. 
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Figure 5. 1 Schematic illustration of green fluorescent TMBP-GFP cell sorting using 
FACS from different milieus and subsequent microarray analysis. 
TMBP-GFP were generated as described in detail previously (49). Activated T cells (Tblast) were 
obtained 2 days post re-stimulation in vitro using thymocytes and MBP antigen, followed by 
FACS sorting. Resting T cells (Tresting) were obtained 7 days post antigen exposure followed 
by FACS sorting. AT-EAE was induced as described before by injection of 5 million of in 
vitro activated TMBP-GFP (44). FACS sorting of TMBP-GFP cells from spleen (Tspleen) and TMBP-GFP 
cells from CNS (TCNS) was performed, 3.5 days post AT-EAE induction. RNA was isolated 
and reverted into cDNA followed by cRNA synthesis for microarray analysis.  
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Figure 5. 2 Microarray dataset viewed as expression plot. 
Annotated genes (17694 genes) from the microarray dataset were plotted with fold values on 
ordinate and TMBP-GFP cell states on abscissa. An imaginary line drawn in magenta indicates 
zero fold value. The transcriptomes of three T cell states viz, Tactivated, Tmigratory and Teffector were 
investigated. Tactivated transcriptome was represented as gene expression fold change values, 
obtained by dividing gene expression values of Tblast by Tresting. Tmigratory transcriptome was 
represented as gene expression fold change values, obtained by dividing gene expression 
values of Tspleen by Tblast whereas Teffector transcriptome was represented as gene expression fold 
change values, obtained by dividing gene expression values of TCNS by Tblast. Genes that were 
upregulated in Tactivated were downregulated in Tmigratory and Teffector and vice versa.  
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Figure 5. 3 Heat Map representation of cluster analysis of annotated genes. 
Average linkage hierarchical clustering of annotated genes is depicted as a heat map with 
dendrogram. Three T cell states viz., Tactivated, Tmigratory and Teffector were investigated. Tactivated 
transcriptome was represented as gene expression fold change values, obtained by dividing 
gene expression values of Tblast by Tresting. Tmigratory transcriptome was represented as gene 
expression fold change values, obtained by dividing gene expression values of Tspleen by Tblast 
whereas Teffector transcriptome was represented as gene expression fold change values, 
obtained by dividing gene expression values of TCNS by Tblast. Scale for colour code is shown 
on the top and values are log transformed to the base 2. Coloured bars labelled alphabetically 
indicate clustered genes. 
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Figure 5. 4 Depiction of clusters A-F. 
Annotated genes were analysed via average linkage hierarchical cluster analysis and were 
grouped into 6 clusters, labelled here A to F. These are depicted as a heat map with a 
dendrogram separately. 
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Figure 5. 5 Pie chart analysis of clusters A to F. 
Clusters A to F were individually analysed using Gene Ontology annotations. Gene expression 
changes (either upregulated or downregulated) in cluster A to F were plotted as pie charts. 
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Figure 5. 6 Cell cycle genes and chemokine receptors are clustered. 
A part of cluster E depicts clustering of differentially regulated cell cycle genes in Tactivated, 
Tmigratory and Teffector transcriptomes. A part of cluster D depicting clustering of differentially 
regulated inflammatory chemokine receptors in Tactivated, Tmigratory and Teffector transcriptomes. 
Fold values are colour coded and scale is shown on the top. 
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Figure 5. 7 Differential regulation of cell migration and cell cycle processes. 
This graph depicts the percentage of annotated genes differentially regulated in four biological 
processes, viz. cell adhesion, cell migration, cell cycle and metabolism in  the Tmigratory state 
(Tspleen/Tblast).  
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5.3 Gene Ontology based analysis of microarray expression data 
GO consortium classifies genes into molecular functions, biological processes and 
cellular components which is particularly useful for getting an overview of 
quantitative changes pertaining to each category.  
 All genes that were differentially regulated were chosen for GO analysis. The 
clustered genes were assigned the GO annotation and subsequently were plotted in pie 
charts. In clusters B to F, a major proportion of regulated genes did not belong to any 
of the biological processes such as apoptosis, signal transduction, cell growth, immune 
response, metabolism and transport (Figure 5. 5). 
Most of the upregulated genes in a Tmigratory, state in GO, belonged either to the 
plasma membrane (28%) or the gene ontology group of secreted proteins (10%) which 
was in contrast to Tactivated cell transcriptome where nuclear (38%) and cytoplasmic 
(30%) proteins predominated (Table 5. 3). Membrane factors upregulated in a Tactivated 
state were involved in auxiliary transport activity for e.g. (solute carrier family 7, 
member 1, SLC7A1), solute carrier family 16, member 1, SLC16A1, transferrin 
receptor ,TFRC) (31%), GTPase activity (guanine nucleotide binding protein alpha 
inhibiting activity polypeptide 1, GNAI, member RAS oncogene family RAB34, 
RAB34) (12%) or protein binding (phospholipid scramblase 1, PLSCR1) (6%) (Table 
5. 2) (Appendix 1). In a Tmigratory state this group of regulated genes rather belonged to 
membrane receptor activity (CD44, ITGβ1, killer cell lectin-like receptor subfamily D, 
member 1, KLRD1, tumour necrosis factor receptor superfamily, member 1B, 
TNFRSF1B) (35%), calcium ion binding activity (pleckstrin, PLEK, S100 calcium 
binding protein A4, S100A4, S100 calcium binding protein A9, S100A9) (13%) or fell 
into the category of undefined molecular functions (GLIPR1, synaptotagmin-like 1, 
SYTL1) (11%) (Appendix 2). Clearly, membrane molecules in a Tmigratory state are 
involved in cell migration machinery. 
Biological processes such as cell adhesion, cell migration, cell communication, 
immune response and signal transduction were the prominently upregulated processes 
in a Tmigratory state whereas processes such as metabolism and cell cycle/proliferation 
formed the majority of the Tactivated pie chart (Table 5. 4, Table 5. 5).  
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Cell adhesion molecules such as CD44, ITGβ1 and SELL play a crucial role in T 
lymphocyte adhesion on the luminal side of blood vessels and were all upregulated in 
Tspleen compared to Tblast. In particular, studies involving blocking anti-bodies revealed 
that both CD44 and ITGβ1 contribute to clinical disease in EAE by inhibiting 
leukocyte extravasation to the CNS (53). In Tspleen  compared to Tblast in addition to 
well-known cell adhesion genes, several novel cell adhesion genes were also 
upregulated, namely, EMP1, CD97 antigen (CD97), and NRP1 (Table 5. 1) (Appendix 
2). The majority of cell adhesion genes were downregulated in the Tactivated state (69% 
downregulated; 31% upregulated) whereas in the Tmigratory state 55% of cell adhesion 
genes that underwent change were upregulated (Table 5. 4, Table 5. 5).  
 GO biological process that underwent significant change in both Tactivated and 
Tmigratory states were similar such as cell metabolism (Tactivated; 348 genes, Tmigratory; 297 
genes), cell communication (Tactivated; 145 genes, Tmigratory; 159 genes), biological 
processes unknown (Tactivated; 56 genes, Tmigratory; 47 genes) and transport (Tactivated; 53 
genes, Tmigratory; 46 genes). However, the number of cell migration genes that 
underwent changes in the Tmigratory state was higher than that of the Tactivated state 
(Tactivated; 10 genes, Tmigratory; 23 genes) and most of them were upregulated in the 
Tmigratory state, implying an apparent migratory genotype acquired by Tspleen 3.5 days 
post adoptive transfer of TMBP-GFP cells. (Table 5. 4, Table 5. 5).  
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GO: Molecular Class Numbers of 
genes changed 
Upregulated in 
Tactivated state 
Downregulated 
in Tactivated state 
Centrosome 12 11 1 
Cytoplasm 182 114 68 
Cytoskeleton 1 0 1 
Endoplasmic 
Reticulum 26 13 13 
Extracellular 20 10 10 
Golgi apparatus 18 2 16 
Kinetochore 1 1 0 
Lysosome 10 2 8 
Microtubule 3 2 1 
Mitochondrion 3 2 1 
Nucleus 217 144 73 
Perinuclear region 1 0 1 
Peroxisome 7 5 2 
Plasma membrane 103 28 75 
Ribosome 3 3 0 
Table 5. 2 GO: Molecular Class based annotations of differentially regulated 
transcripts in Tactivated transcriptome. 
GO: Molecular Class Numbers of 
genes changed 
Upregulated in 
Tmigratory state 
Downregulated 
in Tmigratory state 
Centrosome 7 1 6 
Cytoplasm 84 53 31 
Cytoskeleton 1 1 0 
Endoplasmic 
Reticulum 25 7 18 
Extracellular 36 20 16 
Golgi apparatus 11 8 3 
Intermediate filament 1 1 0 
Lysosome 5 3 2 
Microsome 3 1 2 
Mitochondrion 56 4 52 
Nucleus 207 49 158 
Perinuclear region 1 1 0 
Peroxisome 5 0 5 
Plasma membrane 87 59 28 
Ribosome 2 0 2 
Table 5. 3 GO: Molecular Class based annotations of differentially regulated 
transcripts in Tmigratory transcriptome. 
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GO: Biological 
Process 
Numbers of genes 
changed 
Upregulated in 
Tactivated state 
Downregulated in 
Tactivated state 
Apoptosis 11 2 0 
Process unknown 56 33 23 
Cell adhesion 29 9 20 
Cell migration 10 4 6 
Cell 
communication 
145 56 89 
Cell cycle 15 14 1 
Cell growth 33 17 16 
DNA repair 3 3 0 
DNA replication 3 3 0 
Energy pathways 1 0 1 
Immune response 20 6 14 
Metabolism 348 244 104 
Protein folding 4 3 1 
Signal transduction 13 2 11 
Transport 53 28 25 
Table 5. 4 GO: Biological Process based annotation of differentially regulated 
transcripts in Tactivated transcriptome. 
GO: Biological 
Process 
Number of genes 
changed 
Upregulated in 
Tmigratory state 
Downregulated in 
Tmigratory state 
Apoptosis 9 5 4 
Process unknown 47 15 32 
Cell adhesion 37 22 15 
Cell migration 23 16 7 
Cell 
communication 
159 91 68 
Cell cycle 15 3 12 
Cell growth 43 19 24 
DNA repair 3 0 3 
DNA replication 3 0 3 
Energy pathways 1 1 0 
Immune response 25 20 5 
Metabolism 297 54 243 
Protein folding 3 0 3 
Signal transduction 11 9 2 
Transport 46 13 33 
Table 5. 5 GO: Biological Process based annotation of differentially regulated 
transcripts in Tmigratory transcriptome. 
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5.4 Pathway based analysis of microarray data 
To determine signalling pathways implicated in T cell migration, GenMAPP was used 
for pathway-based analysis of the expression dataset of Tblast, Tresting and Tspleen cells. 
The pathways that underwent major changes in activated Tblast cells compared to 
Tresting cells (Tactivated) were the cholesterol biosynthetic (Figure 5. 8) and cell cycle 
pathways (Figure 5. 10). Antigen-specific T cell activation resulted in cell cycle 
progression by upregulation of the CDC2 kinase which associates with cyclin A 
(CCNA1) and cyclin B (CCNB). Cyclins required for G1 to S phase transition such as 
cyclin E1 (CCNE1) and cyclin E2 (CCNE2) and cyclins important for G2 phase to M 
phase transition such as CCNA2, cyclin B1 (CCNB1) cyclin B2 (CCNB2) and cyclin 
F (CCNF) were all upregulated. Furthermore, v-myc myelocytomatosis viral oncogene 
homolog (MYC), a transcription factor driving the synthesis of DNA replication genes 
was upregulated and at the same time several transcription factors such as krüppel-like 
factor 2 (KLF2), krüppel-like factor 4 (KLF4), krüppel-like factor 9 (KLF9), B-cell 
translocation gene 1 (BTG1), and B-cell translocation gene 2 (BTG2) that inhibit the 
cell cycle progression were downregulated. Of the many signalling pathways involved 
in the activated phenotype of T cells, the prominent ones were cell division and cell 
metabolism. In the Tactivated state, one of the metabolic pathways, the cholesterol 
biosynthetic pathway, was significantly upregulated (Figure 5. 8). Strikingly, 81% of 
all the genes involved in cholesterol biosynthesis were upregulated. Thirteen genes out 
of a total sixteen genes implicated in the cholesterol pathway were upregulated.  
At the same time, these pathway specific changes were dramatically opposite 
in the Tmigratory state. Both the cell cycle pathway and the cholesterol biosynthetic 
pathway were downregulated in Tspleen cells compared with Tblast cells (Figure 5. 9, 
Figure 5. 11).  
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Figure 5. 8 Cholesterol biosynthetic pathway is upregulated in Tactivated 
transcriptome. 
Overlay of Tactivated transcriptome dataset on cholesterol biosynthetic pathway using 
GenMAPP. Fold values of Tblast with respect to Tresting (Tactivated) is indicated on the right hand 
side of the gene. Red colour = upregulated; Green colour = downregulated; Grey colour = not 
changed and No colour = gene not present in microarray. 
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Figure 5. 9 Cholesterol biosynthetic pathway is downregulated in Tmigratory 
transcriptome. 
Overlay of Tmigratory transcriptome dataset on cholesterol biosynthetic pathway using 
GenMAPP. Fold values of Tspleen with respect to Tblast (Tmigratory) is indicated on the right hand 
side of the gene. Red colour = upregulated; Green colour = downregulated; Grey colour = not 
changed and No colour = gene not present in microarray. 
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Figure 5. 10 Cell cycle pathway is upregulated in Tactivated transcriptome. 
Overlay of Tactivated transcriptome dataset on cell cycle pathway using GenMAPP. Fold values 
of Tblast with respect to Tresting (Tactivated) are indicated on the right hand side of the gene. Red 
colour = upregulated; Green colour = downregulated; Grey colour = not changed and No 
colour = gene not present in microarray. 
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Figure 5. 11 Cell cycle pathway is downregulated in Tmigratory transcriptome. 
Overlay of Tmigratory transcriptome dataset on cell cycle pathway using GenMAPP. Fold values 
of Tspleen with respect to Tresting (Tmigratory) are indicated on the right hand side of the gene. Red 
colour = upregulated; Green colour = downregulated; Grey colour = not changed and No 
colour = gene not present in microarray. 
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 qPCR Microarray 
GENE Tmigratory Teffector Tmigratory Teffector 
Btg1 2.34 1.70 2.60 2.00 
Btg2 1.88 1.12 4.30 3.50 
Egr1 0.72 7.59 1.79 2.72 
Egr2 2.70 45.42 1.61 2.46 
Egr3 1.28 11.99 1.69 3.10 
Klf4 6.54 20.18 2.32 1.71 
Tob1 5.00 13.17 2.66 1.72 
Table 5. 6 qPCR and microarray data indicating up regulation of quiescence 
factors. 
This table shows quantitative PCR fold values and microarray fold values for ex-vivo sorted 
TMBP-GFP cells from spleen and CNS compared with in vitro activated T cell blasts. Values are 
from an average of three independent measurements. 
However, cell quiescence inducing transcription factors such as KLF2, KLF4, KLF9, 
krüppel-like factor 10 (KLF10), BTG1 and BTG2 crucial for inhibiting cell cycle 
progression were all upregulated in both the Tmigratory state and the Teffector states This 
was confirmed by quantitative PCR analyses (Table 5. 6).  
A cell migration signalling pathway was generated with the GenMapp program 
(Figure 5. 11). In this pathway almost all the genes important for the migratory 
signalling pathway were upregulated in the Tmigratory state. Genes related to IL2R 
signalling were decreased. The same held true for genes involved in ERK signalling. 
However, Tec kinase signalling mediated by T cell-specific non- receptor TXK 
tyrosine kinases (TXK), which function downstream of integrin receptors and 
chemokine receptors, was upregulated. The guanine nucleotide Exchange Factors 
(GEFs) (rho/Rac guanine nucleotide exchange factor 18, ARHGEF18, rho guanine 
nucleotide exchange factor 3, ARHGEF3) were upregulated. GEFs acting as control 
switches by stimulating the exchange of GDP for GTP to generate the active form of 
RhoGTPases are essential for cell migration. Interestingly, the LIM domain containing 
proteins zyxin (ZYX) and four and a half LIM domains 2 (FHL2) were also 
upregulated. LIM domain proteins are localized to focal adhesions and nucleus in an 
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integrin dependent manner to promote cell spreading and migration. Moreover, FHL2 
has been reported to inhibit cell proliferation by directly inhibiting mitogen-activated 
protein kinase 2 (ERK2) (54).  
In addition, ZYX, a regulator of actin filament assembly, inhibits mitotic 
progression by interacting with large tumour suppressor, homolog 1 (LATS1) tumour 
suppressor (55). Many molecular mediators of cell migration apparently seem to play 
a role in inhibiting signals for cell proliferation. The well-studied cell cycle 
progression inhibitor KLF2, expressed in naïve T cells, was recently reported to be 
involved in controlling cell migration in naïve T cells by directly regulating thymic 
egress receptor sphingosine-1-phosphate receptor 1 (S1P1) and lymph node homing 
receptors, SELL and CC-chemokine receptor (CCR7) (56). KLF4, a zinc finger 
containing transcription factor that inhibits cell proliferation by inhibiting G1/S 
progression of cell cycle, was upregulated more than 2 fold in Tspleen compared to 
Tblast. Moreover, KLF4 expression in TMBP-GFP cells in different milieus such as spleen, 
blood and CNS coincide with cell cycle progression as measured by propidium iodide 
staining, providing functional evidence of cell cycle inhibition in Tmigratory and Teffector 
state (Figure 5. 13, Figure 5. 15).  
These transcriptome analyses reveal a surprisingly reciprocal relationship 
between cell division and cell migration pathways between the Tactivation and Tmigratory 
states. Hence, the in-silico analysis of the microarray data suggests that cell cycle 
controlling factors play a role in regulating cell migration pathways and vice versa. To 
consolidate these results transcriptomic data was validated by quantitative PCR 
analyses and a functional in vitro and in vivo testing of selected candidate genes was 
performed. 
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Figure 5. 12 Cell migration pathway is upregulated in Tmigratory transcriptome. 
Overlay of Tmigratory transcriptome dataset on cell migration pathway generated using 
GenMAPP. Fold values of Tspleen with respect to Tresting (Tmigratory) are indicated on the right 
hand side of the gene. Red colour = upregulated; Green colour = downregulated; Grey colour 
= not changed and No colour = gene not present in microarray. 
.
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Figure 5. 13 Intracellular propidium iodide staining of DNA for cell cycle analysis by 
flow cytometry. 
In vitro activated Tblast cells, and spleen homogenate cells, gradient purified blood leukocytes 
and gradient purified CNS mononuclear cells from a diseased animal, 3.5 days post AT-EAE 
induction, were fixed, permeabilized and stained for nuclear DNA using propidium iodide. 
FACS acquisition was done by gating on GFP positive T cells Percentage of cells in different 
phases of cell cycle were analysed and shown here. The histograms are representative of three 
independent experiments. 
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5.5 Validation of microarray data 
 
 
Gene 
name 
Gene Description Primer probe 
ID 
Accession 
number 
ADAM8 A disintegrin and metalloproteinase domain (ADAM) 15 (metargidin) Rn00571913_m1 BI288110 
ADD3 Adducin 3, gamma Rn00580668_m1 AA894279 
ARHGAP
4 Rho GTPase activating protein 4 Rn00595213_m1 BE111827 
ASNS Asparagine synthetase Rn00565180_m1 U07202 
BARD1 BRCA1-associated RING domain protein 1 Rn00575185_m1 NM_022622 
BIRC5 Baculoviral IAP repeat-containing 5 (survivin) Rn00574012_m1 NM_022274 
BNIP3 BCL2/adenovirus E1B 19 kDa-interacting protein 3 Rn00821447_g1 NM_053420 
BSG Basigin Rn00562874_m1 NM_012783 
BTG2 B-cell translocation gene 2, anti-proliferative Custom designed BI288701 
CASP4 Caspase 11 Rn00586960_m1 NM_053736 
CCNB1 Cyclin B1 Rn00596848_m1 X64589 
CD38 CD38 antigen Rn00565538_m1 BI289418 
CDC25B Cell division cycle 25B Rn00592081_m1 NM_133572 
CDKN1A Cyclin-dependent kinase inhibitor 1A Rn00589996_m1 U24174 
DNMT1 DNA (cytosine-5-)-methyltransferase 1 Rn00709664_m1 AI179516 
EMP1 Epithelial membrane protein 1  Custom designed BI275741 
FABP5 Fatty acid binding protein 5, epidermal Rn00821817_g1 U13253 
FASLG Tumour necrosis factor (ligand) superfamily, member 6 Rn00563754_m1 NM_012908 
FHL2 Four and a half LIM domains 2 Rn00581565_m1 NM_031677 
HDAC3 Histone deacetylase 3 Rn00584926_m1 NM_053448 
HMGA1 High mobility group AT-hook 1 Rn00595021_m1 BG378885 
HMMR Hyaluronan mediated motility receptor Rn00564204_m1 AI171185 
IL17F Interleukin 17F Custom designed BI288683 
ILF3 Interleukin enhancer binding factor 3 Rn00584682_m1 NM_053412 
INSIG1 Insulin induced gene 1 Rn00574380_m1 NM_022392 
ITGB1 Integrin beta 1 Rn00566727_m1 NM_017022 
JUN v-jun sarcoma virus 17 oncogene homolog (avian) Rn00572991_s1 BI288619 
KLF4 Krüppel-like factor 4 (gut) Rn00821506_g1 NM_053713 
LGALS1 Lectin, galactose binding, soluble 1 Rn00571505_m1 NM_019904 
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Gene 
name 
Gene Description Primer probe 
ID 
Accession 
number 
MIF Macrophage migration inhibitory factor Rn00821234_g1 NM_031051 
PBEF1 Pre-B-cell colony-enhancing factor Rn00822046_m1 BM384211 
PDCD8 Programmed cell death 8 (apoptosis-inducing factor) Rn00442540_m1 AF262320 
PYCARD Apoptosis-associated speck-like protein containing a CARD Rn00597229_g1 BI282953 
S100A4 S100 calcium-binding protein A9 (calgranulin B) Rn00561700_m1 NM_012618 
S100A8 S100 calcium-binding protein A9 (calgranulin B) Rn00587579_g1 NM_012618 
S1P1 Sphingosine-1-phosphate receptor 1 Custom designed BI295971 
SLPI Secretory leukocyte protease inhibitor Rn00670378_m1 NM_053372 
SOD1 Superoxide dismutase 2 Rn00566942_g1 NM_017050 
TCP1 T-complex protein 1 Rn00562030_m1 NM_012670 
TNFRSF1
1B 
Tumour necrosis factor receptor 
superfamily, member 11b 
(osteoprotegerin) 
Rn00563499_m1 NM_012870 
TNFRSF8 Tumour necrosis factor receptor superfamily, member 8 Rn00569503_m1 NM_019135 
TOB1 Transducer of ERBB2, 1 Rn00591220_s1 NM_133317 
TP53 Tumour protein p53 Rn00755717_m1 AY009504 
Table 5. 7 List of genes selected for microarray data validation by quantitative 
PCR. 
5.5.1 PCR based validation 
Quantitative real-time PCR is a commonly used validation tool for confirming gene 
expression results obtained from microarray analysis. A set of genes was chosen for 
validation by qPCR, based on their known role in T cell function (Table 5. 7). qPCR 
was performed on the same source of cDNA that was used for the microarray 
including in vitro activated TMBP-GFP blast cells and ex vivo sorted TMBP-GFP cells from 
spleen. Gene expression was normalized with respect to the house keeping gene, β 
actin as internal control. Comparison of fold values in the Tmigratory state (Tspleen Vs 
Tblast) between microarray and qPCR showed a similar trend in their regulation pattern. 
However, the magnitude of fold values for corresponding genes differed (Figure 5. 
14).  
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Figure 5. 14 Validation of microarray data by qPCR. 
Genes (43 genes) from microarray data were chosen based on their expression in lymphocytes. 
Gene expression was measured in Tblast and Tspleen using qPCR. cDNA source was the same as 
that used for microarray. A comparison of gene expression fold value change in Tmigratory 
transcriptome was performed by plotting gene symbols on abscissa and corresponding fold 
values on ordinate. β actin mRNA expression was used as an internal standard. 
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5.5.2 Antibody based validation 
Earlier studies have already shown via flow cytometry an upregulation of chemokine 
receptors and a downregulation of activation markers in Tspleen on the protein level 
(44). To consolidate the microarray regulation independently, KLF4 was chosen for 
antibody-based validation. KLF4 was downregulated in activated T cells (Tblast) in 
vitro when compared with ex vivo sorted T cells from spleen (Tspleen) and CNS (TCNS) 
(Figure 5. 14).  
 
 
Figure 5. 15 Differential regulation of KLF4 in vivo. 
Intracellular staining for KLF4 expression by flow cytometry. In vitro activated Tblast cells, and 
spleen homogenate cells, gradient purified blood leukocytes and gradient purified CNS 
mononuclear cells from a diseased animal, 3.5 days post AT-EAE induction, were fixed, 
permeabilized and stained for KLF4. FACS acquisition was done by gating on GFP positive T 
cells Overlay of KLF4-specific antibody staining with isotype control staining is shown. (Grey 
= Isotype control; Red = KLF4 antibody) Shown is a representative histogram of three 
independent experiments. Illustration depicts increasing amounts of KLF4 expression post 
activation in spleen and CNS. 
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5.6 Bioinformatics prediction of KLF4 as a common 
transcriptional regulator for inflammatory chemokine receptors 
The following, describes the results of the study examining the role of KLF4 as 
potential master regulator that drives the transcriptomic transition from activated T 
cell state to migratory T cell phenotype. To achieve this aim, Matinspector™ was 
used, a bioinformatics program that identifies potential transcription factor binding 
sites (TFBS) in nucleotide sequences (58). The results from this analysis identified 
KLF4 as a common transcription factor binding to a region within 1000 base pairs 
upstream of transcription start site (TSS) of CCR1, CCR2, CCR3 and CCR5 but not 
CXCR3 (Table 5.9). Inflammatory chemokine receptors belonging to the CC-
chemokine receptor subfamily showed up in our microarray cluster analysis Figure 5. 
6). CCR1, CCR2 and CCR5 were found to be upregulated both at mRNA and protein 
level in Tmigratory cells as well as in Teffector cells (Table 5. 8). Upregulation of these 
receptors at protein level has been shown previously (Figure 5. 16) (57). The receptors 
were also clustered in chromosome 8 of rat genome indicating a potential co-
regulatory mechanism (Figure 5. 17). 
 
Gene Symbol Microarray fold values qPCR fold values 
 Tactivated Tmigratory Tactivated Tmigratory 
CCR1 1.05 1.60 n.d n.d 
CCR2 0.38 4.33 0.21 4.46 
CCR5 0.14 4.50 0.13 1.42 
Table 5. 8 Inflammatory chemokine receptors’ transcripts are upregulated in 
Tmigratory transcriptome.  
Comparison of microarray and qPCR data for inflammatory chemokine receptors in the 
Tactivated and Tmigratory states. qPCR and microarray data showing up regulation of CCR1, CCR2 
and CCR5. This table shows microarray gene expression fold values and qPCR gene 
expression fold values of Tactivated and Tmigratory transcriptome. cDNA was synthesized from in 
vitro activated T cells blasts (Tblast) and ex-vivo sorted green fluorescent T cells from spleen 
(Tspleen) and CNS (TCNS) β actin mRNA expression was used as an internal standard. Values 
are from an average of three independent measurements. (n.d not determined) 
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Figure 5. 16 Inflammatory chemokine receptors are upregulated in Tspleen. 
Intracellular staining for chemokine receptor expression by flow cytometry. Comparsion of 
chemokine receptor expression between in vitro cultured TMBP-GFP cells (blue histogram) and 
Tspleen cells (pink histogram) from spleen of AT-EAE rat 84 hrs post adoptive transfer of TMBP-
GFP. (Data adapted from Flügel et al (44). 
 
 
Figure 5. 17 Inflammatory chemokine receptors are clustered in the genome. 
Ensemble genome browser image for rat chromosome 8. Inflammatory chemokine receptors 
CCR1, CCR2, CCR3 and CCR5 are depicted and boxed in red. 
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Chemokine receptor Predicted KLF4 binding 
site 
Position (from-to) 
upstream of TSS 
CCR1 aagaagagaAGGG 652 – 664 
CCR2 gtcAAAGgcactt 249 – 261 
CCR3 cagaaagggAGGG 834 – 846 
CCR4 aaaaaaaaaAGGG 571 – 583 
CCR5 
gaagaccaaAGGG 
accAAAGggtctc 
attAAAGgtatta 
46 - 58 
50 - 62 
718 – 730 
CXCR3 None    - 
Table 5. 9 KLF4 binding motifs are present in inflammatory chemokine receptors. 
KLF4 binding motifs upstream of TSS in chemokine receptors, obtained using Matinspector™ 
is shown. The position of the binding motif from TSS in chemokine receptors is also shown. 
Base pairs marked in red appear in a position where the transcription factor matrix exhibits a 
high conservation profile. Base pairs in capital letters denote the core sequences used by 
Matinspector™. 
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5.7 Overexpression of KLF4 induces cell cycle arrest and 
upregulates CCR2 and CCR5 
KLF4 is a zinc finger-containing transcription factor which is known to negatively 
influence the progression of G1/S phase of the cell cycle (59,60). In order to 
investigate the role of cell cycle inhibition by KLF4 in chemokine receptor regulation, 
KLF4 was overexpressed in T cells by retroviral-mediated transduction of antigen 
specific primary T cells. Overexpression was assessed by performing qPCR using 
standardized qPCR primers for KLF4 (Figure 5. 18). Overexpression of KLF4 full 
length cDNA in TMBP-GFP cells resulted in a strong inhibition of G1/S cell cycle 
progression from 58% to 85% in G1 phase confirming overexpression of functional 
KLF4 protein and its ascribed function (59) (Figure 5. 19).  
 
Figure 5. 18 Standardization of KLF4 qPCR primers. 
Standard dilution curves were plotted using cDNA prepared from resting T lymphocytes. 
Average Ct values are plotted on ordinate and cDNA dilutions are plotted on abscissa. A 
standard curve slope of 3.32 indicates a PCR reaction with 100% efficiency. 
 
Figure 5. 19 Overexpression of KLF4 inhibits cell cycle progression in MBP-specific T 
cells. 
(a) Quantitative PCR on in vitro cultured KLF4-transduced TMBP-GFP cells compared to control 
TMBP-GFP cells four days post retroviral transduction. (b) Propidium iodide staining for cell 
cycle analysis of TMBP-GFP and TMBP-KLF4. 
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Moreover, qPCR performed on RNA isolated from TMBP-GFP cells overexpressing 
KLF4 (Figure 5. 19a) indicated upregulation of chemokine receptors CCR2 (~20 fold) 
and CCR5 (~5 fold), downregulation of, IL2R (~4 fold) but not CXCR3 (Figure 5. 
20). Earlier studies reported on upregulation of CCR2 upon IL2 deprivation (61).  
 
 
Figure 5. 20 Overexpression of KLF4 upregulates CCR2, CCR5 but not CXCR3 in 
MBP specific T cells. 
Quantitative PCR of KLF4 transduced in vitro cultured TMBP-GFP. TMBP-GFP cells were 
retrovirally transduced with full length rat KLF4 cDNA and four days post transduction green 
fluorescent CD4+ T cells were FACS sorted along with GFP control T cells. Gene expression 
of chemokine receptors CCR2 (red), CCR5 (blue), IL2R (green) and CXCR3 (grey) was 
measured using quantitative PCR normalized to β actin as an internal standard. Data shown 
here is representative of three independent experiments. 
Regulation of CCR2 and CCR5 expression by KLF4 was confirmed using different 
cell lines. Overexpression of KLF4 in OVA-specific T cells, exhibited upregulation of 
CCR2 and CCR5 both in activated and resting conditions (Table 5. 10). RBL1 (Rat 
basophilic  leukaemia 1) is a histamine releasing cell line commonly used in 
inflammation, allergy and immunological research. KLF4 overexpression in RBL1 
induced at least 2 fold upregulation of CCR2 and CCR5 mRNA compared to control 
transduced RBL1 cell line (Figure 5. 21).   
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 TOVA-GFP 
(ACTIVATED) 
TOVA-KLF4 
(ACTIVATED) 
FOLD VALUES 
(TOVA-KLF4/TOVA-GFP) 
CCR2 1.15E-03 4.63E-03 4.03 
CCR5 1.44E-03 2.98E-03 2.07 
 TOVA-GFP 
(RESTING) 
TOVA-KLF4 
(RESTING) 
FOLD VALUES 
(TOVA-KLF4/TOVA-GFP) 
CCR2 2.65E-03 5.37E-03 2.03 
CCR5 1.32E-03 3.70E-03 2.80 
Table 5. 10 Overexpression of KLF4 upregulates CCR2 and CCR5 in ovalbumin-
specific T cells. 
Quantitative PCR of in vitro cultured KLF4-transduced ovalbumin-specific T cells (TOVA-
GFP). TOVA-GFP cells were retrovirally transduced with full length rat KLF4 cDNA and 
green fluorescent CD4+ T cells were FACS-sorted 2 and 6 days post transduction along with 
GFP control T cells. Gene expression of chemokine receptors CCR2 and CCR5 was measured 
using quantitative PCR normalized to β actin as an internal standard. Data is representative of 
three independent experiments. 
 
 
Figure 5. 21 Overexpression of KLF4 upregulates CCR2 and CCR5 in RBL1 cell 
lines. 
Quantitative PCR of in vitro cultured KLF4-transduced RBL1 cell line. RBL1 cell lines were 
retrovirally transduced with full length rat KLF4 cDNA and green fluorescent RBL1 cell lines 
were FACS sorted along with GFP control transduced RBL1 cells. Gene expression levels for 
KLF4 (red) and chemokine receptors, CCR2 and CCR5 (black) were determined in KLF4- 
and GFP-transduced RBL1 cells. β actin mRNA expression served as internal standard for 
normalization. Data obtained were from averages of triplicate measurements. 
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5.8 Transcriptional activity of KLF4 on CCR2 and CCR5 
promoters 
In order to further corroborate the role of KLF4 in regulating the expression of 
inflammatory chemokine receptors, a luciferase assay was performed using reporter 
constructs containing promoter regions of genes encoding the chemokine receptors 
CCR2, CCR5 and CXCR3. Promoter regions comprised of 1000 base pairs upstream 
and 100bp downstream of the transcription start site (TSS). Matinspector™ prediction 
results indicated a KLF4 binding region in the TSS upstream of CCR2, CCR5 but not 
CXCR3 (Table 5. 9).  
 Co-transfection assays with KLF4 and reporter constructs in cultured 293T 
cells indicated upregulation of both CCR2 and CCR5 promoter activities by at least 2 
fold (Figure 5. 22) whereas CXCR3 did not show an increase in promoter activity 
compared to pGL3 empty reporter transfections. Taken together these results suggest 
KLF4 inhibits cell cycle progression and regulates migratory molecules such as 
inflammatory chemokine receptors CCR2 and CCR5. The results also indicate that 
KLF4 might be one regulator gene which coordinates the transition from activated to 
migratory state of effector T cells by tuning negatively the proliferative genes and 
positively, the migratory genes. 
 
Figure 5. 22 Dual luciferase assay for CCR2, CCR5 and CXCR3 promoter activity. 
Luciferase assay was performed after co-transfection of the pMSCVneo vector or of 
pMSCVneo-KLF4 with PGL3 reporter constructs such as PGL3, PGL3-CXCR3, PGL3-CCR2 
and PGL3-CCR5 in 293T cells. Luciferase activity was measured 48 hours after transfection. 
Luciferase activity is presented relative to that of pMSCVneo vector control after 
normalization with renilla luciferin. Student’s t-Test p value, * denotes p < 0.5, ** denotes p < 
0.01 and *** denotes p < 0.001. Date shown is a representative of three independent 
experiments and measurement was done in triplicates. 
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5.9 Identification of differentially regulated membrane molecules 
as potential candidate genes 
Genes that are expressed on the T cell surface and upregulated in Tmigratory state (Tspleen 
vs Tblast) can serve as potential candidate genes for therapeutic intervention in AT-
EAE models. Retransfer experiments, wherein Tspleen cells three days post adoptive 
transfer were injected into naïve syngeneic rats, clearly demonstrated the early 
infiltrating capacity of  migratory Tspleen cells to CNS within 24 hours (Figure 5. 23) 
(44). Transmembrane molecules that are differentially regulated in Tspleen cells, can 
thus be regarded collectively as imparting the passport to T cells to infiltrate the CNS.  
 Membrane proteins can be of several types based on their association with 
their lipid bilayer, such as transmembrane protein, cytosolic membrane protein, 
external membrane protein and peripheral membrane protein. However, based on their 
topology, UniProt defines the following classification for transmembrane proteins 
(62). 
• Type I: Protein spanning the membrane once, with its N-terminus on 
the extracellular side of the membrane and removal of its signal sequence. 
• Type II: Protein spanning the membrane once, with its N-terminus on 
the cytoplasmic side of the membrane. The transmembrane domain is located 
close to the N-terminus and it functions as an anchor. 
• Type III: Protein spanning the membrane once, with its N-terminus on 
the extracellular side of the membrane and no signal sequence. 
• Type IV: Protein spanning the membrane once, with its N-terminus on 
the cytoplasmic side of the membrane. The transmembrane domain is located 
close to the C-terminus and it functions as an anchor. 
• Multipass: Protein spanning the membrane more than once. 
• GPI-anchored: Protein bound to the lipid bilayer of a membrane through a GPI-
anchor (glycosylphosphatidylinositol anchor), a complex oligoglycan linked to 
a phosphatidylinositol group, resulting in the attachment of the C-terminus of 
the protein to the membrane. 
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Microarray data analysis revealed several plasma membrane proteins that were 
differentially regulated in Tspleen compared to Tblast (Table 5. 11), including ITGB1, 
S1P1, CCR2 and CC-chemokine receptor 6 (CCR6) (Table 5. 12).  
Drug target molecules Drugs in development Companies 
α4β1 Natalizumab Biogen-Idec 
EDG1 (S1P1) FTY-720 Novartis 
CCR2 MK0812 ChemoCentryx 
CCR6 mAb, small molecule G2 Therapies 
Table 5. 11 List of cell membrane receptors which are established drug targets for 
multiple sclerosis. 
 
Gene 
symbol 
Tspleen vs 
Tblast 
Molecular function Transmembrane 
protein type 
BSG 0.4300 Receptor activity  TYPE I 
CCR2 4.3330 
G-protein coupled receptor 
activity  
MUTI-PASS 
CCR5 4.4952 
G-protein coupled receptor 
activity  
MUTI-PASS 
CCR6 2.9268 
G-protein coupled receptor 
activity  
MUTI-PASS 
CD200 0.2836 Immunoglobulin receptor activity TYPE I 
CD38 3.0527 Hydrolase activity  TYPE II 
CD44 2.4723 Receptor activity  TYPE I 
CD69 7.7670 Receptor activity  TYPE II 
CD83 1.9859 Molecular function unknown  TYPE I 
CD97 2.4615 Receptor activity  MULTI-PASS 
CSF1R 2.0229 Transmembrane receptor activity TYPE I 
CXCR4 2.9185 
G-protein coupled receptor 
activity  
MUTI-PASS 
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EDG1 4.1539 
G-protein coupled receptor 
activity  
MUTI-PASS 
EMP1 5.2180 Cell adhesion molecule activity  MULTI-PASS 
FASLG 2.1241 Receptor binding  TYPE II 
FXYD5 3.0887 Cell adhesion molecule activity  TYPE I 
GABBR1 2.2494 
G-protein coupled receptor 
activity  
MUTI-PASS 
GLIPR1 3.9142 Molecular function unknown  TYPE I 
GPC1 0.4674 Receptor activity  GPI-ANCHORED 
GPNMB 2.8633 Molecular function unknown  TYPE I 
HCST 2.9049 
Receptor signalling complex 
scaffold activity 
TYPE I 
IFNGR1 2.5023 Transmembrane receptor activity TYPE I 
IGSF6 2.0765 Antigen binding  TYPE I 
ITGB1 5.6106 Receptor activity  TYPE I 
ITGB7 5.1213 Receptor activity  TYPE I 
JAM3 0.4815 Cell adhesion molecule activity  TYPE I 
KDR 0.2806 
Transmembrane receptor protein 
tyrosine kinase activity 
TYPE I 
KLRD1 8.0694 Receptor activity  TYPE II 
LTB 2.1241 Cytokine activity  TYPE II 
NRP1 2.4536 Receptor activity  TYPE I 
PLAUR 3.0884 Receptor activity  GPI-ANCHORED 
RAMP1 2.0671 Transporter activity TYPE I 
RAMP2 2.8365 Transporter activity  TYPE I 
SCARB1 0.3199 Receptor activity  TYPE I 
SELL 2.4411 Cell adhesion molecule activity  TYPE I 
SORL1 2.2598 Transmembrane receptor activity TYPE I 
TFRC 0.2604 
Auxiliary transport protein 
activity  
TYPE II 
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TNFRSF1B 3.1115 Receptor activity  TYPE I 
TNFRSF4 0.3819 Receptor activity  TYPE I 
TNFRSF8 0.1494 Receptor activity  TYPE I 
TYROBP 2.6851 Receptor activity  TYPE I 
VAMP3 2.5110 Protein binding  TYPE IV 
Table 5. 12 List of cell membrane molecules differentially regulated in Tspleen cells 
compared to Tblast cells as indicated by microarray data. 
5.10 EMP1 as a novel candidate gene 
As a potential effector molecule regulating autoaggressive T cell motility the 
multipass integral membrane protein, EMP1 or tumour-associated membrane protein 
(TMP), was tested. EMP1 belongs to the PMP22/EMP/MP20/Claudin superfamily of 
tetraspan membrane proteins and to a gene family consisting of EMP1, EMP2, EMP3 
and peripheral myelin protein 22 (PMP22). 
5.11 Bioinformatics based structural features of EMP1 
A computer based algorithm called SOSUI, was used to determine the hydropathy 
plots of EMP1 protein sequence. EMP1 was found to have four transmembrane helices 
with their amino- and carboxy-terminal tails extending into the cytoplasm (Table 5. 
13)-.  
 
Number N-Terminal Transmembrane Region C-Terminal Type Length 
1 5 LAGLFVVHIATAIMLFVSTIANV 27 PRIMARY 23 
2 64 VQAFMILSIIFSIISLVVFVFQL 86 PRIMARY 23 
3 96 FLSGSTMLVCWLCILIGVSIYT 117 PRIMARY 22 
4 135 YCFILTWICFCFSFIIGILYMVL 157 PRIMARY 23 
Table 5. 13 Prediction for transmembrane helix regions in EMP1 amino acid 
sequence. 
Prediction was performed using SOSUI, a WWW-based tool to predict transmembrane helices 
in a given amino acid sequence (66). Rat EMP1 protein sequence from NCBI (NP_036975.1) 
was used as input to determine transmembrane regions. 
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ITIM MOTIF
(I/V/L-X-Y-X-X-L/V)
W-GLW-C-C MOTIF
 
Figure 5. 23 ClustalW multiple sequence alignment of mammalian EMP1 protein 
sequences. 
Transmembrane motifs are highlighted in yellow. Conserved W-GLW-CC motif within the 
first extracellular loop is highlighted in turquoise blue. Small and hydrophobic including 
aromatic amino acids (red); Acidic amino acids (blue); Basic amino acids (magenta), 
hydroxyl, basic, amine and glutamine (green) Predicted Immunoreceptor Tyrosin-based 
Inhibitory Motif in the C-terminus of EMP1 is underlined. "*" denotes residues in that column 
are identical in all sequences in the alignment. ":" denotes conserved substitutions. "." denotes 
semi-conserved substitutions. Predicted Immunoreceptor Tyrosine-based Inhibitory Motif in 
the C-terminus of EMP1 is underlined. 
 
Figure 5. 24 Phylogram tree for mammalian EMP1 are related. 
Phylogenetic relationship among mammalian EMP1 protein sequences. Rat and Mouse EMP1 
are closely related. 
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Phylogram
 
Figure 5. 25 ClustalW multiple sequence alignment of rat EMP1 family amino acid 
sequences. 
Multiple sequence alignment of EMP1, EMP2, EMP3 and PMP22 protein sequences 
performed using ClustalW algorithm. Transmembrane motifs are highlighted in yellow. Small 
and hydrophobic including aromatic amino acids (red); Acidic amino acids (blue); Basic 
amino acids (magenta), hydroxyl, basic, amine and glutamine (green) Predicted 
Immunoreceptor Tyrosin-based Inhibitory Motif in the C-terminus of EMP1 is underlined. "*" 
denotes residues in that column are identical in all sequences in the alignment. ":" denotes 
conserved substitutions. "." denotes semi-conserved substitutions. The phylogeny tree 
illustrates the close relationship of EMP1 to EMP2. 
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Figure 5. 26 Computer based prediction of EMP1 topology. 
This model was generated from sequence analysis results. The image depicts the conserved 
structural features of the EMP family. EL1 and EL2 denote the extracellular loops 1 and 2. 
TM1, TM2, TM3 and TM4 are the transmembrane domains. 
Mammalian EMP1 harbours a short intracellular cytoplasmic amino-terminal 
sequence of 4 residues followed by a large extracellular loop (EL1) of 36 residues, a 
short 9-residue intracellular loop, another extracellular loop (EL2) of about 16 
residues and a carboxy-terminal cytoplasmic tail of three positively charged residues 
(Figure 5. 23). Emp1 is closely related to EMP2 and among different species rat 
EMP1 closely related to mouse EMP1 (Figure 5. 24, Figure 5. 25)  
Moreover, there are structural similarities between EMP1 and tight junction 
proteins, such as claudins. The topology of EMP1 resembles the tight junction proteins 
occludin and claudin in the BBB (51). Unlike tetraspanins, the first loop is larger than 
the second loop. The first extracellular loop of EMP1 contains W-GLW-C-C motif 
characteristic of the claudin family, indicating a potential functional overlap between 
EMP1 and claudins (Figure 5. 24). In contrast to claudins and occludin, which are 
linked to the cytoskeleton via tight junction protein 1 (TJP1) the intracellular tail of 
EMP1, consisting of only three residues, may lack the ability to bind other 
cytoplasmic proteins. The short cytosolic C-terminal residues are positively charged 
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comprising of Arg-Arg-Lys (RKK) (Figure 5. 26). CD3γ also contains RKK motif, in 
the absence of which the protein is targeted directly from the trans-Golgi network to 
lysosomes without going through the cell surface and is considered to be an 
endoplasmic reticulum retention motif (ER) (67). Immunoreceptor tyrosine-based 
inhibitory motif (ITIM) is defined by the six amino acid consensus sequence 
(Ile/Val/Leu)-X-Tyr-X-X-(Leu/Val) occurring in the cytosolic domain of many 
membrane bound receptors (68). Interestingly EMP1 bears such an ITIM motif 
conserved across species in their predicted fourth transmembrane domain. 
5.12 Expression of EMP1 in T cells  
Gene expression profiling of Tspleen and Tblast revealed upregulation of EMP1 in a 
Tmigratory state. In order to validate the microarray data for EMP1, qPCR was 
performed after optimizing primers by a standard dilution curve. (Figure 5. 27). EMP1 
and EMP3 are expressed in TMBP-GFP cells but the expression of EMP2 was too low to 
be detected in T cells (Figure 5. 28). EMP1 was ~3 fold upregulated in migratory 
Tspleen cells compared to Tblast whereas EMP3 was around ~2 fold downregulated in 
migratory Tspleen cells.  
 
Figure 5. 27 Standardization of EMP1, EMP2 and EMP3 qPCR primers. 
Primers were designed to span the exon-exon junction of all the genes. Standard dilution 
curves were plotted using cDNA which was prepared from total CNS of AT-EAE animal 5 
days post transfer of TMBP-GFP cells. A standard curve slope of 3.32 indicates a PCR reaction 
with 100% efficiency. 
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EMP1 protein was detected in activated TMBP-GFP cells (Tblast) by both immunoblot and 
immunocytochemistry. Intracellular staining for EMP1 in Tblasts indicated a granular 
staining pattern in T cells (Figure 5. 29). 
 
Figure 5. 28 Differential regulation of EMP1 family genes in T cells. 
cDNA was prepared from Tblasts, Tresting and ex vivo sorted Tspleen and TCNS and qPCR was 
performed to assess the expression of EMP1, EMP2 and EMP3. EMP2 transcript was not 
detected indicating absence of EMP2 expression in T cells. Gene expression was normalized 
using β actin as internal control. Data is representative of three independent experiments. 
 
Figure 5. 29 EMP1 protein detection in activated T lymphocytes. 
(a) Immunoblot for EMP1 and actin performed on in vitro activated TMBP-GFP cells. Molecular 
weight of EMP1 is 18 kDa. (b) Immunocytochemistry for EMP1 expression done on in vitro 
activated TMBP-GFP cells after cytospin. Confocal microscopy was used to examine the 
intracellular distribution of EMP1 in T cells. 10× magnification; Magnification bar: 10 µm 
Inset 20 × magnifications. 
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5.13 Cloning of EMP1 full length cDNA from activated TMBP-GFP 
cells 
The EMP1 transcript is 2685 base pairs long with a coding region of 483 base pairs 
(Figure 5. 30). The cDNA was amplified by PCR from in vitro-activated TMBP-GFP 
cells (Figure 5. 30) and subsequently, cloned into the mammalian retroviral expression 
vector pMSCVneoIRES2-EGFP (Figure 5. 30). TMBP cells were transduced using 
GP+E packaging cells producing EMP1-GFP retrovirus particles (50).  
 
 
Figure 5. 30 Cloning of rat EMP1 from activated T cells. 
(a) Schematic illustration of rat EMP1 mRNA. Full length coding sequence are colour coded 
in red and untranslated regions are indicated in grey. PCR primers with restriction enzyme for 
cloning used for amplification of full length cDNA are depicted. (b) EMP1 full length cDNA 
was amplified by PCR and agarose gel picture of PCR result is shown. (c) Plasmid map of 
mammalian retroviral expression vector used for GFP and EMP1 transduction in T cells. 
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5.14 Analysis of gene expression changes in EMP1 overexpressing T 
cells 
In order to characterize the functional properties of TMBP-EMP1 cells, a gene expression 
study for standard cytokines and transcription factors was performed (Figure 5. 31). 
Expression of cytokines such as interleukin 4 (IL4), interleukin 10 (IL10), IFNγ and 
IL17 and transcription factors such as RAR-related orphan receptor gamma (RORγ), 
forkhead box P3 (FOXP3) and T-box expressed in T cells (TBET) was by qPCR of in 
vitro cultured activated T cells . TMBP-GFP was always used as a control for comparison. 
The mRNA expression for cytokines and transcription factor did not change upon 
EMP1 overexpression in MBP-specific T cells (Figure 5. 32 and Figure 5. 33). 
 
Figure 5. 31 Gene overexpression of EMP1 in activated T cells. 
Quantitative PCR was performed on in vitro activated EMP1 transduced and GFP transduced 
control T cell blasts confirming overexpression of EMP1. β actin was used as internal control. 
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Figure 5. 32 Gene expression of cytokines. 
Quantitative PCR performed on in vitro cultured activated MBP-specific T cells. TMBP-EMP1, 
EMP1 overexpressing MBP-specific T cells; TMBP-GFP, GFP control MBP-specific T cells. IL4, 
Interleukin 4; IL10, Interleukin 10; IFNγ, Interferon Gamma; IL17, Interleukin 17 
 
Figure 5. 33 Gene expression of transcription factors. 
Quantitative PCR performed on in vitro cultured activated MBP-specific T cells. TMBP-EMP1, 
EMP1 overexpressing MBP-specific T cells; TMBP-GFP, GFP control MBP-specific T cells. 
RORG, RAR related Orphan Receptor Gamma; FOXP3, Forkhead box P3; TBET, T-Box 
Expressed in T cells. 
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5.15 EMP1 overexpressing T cells proliferate normally 
It was reported in previous study that overexpression of EMP1 in a cancer cell line 
inhibits proliferation (69). However, overexpression in T cells did not affect the 
proliferation ability of T cells in vitro. To test the proliferation ability of TMBP-EMP1, a 
thymidine incorporation assay was performed. Results from proliferation assay also 
indicated that TMBP-EMP1 are MBP specific (Figure 5. 34). 
 
Figure 5. 34 Proliferation assay of in vitro cultured T cells. 
T cells were stimulated using different antigens viz Φ, no antigen; MBP, Myelin Basic 
Protein; OVA, Ovalbumin and CON-A, Concanavallin A. 48 hours post antigen exposure 
thymidine [3H] was added and radioactivity was measured after 16 hours using β counter. 
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5.16 Overexpression of EMP1 induces enhanced T cell motility in 
matrigel 
In order to characterize the migration ability of EMP1-overexpressing T cells, time 
lapse video microscopy of T cells in a 3D matrigel was performed. Whereas activated 
TMBP-GFP cells showed a largely confined motility pattern within the matrigel, TMBP-
EMP1 cell were significantly more agile. Plots of tracks of 100 cells are shown in Figure 
5. 35. The majority of TMBP-EMP1 moved with higher speed compared to control T cells 
with an average velocity (5.6 versus 8.1 μm/min, respectively). Accordingly the cell 
trajectories of TMBP-EMP1 cells recorded in a 10 min time interval were significantly 
longer (Figure 4.36). 
 
 
 
Figure 5. 35 Matrigel T lymphocyte motility assay in vitro. 
Activated green fluorescent T cells overexpressing EMP1 (TMBP-GFP-EMP1) were incubated in 
matrigel and time lapse video microscopy was performed to observe T cell migration in 3D 
matrigel under controlled oxygen, temperature and pH conditions. The same was done with 
GFP control T cells (TMBP-GFP). Migratory paths were tracked and motility was analysed using 
ImageJ software. Individual cell track is colour coded. Both ordinate and abscissa denote 
distance traveled in μm. Data is representative of three independent experiments. 
Results 
 
 80 
5.17 EMP1 overexpressing encephalitogenic T cells induce 
accelerated onset of EAE  
Adoptive transfer EAE was induced in Lewis rats by the injection of 3 million 
activated TMBP-EMP1 or TMBP-GFP cells. Transfer of T cells was performed using three 
different routes of administration including i.v., s.c. and i.p. The disease course was 
observed in these rats for twelve days by monitoring their body weight and clinical 
score.  
TMBP-EMP1 cells induce transfer EAE, which was indistinguishable from the one 
of TMBP-GFP cells, when the T cells were applied i.v. (Figure 5. 38). However, when 
cells were transferred i.p. or s.c., disease started at least 24 h earlier (Figure 5. 36 and 
Figure 5. 37). This earlier onset included both paralytic symptoms and weight loss. In 
order to determine the cause of this disease acceleration, the T cell distribution in 
different organs at day of onset of clinical disease was determined after s.c. and i.v. 
transfer of TMBP-EMP1 cells. The clinical score in the EMP1 group (s.c. applied TMBP-
EMP1 cells) paralleled with the infiltration of TMBP-EMP1 cells into the CNS. At this time 
point the numbers of control TMBP-GFP cells within the CNS were significantly lower 
(Figure 5. 36 and Figure 5. 37). However, there was no significant difference in T cell 
numbers in the CNS of the EMP1 group and GFP groups of animals that received 
encephalitogenic T cells after i.v. transfer.  
In order to further investigate the early onset of EAE by i.p route of transfer, a 
time course experiment was performed to count the distribution of TMBP-GFP cells in 
different organs at different time points during the course of EAE. The results indicate 
that TMBP-EMP1 cells appear earlier in the analysed organs, i.e. lung, liver, spleen, 
paraaortal lymph node and mesenteric lymph nodes (Table 5. 14). Interestingly on day 
4 post transfer, the numbers of TMBP-EMP1 cells were similar to TMBP-GFP in several 
organs except the parathymic lymph node, meninges and CNS. When injected s.c or 
intra peritoneally, TMBP-EMP1 cells migrated faster to the draining lymph nodes (Figure 
5. 39). This is in concordance with the in vitro finding of higher motility in 3D 
matrigel. 
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Figure 5. 36 Adoptive transfer EAE induced by intraperitoneal injection and 
migratory pattern of encephalitogenic T cells in vivo 5 days post intra peritoneal 
injection. 
(a) Clinical course of AT-EAE induced by intra-peritoneal (i.p.) transfer. (b) Migration of 
green fluorescent encephalitogenic T cells to different organs, 4 days post transfer was 
determined by flow cytometry. Student’s t-Test p value, * denotes p < 0.5, ** denotes p < 0.01 
& *** denotes p < 0.001. 
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Figure 5. 37 Adoptive transfer EAE induced by sub cutaneous injection and 
migratory pattern of encephalitogenic T cells in vivo 5 days post sub cutaneous injection. 
(a) Clinical course of AT-EAE induced by sub-cutaneous (s.c.) transfer. (b) Migration of 
green fluorescent encephalitogenic T cells to different organs, 4 days post transfer was 
determined using flow cytometry. Student’s t-Test p value, * denotes p < 0.5, ** denotes p < 
0.01 & *** denotes p < 0.001. 
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Figure 5. 38 Adoptive transfer EAE induced by intra venous injection and migratory 
pattern of encephalitogenic T cells 4 days in vivo post intra-venous injection. 
(a) Clinical course of AT-EAE induced by intra-venous (i.v.) transfer. (b) Migration of green 
fluorescent encephalitogenic T cells to different organs, 4 days post transfer was determined 
using flow cytometry. Data is average of three independent experiments. 
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Figure 5. 39 Migration of EMP1 overexpressing T cells to the draining lymph nodes. 
10 million green fluorescent EMP1 transduced T cells (TMBP-EMP1) were injected 
subcutaneously either in leg flank or under the skin of the animal’s back in two separate 
groups. As a control GFP transduced T cells (TMBP-GFP) were injected similarly. 24 hours post 
sub cutaneous injection, the number of TMBP-GFP and TMBP-EMP1 reaching the draining lymph 
nodes were determined by flow cytometry. Data indicate average of three independent 
experiments. 
 
Figure 5. 40 Active EAE induced in memory animals by MBP/CFA immunization. 
Memory animals were generated by neonatal transfer of 2.5 million TMBP-GFP and TMBP-EMP1 
cells in two separate groups of animals and EAE was induced after 6-8 weeks. Clinical course 
was monitored for 13 days post disease induction. Data is average of three animals in a group. 
Student’s t-Test p value, * denotes p < 0.5, ** denotes p < 0.01 & *** denotes p < 0.001. 
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 Day 1 p.i.p.t Day 2 p.i.p.t Day 3 p.i.p.t 
 TMBP-GFP TMBP-EMP1 TMBP-GFP TMBP-
EMP1 
TMBP-GFP TMBP-EMP1 
ILN 0 0 0 7.16×103 2.73×105 2.97×105 
PLN 0 0 0 0 5.69×104 5.05×104 
P.thy 0 1.10×104 9.03×104 4.52×104 2.81×106 8.49×106 
Lungs 0 0 5.98×102 7.62×103 4.32×104 2.80×104 
Liver 0 0 9.36×102 2.37×104 7.61×104 1.56×105 
Spleen 0 0 3.78×103 3.88×105 1.07×106 1.52×106 
P.aorta 0 0 0 1.21×106 2.01×106 1.85×106 
Mesenteric 0 0 3.11×103 4.27×105 1.19×106 1.30×106 
Meninges 0 0 0 0 3.64×105 7.28×105 
T.CNS 0 0 0 0 3.68×105 7.72×105 
Blood 0 0 2.87×102 1.73×106 3.90×104 4.12×104 
Table 5. 14 Encephalitogenic T cells migration to different organs post intra 
peritoneal transfer (p.i.p.t). 
Cell numbers in various organs were counted by flow cytometry day 1,day 2 and day 4 post 
intraperitoneal transfer of 3 million of TMBP-GFP (white columns) and TMBP-EMP1 (grey columns). 
Green fluorescent TMBP-GFP and TMBP-EMP1 cells were injected in two different groups of 
animals. ILN, Inguinal lymph Node; PLN, Popliteal lymph node; P.thy, Parathymic lymph 
node; P.aorta, Para aortal lymph node; T.CNS, Total spinal cord. 
 Migration to draining lymph nodes by TMBP-EMP1 cells was analysed by two 
independent experiments. In one experiment, the same animals were injected 
subcutaneously with both control TMBP-GFP and TMBP-EMP1 cells but in two different leg 
flanks. GFP positive cells from the draining lymph nodes were enumerated 24 hours 
post injection by FACS. In another experiment, two different groups of animals were 
separately injected subcutaneously with control TMBP-GFP or TMBP-EMP1 but into the 
lower back of the animal. GFP positive cells were counted from draining lymph nodes, 
24 hours after injection by FACS (Figure 5. 39). EMP1 overexpressing T cells 
migrated earlier to the draining lymph nodes in both the settings. 
Results 
 
 86 
 Using an autoimmune memory model, migration of genetically modified 
MBP-specific T cells from periphery to the CNS can be assessed during active EAE. 
In this model, TMBP-GFP cells are embedded in the immune system of neonatal rats such 
that these cells then remain engrafted until adulthood without affecting the health of 
the hosts. Moreover, TMBP-GFP cells maintain a memory phenotype with SELL and 
CD45RC low but high CD44 (70). Active EAE induction in these memory animals by 
immunization with MBP/CFA induced disease between day 5 and day 6. However, 
immunization of animals harbouring memory TMBP-EMP1 cells induced an accelerated 
disease with higher clinical scores on day 5 and day 6 compared to the control group 
of TMBP-GFP memory animals (Figure 5. 40). All the animals in EMP1 group became 
sick on day 5 post immunization with clinical scores of ∼0.5 whereas only one animal 
got a mild score in the GFP group (Figure 5. 40). Moreover, the following day all 
animals in the EMP1 group developed severe disease with a clinical score of 3 
whereas control group exhibited mild clinical scores of 1.  
In conclusion, using adoptive transfer and active EAE model in memory 
animals, the results indicate a pro migratory role of EMP1 in directing TMBP-GFP cells 
into circulation subsequently facilitating early entry into the CNS.  
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Figure 5. 41 Encephalitogenic T cell infiltration to CNS post AT-EAE induction. 
CNS tissue from 5 days s.c. transfer of TMBP cells were fixed in 4% PFA and prepared for 
microtome sectioning. Slices viewed using 10X objective. Magnification bar: 10 µm. Upper 
panel images show no GFP positive TMBP-GFP infiltration in CNS tissue of an animal from GFP 
groups. Lower panel images show many GFP positive TMBP-EMP1 cells infiltration into the CNS 
parenchyma on the onset of disease distributed evenly both in white matter (WM) and grey 
matter (GM). Data is representative of three independent experiments. 
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5.18 EMP1 overexpressing T cells infiltrate earlier into the CNS 
parenchyma 
In order to test if the accelerated disease onset correlated with the capacity of TMBP-
EMP1 cells to invade the CNS parenchyma, morphological analyses using confocal laser 
scanning microscopy were performed. CNS tissue was prepared from animals of the 
GFP and EMP1 groups 5 days post s.c. transfer of the T cells. The analyses revealed 
that TMBP-EMP1 cells infiltrated deep into the CNS parenchyma. In contrast at this time 
point there were no significant TMBP-GFP cell infiltrates detectable (Figure 5. 41). Early 
migration of TMBP-EMP1 cells into CNS following sub-cutaneous transfer paralleled with 
the T cell specific gene expression in an inflamed CNS (Figure 5. 42). Gene 
expression was analysed by performing a quantitative PCR on total CNS from two 
groups of animals (n=3). These data confirm that TMBP-EMP1 cells arrive earlier at their 
target organ, most likely due to enhanced locomotion activity. 
 
 
 
Figure 5. 42 Encephalitogenic T cell migration coincides with expression of T cell 
specific genes in CNS post AT-EAE. 
Quantitative PCR was performed on total CNS of EAE animals 5 days post s.c. injection of 
TMBP-EMP1 (EMP1 Group) and TMBP-GFP (GFP Group) to quantify the expression of CD3, TXK, 
IFNγ, IL17 and IL4. Data is average of three animals in a group. 
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6. Discussion 
Multiple sclerosis is triggered by infiltration of brain antigen specific T lymphocytes into 
the CNS. The specific molecular determinants which control the migration of 
encephalitogenic T cell into the CNS remained unclear. Despite several microarray based 
gene profiling studies and considerable knowledge of EAE models and human MS, a 
global survey of gene expression of encephalitogenic T cells in EAE has been lacking. 
The aim of this PhD thesis was to perform a systematic transcriptomic analysis of 
encephalitogenic T cells in order to identify novel molecular factors that are crucial for 
CNS migration in EAE. 
 Adoptive transfer EAE in Lewis rat is a monophasic disease which follows a 
highly predictable disease course. Intriguingly, the onset of the disease occurs only after 
an obligatory latency of at least 3 days, irrespective of the number of autoreactive T cells 
injected (44). At the time of injection, encephalitogenic T cells are maximally activated 
and characterized by upregulation of activation markers such as IL2R, IFNγ and OX40 
antigen. Before migrating to target organ, they accumulate in the spleen, where 
aforementioned activation markers are downregulated. Instead, migratory molecules such 
as CCR1, CCR2, CCR3, CCR5, and CXCR4 are upregulated (44). Once in their target 
organ, these T cells are reactivated but keep their migratory molecules high. 
Nevertheless, the molecular and cellular mechanisms which guide migration of 
encephalitogenic T cells to CNS are largely unknown. 
 In this study, an oligonucleotide microarray was used to detect differentially 
regulated genes in encephalitogenic T cells in different milieus such as in vitro activated, 
in vitro resting, ex vivo spleen and ex vivo CNS (Figure 5. 1). Affymetrix Rat 230 Set 2.0, 
the oligonucleotide array used for analysis consisted of ~31000 transcripts, of which only 
a small percentage of ~5% underwent differential regulation (Table 5. 1). In this study, it 
was attempted to identify molecular changes at the transcriptomic level that are necessary 
to allow activated encephalitogenic T cells to migrate to the CNS and cause 
inflammation. An average linkage hierarchical cluster analysis of Tactivated, Tmigratory and 
Teffector transcriptome was performed to identify groups of genes that are co-regulated and 
to compare different T cell states in vivo. Transcriptomic analysis including cluster, gene 
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ontology and pathway-based analyses, in an unbiased manner, indicated inhibition of cell 
proliferation or cell cycle progression machinery in Tspleen, but induction of cell migration 
transcriptome (Figure 5. 6). In vitro-activated encephalitogenic T cell blasts, when 
compared to their resting state 7 days post stimulation, exhibited a strong upregulation of 
cell cycle genes. This cluster of cell cycle regulators included Cyclin E1 and Cyclin E2, 
proteins required for cell cycle progression from G1 phase to S phase, and Cyclin A2, 
Cyclin B1, Cyclin B2 and Cyclin F, proteins required for G2 phase to M phase transition. 
Also within the same upregulated cluster in Tactivated were genes involved in cell 
metabolism such as HMGCR, an enzyme involved in cholesterol biosynthesis, and other 
genes involved in DNA metabolism. At the same time, transcription regulators that 
inhibit cell cycle progression were downregulated suggesting a tightly controlled 
transcriptome for cell proliferation and cell metabolism during T cell activation. In 
contrast, effector T cells in CNS show activation but not cell cycle progression and 
proliferative response. All the cell cycle inhibiting transcription factors such as BTG2, 
KLF4 and TOB1 are upregulated and they keep expression of cell migration molecules 
such as CCR2, CCR5 and EDG1 high. There is a strong upregulation of activation 
markers such as IL2R and IFNγ. 
 Around 3 days post transfer of encephalitogenic T cells, a high number of cells 
accumulate in the spleen with a striking downregulation of activation markers such as 
IL2R, IFNγ and OX40 antigen (44). Studies extrapolating a direct molecular correlation 
of T cell activation and T cell migration are lacking. Chchlinska et al has shown that IL2 
deprivation inhibits cell cycle progression in lymphoblasts, and other independent studies 
reported upregulation of chemokine receptors upon IL2 deprivation in lymphocytes 
(61,71,72). Along the same line, the transcriptomic analysis of Tspleen vs Tblast also 
revealed upregulation of a large number of genes important for migratory signalling 
pathway and downregulation of cell cycle activating genes (Figure 5. 7, Figure 5. 11 and 
Figure 5. 12). One of the cardinal markers of activation, IL2R, whose stimulation 
activates ERK signalling subsequently inducing mitosis, was downregulated. At the same 
time, DUSP5, an inhibitor of ERK signalling was upregulated in the Tmigratory 
transcriptome. TXK, T cell specific kinase acting downstream of integrin receptor and 
chemokine receptor signalling was also upregulated more than 2 fold. Guanine nucleotide 
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exchange factors, such as ARHGEF18, ARHGEF3, the control switches for RhoGTPases 
which are essential for cell migration were upregulated. Furthermore, among this 
upregulated cluster, there were several molecules of the cell locomotion apparatus, such 
as ZYX and FHL2, and genes involved in cell migration such as CCR2, CCR7 and S1P1 
(Figure 5. 12).  
 Microarray-based studies of gene expression can be extremely informative 
because the high throughput technology allows the gathering of enormous amounts of 
information on gene regulation. At the same time, a large dataset needs effective 
databases and resources for management and analysis. One of the pitfalls of microarray 
based experiments is the occurrence of false positives and they very often demand 
validation by more reliable experiments such as real time PCR and antibody based 
methods to confirm regulation at the protein level. Although the number of regulated 
transcripts in microarray data reached only ~5% of total available transcripts, this sums 
up to approximately 1500 genes, which cannot be easily validated by qPCR. Hence, a list 
of 43 genes with defined functional impact on T cell biology was validated by qPCR. The 
comparison of the microarray and qPCR data showed a similar regulation pattern, 
although the magnitude of fold regulation was lower in the microarray (Figure 5. 14).  
 The comparative transcriptome analysis between highly proliferative activated T 
cells and migratory T cells demonstrates an inverse correlation between cell cycle and the 
cell migration pathways. Moreover, effector T cells in CNS display a unique functional 
state: they upregulate activation molecules but not factors controlling cell cycle 
progression. Furthermore, they maintain high levels of genes controlling migratory 
properties. In order to corroborate this finding, an approach was taken which combined 
bioinformatics with in vitro experimental assays such as cell cycle assays, quantitative 
PCR and luciferase assays.  In our transcriptome analysis, very often cell cycle genes and 
cell migration genes were found to be clustered and among them also were transcription 
factors known to inhibit cell cycle progression such as KLF4, BTG1, BTG2 and TOB1. 
All these transcription factors inhibit the cell cycle transition from the G1 phase to the S 
phase. Among the cell migration molecules that were found to be clustered were CCR1, 
CCR2, CCR3, CCR5 and CCR6. The upregulation of these inflammatory chemokine 
receptors in encephalitogenic effector T cells has been published earlier (44). 
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Furthermore, genes for inflammatory chemokine receptors such as CCR1, CCR2, CCR3 
and CCR5 were all clustered in the genome of both rat and mouse (Figure 5. 17).  
A bioinformatics approach was employed to identify a common cell cycle 
inhibiting transcription factor that would additionally be involved in the regulation of 
inflammatory chemokine receptor expression. KLF4, a zinc finger transcription factor, 
was identified using the web based transcription factor binding site prediction program 
Matinspector™ (Table 5. 9) (58). Upon overexpression, KLF4 not only inhibited the cell 
cycle progression in encephalitogenic T cells but also led to upregulation of CCR2 and 
CCR5 (Figure 5. 19 and Figure 5. 20). A similar regulatory activity of KLF4 was found 
in a rat leukaemia cell line (Figure 5. 21). Luciferase promoter assays further 
corroborated these findings (Figure 5. 22). These data indicate a transcriptional program 
which simultaneously regulates cell cycle as well as cell migration in effector T cells. 
Unfortunately, downregulation of the cell cycling proved to be a hindrance for the 
generation and expansion of encephalitogenic TMBP cells. Therefore, the function of 
KLF4 in effector T cells could not be tested during AT-EAE. Nevertheless, our in vitro 
results hint to a regulatory role of Krüppel-like factors in CD4+ lymphocyte migration.  
Interestingly, Sebzda et al recently showed that KLF2, a different member of the 
Krüppel-like family, might be involved in regulating the migration of naïve T cells by 
repressing chemokine receptor gene expression (73). KLF2 is a zinc finger transcription 
factor that inhibits cell proliferation by inhibiting G1/S phase progression of cell cycle. 
Several reports over the last few years have established a transcription regulation of 
migratory receptors by KLF2, for instance that, KLF2 upregulates expression of S1P1 
and CCR7 (73,74).  
 In a summary, a systematic transcriptomic analysis of activated T cells from in 
vitro and migratory encephalitogenic T cells from spleen reveal a link between cell cycle 
regulators and cell migration control. Moreover, these results provide a molecular 
explanation for prodromal period of EAE. The current results can be depicted in a model 
as shown in Figure 4.44 
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Figure 6. 1 Model illustrating the molecular changes taking place in encephalitogenic T 
cells from the time of injection until they reach their target organ. 
Upregulation is indicated by ascending triangle and downregulation by descending triangle. Time 
point days post transfer is indicated. 
 In an attempt to identify and test potential new therapeutic targets on 
autoaggressive effector T cells, a focus of the transcriptome analysis was put on 
differentially regulated membrane molecules. Intriguingly, members of regulated genes 
in migratory T cells included some of the well-known drug targets for multiple sclerosis 
such as integrin α4β1, S1P1, CCR2 and CCR6.  
Here the role of EMP1 was tested in T cell migration during EAE. EMP1 was 
chosen for the following reasons: i) EMP1 transcript was found upregulated in migratory 
Tspleen cells (Figure 4.29); ii) EMP1 is a 4-transmembrane protein belonging to a novel 
gene family and was originally isolated as a gene differentially expressed in brain 
tumours (63). Its role in T cells has not been characterized; iii) Other 4-transmembrane 
proteins such as CD9, CD81 and CD151 that were first cloned in screens relating to 
tumorigenesis, were found to promote cell migration by associating with integrins 
(64,65).  
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One of the striking features of the members of this family is the shared structural features 
of both tight junction proteins such as claudins and of tetraspanins such as CD151. 
Moreover, EMP1 has recently been reported to be a part of the blood brain barrier 
junction protein. Multiple sequence alignment of EMP1 protein sequences from different 
species showed certain conserved motifs such as the W-GLW-C-C and ITIM motifs 
(Figure 5. 23). The W-GLW-C-C motif is a characteristic feature of claudins that occurs 
in the first extracellular loop is considered to play a role in homophilic and heterophilic 
interactions. The occurrence of the ITIM motif in EMP1 is surprising, since normally 
ITIM is a conserved sequence of amino acids found in the cytoplasmic tails of many 
inhibitory receptors of the immune system. However, there are reports showing a role of 
ITIM in cell migration and motility (75,76). So far there has been only one report 
indicating the expression of EMP1 in T lymphocytes (77), however, our RNA and protein 
data clearly confirm its expression in T cells (Figure 5. 29). Although overexpression of 
EMP1 in a cancer cell line inhibits cell proliferation (69), there was no such effect on T 
cell proliferation (Figure 5. 34). Furthermore, encephalitogenic T cells overexpressing 
EMP1 exhibited similar cytokine production as that of control transduced T cells (Figure 
5. 32 and Figure 5. 33). However, EMP1 overexpression induced an increased motility of 
activated lymphocytes in a 3D matrigel motility assay. Activated T cells are barely motile 
when incubated with the matrigel but EMP1 T cells exhibited a highly motile behaviour 
(Figure 5. 35). In order to evaluate this phenotype, EMP1 overexpressing 
encephalitogenic T cells (TMBP-EMP1), were injected three different routes, i.e. 
intravenously, intraperitonealy and subcutaneously. It is well conceivable that the latter 
two milieus confront migrating T cells with distinct structural barriers before the effector 
T cells can enter their target organ via the blood circulation. Accordingly, the onset of 
clinical AT-EAE is significantly delayed if the T cells are applied s.c. and i.p. compared 
to i.v. (Figure 5. 36, Figure 5. 37and Figure 5. 38). Interestingly, EMP1 overexpression in 
effector T cells clearly accelerated the onset of disease when the T cells were transferred 
i.p. or s.c., but not after i.v. This could be explained by the early migration of EMP1 T 
cells from connective tissue to draining lymph nodes (Figure 5. 39) and hence their 
migration to blood circulation and subsequently early migration to the CNS.  
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 Further investigations using knockdown or knockout approaches could more 
clearly elucidate the function of EMP1 in T cell function. 
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Abbreviations 
ACK   Ammonium Chloride Potassium erythrocyte lysis buffer 
APC   Antigen presenting cells 
ARHGAP4  Rho GTPase activating protein 4 
ARHGEF18  Rho/Rac guanine nucleotide exchange factor 18 
ARHGEF3  Rho guanine nucleotide exchange factor  
AT-EAE  Adoptive transfer experimental auotimmune encephalomyelitis 
BBB   Blood-brain barrier 
BSA   Bovine serum albumin 
BTG1   B-cell translocation gene 1 
BTG2   B-cell translocation gene 2  
CCL2    CC-chemokine ligand 2 
CCL25  CC-chemokine ligand 25  
CCNA1  Cyclin A1 
CCNA2  Cyclin A2 
CCNB1  Cyclin B1 
CCNB2  Cyclin B2 
CCNE1  Cyclin E1 
CCNF   Cyclin F 
CCR1   CC-chemokine receptor 1 
CCR10  CC-chemokine receptor 10 
CCR2   CC-chemokine receptor 2 
CCR4   CC-chemokine receptor 4 
CCR5   CC-chemokine receptor 5 
CCR9   CC-chemokine receptor 9 
CD44   CD44 antigen 
CDC20  Cell division cycle 20 homolog  
CFA   Complete Freund's Adjuvant 
CKAP5  Cytoskeleton associated protein 5  
CNS   Central nervous system 
CXCL2  CXC-chemokine ligand 2 
CXCR3  CXC-chemokine receptor 3  
CYP51  Cytochrome P450, family 51 
DAAM1  Dishevelled associated activator of morphogenesis 1 
DMEM  Dulbecco’s Modified Eagle’s Medium 
DUSP5  Dual specificity phosphatase 5  
DUT   Deoxyuridine triphosphatase  
EAE   Experimental autoimmune encephalomyelitis 
EH   Eagle's HEPES medium 
EL1   Extracellular loop 1 
EL2   Extracellular loop 2 
ELISA   Enzyme linked immunosorbent assay 
EMP1   Epithelial membrane protein 1 
EMP2   Epithelial membrane protein 2 
Abbreviations 
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EMP3   Epithelial membrane protein 3 
ERK2   Mitogen-activated protein kinase 2  
FACS   Fluorescent activated cell sorting 
FHL2   Four and a half LIM domains 2 
FOXP3  Forkhead box P3 
GenMAPP  Gene map annotator and pathway profiler 
GLIPR1  GLI pathogenesis-related 1  
GM   Grey matter of CNS 
GNAI Guanine nucleotide binding protein alpha inhibiting activity 
polypeptide 1 
GO   Gene Ontology 
HBS   HEPES-buffered saline  
HCl   Hydrochloric acid 
HMGCR  3-hydroxy-3-methylglutaryl-Coenzyme A reductase 
HXM   Hypoxanthine xanthine mycophenolic acid medium 
i.e.   that is 
i.p.   intra peritoneum 
i.v.   intra venous 
IF    Immunofluorescence 
IFNγ   Interferon γ 
IGSF6   Immunoglobulin superfamily, member 6 
IH   Immunohistochemistry 
IL10   Interleukin 10 
IL17F   Interleukin 17F 
IL2R   Interleukin 2 receptor 
IL4   Interleukin 4 
IP   Immunoprecipitation 
ITGβ1   Integrin β1 
ITGβ7   Integrin β7  
KLF10   Krüppel-like factor 10 
KLF2   Krüppel-like factor 2 
KLF4   Krüppel-like factor 4 
KLF9   Krüppel-like factor 9 
KLRD1  Killer cell lectin-like receptor subfamily D, member 1 
LATS1  Large tumour suppressor, homolog 1  
mAb   Monoclonal antibody 
MAdCAM1  Mucosal addressin cell adhesion molecule 1 
MBP   Myelin basic protein 
MCM4  Minichromosome maintenance complex component 4 
MCM6  Minichromosome maintenance complex component 6 
MCM7  Minichromosome maintenance complex component 7 
MHC   Major histocompatibility complex 
MRI   Magnetic resonance imaging 
MS   Multiple sclerosis 
MSA   Multiple sequence alignment 
MYC   Myelocytomatosis viral oncogene homolog  
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NRP1   Neuropilin 1 
OVA   Ovalbumin 
p.i.   post immunization 
PAGE   Poly acrylamide gel electrophoresis 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PFA   Paraformaldehyde 
PLAUR  Plasminogen activator, urokinase receptor  
PLEK   Pleckstrin 
PLSCR1  Phospholipid scramblase 1 
PMP22  Peripheral myelin protein 22  
PMVK   Phosphomevalonate kinase 
PPMS   Primary progressive multiple sclerosis 
PRMS   Progressive relapsing multiple sclerosis 
q.s.   quantum sufficit  
qPCR    Quantitative polymerase chain reaction 
RAB34  Member RAS oncogene family RAB34 
RBL1   Rat basophilic leukemia cell line 1 
RM   Restimulation medium 
RORγ   RAR-related orphan receptor γ 
RRMS   Remitting relapsing multiple sclerosis 
s.c.   sub-cutaneous 
S100A4  S100 calcium binding protein A4 
S100A9  S100 calcium binding protein A9 
SDS   Sodium dodecyl sulphate 
SELE   Selectin E 
SELL   Selectin L 
SELP   Selectin P 
SLC16A1  Solute carrier family 16, member 1 
SLC7A1  Solute carrier family 7, member 1 
SPMS   Secondary progressive multiple sclerosis 
SYTL1  Synaptotagmin-like 1 
TBET   T-box expressed in T cells  
TCGF   T cell growth factor 
TCM   T cell medium 
TFBS   Transcription factor binding sites 
TFRC   Transferrin receptor 
TJP1   Tight junction protein 1  
TMP   Tumour membrane protein 1 
TNFRSF1B  Tumour necrosis factor receptor superfamily, member 1B 
TNFα   Tumour necrosis factor α 
TOB1   Transducer of ERBB2, 1  
TSS   Trascription start site 
TXK   T cell-specific non- receptor TXK tyrosine kinases  
VCAM1  Vascular cell adhesion molecule 1  
VCL   Vinculin 
Abbreviations 
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WB   Western blot 
WM   White matter of the CNS 
ZYX   Zyxin 
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Appendix 1. 
List of genes differentially regulated in Tactivated state. 
Gene Symbol Tactivated Biological Process 
Abca2 0.51 Transport  
Abca7 0.54 Transport  
Abcg1 0.44 Transport, Lipid transport  
Abtb1 0.49 Metabolism, Protein metabolism  
Aff4 0.43 Metabolism, nucleotide and nucleic acid metabolism 
Agpat3 0.52 Metabolism  
Ahnak 0.36 Cell growth, cell differentiation, Muscle contraction  
Akap8l 0.38 Metabolism, nucleotide and nucleic acid metabolism 
Amigo 0.52 Cell adhesion 
Apbb1ip 0.45 Cell communication  
Apoe 0.43 Transport  
Arhgap4 0.43 Cell communication  
Arhgap9 0.49 Cell communication  
Arhgef1 0.47 Cell communication  
Arhgef18 0.43 Cell communication  
Arid4a 0.52 Metabolism, nucleotide and nucleic acid metabolism 
Arid5a 0.45 Metabolism, nucleotide and nucleic acid metabolism 
Asb2 0.27 Cell communication  
Ash1l 0.51 Metabolism, nucleotide and nucleic acid metabolism 
Atg16l1 0.54 Transport  
Atp2a3 0.51 Transport, Ion transport 
Atp2b1 0.55 Transport  
B2m 0.44 Immune response  
B3galt4 0.54 Metabolism, Protein metabolism  
Bcl11b 0.34 Metabolism, nucleotide and nucleic acid metabolism 
Bcl6 0.54 Apoptosis  
Bcl9l 0.42 Biological process unknown  
Bet1l 0.53 Transport  
Bin2 0.53 Cell communication  
Btg1 0.40 Cell growth and/or maintenance 
Btg2 0.46 Metabolism, nucleotide and nucleic acid metabolism 
C1qr1 0.42 Cell adhesion 
Calca 0.49 Metabolism, Regulation of physiological process  
Calcoco1 0.33 Metabolism, nucleotide and nucleic acid metabolism 
Card11 0.54 Apoptosis  
Cbx7 0.43 Metabolism, nucleotide and nucleic acid metabolism 
Ccl3 0.22 Immune response  
Ccl5 0.07 Cell communication  
Ccnl2 0.49 Metabolism, nucleotide and nucleic acid metabolism 
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Ccnt2 0.54 Metabolism, nucleotide and nucleic acid metabolism 
Ccpg1 0.33 Biological process unknown  
Ccr2 0.38 Cell communication  
Ccr3 0.31 signal transduction,  
Ccr5 0.14 Cell communication  
Ccr6 0.35 Cell communication  
Cd2 0.34 Immune response  
Cd37 0.49 Immune response  
Cd38 0.50 Metabolism  
Cd3d 0.53 Immune response  
Cd4 0.47 Immune response  
Cd44 0.35 Cell communication  
Cd5 0.52 Immune response  
Cd53 0.54 Immune response  
Cd69 0.37 Immune response  
Cd97 0.51 Cell communication  
Cdc2l6 0.54 Cell communication  
Cdc42ep3 0.39 Cell communication  
Cdkn1b 0.44 Cell communication  
Centd1 0.50 Cell communication  
Cerk 0.38 Cell communication  
Chd3 0.42 Metabolism, nucleotide and nucleic acid metabolism 
Ches1 0.55 Cell communication  
Chsy1 0.46 Metabolism  
Churc1 0.50 Metabolism, nucleotide and nucleic acid metabolism 
Cish 0.46 Cell communication  
Cited2 0.53 Metabolism, nucleotide and nucleic acid metabolism 
Ckb 0.33 Metabolism  
Cklf 0.51 Immune response, Inflammatory response  
Clk1 0.42 Signal transduction  
Clk4 0.47 Cell communication  
Coq6 0.46 Metabolism  
Cox7a2l 0.47 Metabolism  
Cpd 0.20 Metabolism, Protein metabolism  
Cpe 0.42 Metabolism, Protein metabolism  
Cpeb2 0.36 Metabolism, nucleotide and nucleic acid metabolism  
Cpt1a 0.51 Transport, Mitochondrial transport 
Crebl2 0.51 Metabolism, nucleotide and nucleic acid metabolism 
Crot 0.49 Metabolism  
Cst3 0.46 Metabolism, Protein metabolism  
Ctnnd2 0.54 Cell communication  
Ctse 0.34 Metabolism, Protein metabolism  
Ctss 0.42 Metabolism, Protein metabolism  
Ctsw 0.25 Metabolism, Protein metabolism  
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Cxcr3 0.32 Cell communication  
Cyb561d1 0.54 Biological process unknown  
Daam1 0.34 Cell communication  
Dap 0.48 Apoptosis  
Dbp 0.19 Metabolism, nucleotide and nucleic acid metabolism 
Ddx17 0.54 Metabolism, nucleotide and nucleic acid metabolism 
Dgka 0.39 Cell communication  
Dhrs3 0.55 Metabolism  
Dnajb9 0.35 Metabolism, Protein metabolism  
Dok2 0.36 Signal transduction  
Dpp7 0.32 Metabolism, Protein metabolism  
Dusp16 0.54 Cell communication  
Dusp2 0.28 Cell communication  
Dyrk2 0.53 Cell communication  
Ech1 0.55 Metabolism  
Edg1 0.42 Cell communication  
Eef2k 0.48 Metabolism, Protein metabolism  
Egr1 0.45 Metabolism, nucleotide and nucleic acid metabolism 
Emp1 0.45 Cell growth and/or maintenance 
Evl 0.20 Cell growth and/or maintenance 
Eya2 0.48 Apoptosis  
Ezh1 0.44 Metabolism, nucleotide and nucleic acid metabolism 
F2r 0.43 Cell communication  
Farp1 0.51 Cell growth and/or maintenance 
Fbxl11 0.54 Metabolism, Protein metabolism  
Fbxl17 0.45 Metabolism, Protein metabolism  
Fbxl3 0.45 Metabolism, Protein metabolism  
Fbxo11 0.51 Metabolism, Protein metabolism  
Fgl2 0.35 Cell growth and/or maintenance 
Flcn 0.54 Biological process unknown  
Fli1 0.49 Metabolism, nucleotide and nucleic acid metabolism 
Fnbp1 0.53 Biological process unknown  
Fos 0.45 Metabolism, nucleotide and nucleic acid metabolism 
Foxo1a 0.49 Metabolism, nucleotide and nucleic acid metabolism 
Fut8 0.53 Metabolism  
Fxyd5 0.52 Transport, Ion transport, Regulation of cellular process  
Fyco1 0.53 Cell communication  
Fyn  0.46 Cell communication  
Gabbr1 0.36 Cell communication  
Gbp2 0.48 Cell communication  
Gda 0.34 Metabolism  
Gdi1 0.40 Cell communication  
Ggt1 0.54 Metabolism  
Gimap5 0.48 Apoptosis  
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Gimap6 0.54 Signal transduction  
Gimap7 0.32 Cell communication  
Git2 0.51 Cell communication  
Glipr1 0.34 Immune response  
Gmfg 0.35 Cell communication  
Gns 0.49 Metabolism  
Gpsm3 0.44 Cell communication  
Grina 0.44 Signal transduction  
Gsn 0.19 Cell growth and/or maintenance 
Hbp1 0.38 Metabolism, nucleotide and nucleic acid metabolism 
Hcst 0.18 Cell communication  
Hip1 0.52 Cell growth and/or maintenance 
Hpse 0.32 Metabolism  
Id2 0.20 Metabolism, nucleotide and nucleic acid metabolism 
Ifi44 0.55 Biological process unknown  
Il16 0.37 Immune response  
Il17re 0.51 Signal transduction  
Inpp4a 0.55 Metabolism  
Irak2 0.38 Cell communication  
Irf1 0.41 Metabolism, nucleotide and nucleic acid metabolism 
Irf3 0.45 Metabolism, nucleotide and nucleic acid metabolism 
Itgb1 0.38 Cell communication  
Itgb2 0.41 Cell communication  
Itgb7 0.44 Cell communication  
Itm2b 0.53 Cell growth and/or maintenance 
Itm2c 0.30 Biological process unknown  
Klf10 0.55 cell growth  
Klf3 0.51 Metabolism, nucleotide and nucleic acid metabolism 
Klf9 0.43 Metabolism, nucleotide and nucleic acid metabolism 
Kpna1 0.52 Transport  
Lamp1 0.48 Biological process unknown  
Laptm5 0.42 Cell communication  
Lasp1 0.51 Signal transduction  
Lcp2 0.54 Cell communication  
Leprot 0.55 Biological process unknown  
Lgals3bp 0.21 Immune response  
Lgals8 0.43 Signal transduction  
Lmbr1l 0.49 Cell communication  
Lmbrd1 0.53 Biological process unknown  
Lrp10 0.52 Biological process unknown  
Ltb 0.28 Immune response, Inflammatory response  
Maf 0.25 Regulation of gene expression, epigenetic 
Mll 0.52 Metabolism, nucleotide and nucleic acid metabolism 
Mll5 0.50 cell growth  
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Gene Symbol Tactivated Biological Process 
Mmp13 0.18 Metabolism, Protein metabolism  
Mmp9 0.44 Metabolism, Protein metabolism  
Mx1 0.29 Cell communication  
Myadm 0.41 Biological process unknown  
Myd88 0.51 Cell communication  
Myo1d 0.55 Cell growth and/or maintenance 
Nbr1 0.50 Cell communication  
Ncor1 0.48 Metabolism, nucleotide and nucleic acid metabolism 
Ndrg4 0.43 Biological process unknown, Cell differentiation  
Nedd9 0.53 Cell communication  
Nfe2l2 0.52 Metabolism, nucleotide and nucleic acid metabolism 
Nr1d1 0.19 Cell communication  
Nr1d2 0.54 Metabolism, nucleotide and nucleic acid metabolism 
Nr1h2 0.54 Cell communication  
Ogt 0.48 Metabolism, Protein metabolism  
Olfm1 0.46 Biological process unknown  
Optn 0.50 Metabolism, nucleotide and nucleic acid metabolism 
Otud5 0.51 Metabolism, Protein metabolism  
Pacs1 0.51 Transport  
Pbxip1 0.36 Metabolism, nucleotide and nucleic acid metabolism 
Pcaf 0.52 Metabolism, nucleotide and nucleic acid metabolism 
Pctk2 0.47 Cell communication  
Pdcd4 0.48 Apoptosis  
Pde3b 0.38 Metabolism  
Pde4b 0.31 Signal transduction  
Phf1 0.36 Metabolism, nucleotide and nucleic acid metabolism 
Picalm 0.52 Transport, Regulation of endocytosis  
Pip5k1c 0.45 Cell communication  
Pitpnm1 0.35 Metabolism, Lipid metabolism  
Pkn1 0.49 Cell communication  
Plekha3 0.55 Cell communication  
Pnrc1 0.42 Biological process unknown  
Pon2 0.54 Metabolism, Lipid metabolism  
Ppp1r9b 0.49 Cell communication  
Ppt1 0.46 Metabolism  
Prei3 0.52 Biological process unknown  
Prf1 0.49 Transport  
Prkd2 0.52 Cell communication  
Prnp 0.41 Metabolism  
Psap 0.49 Cell communication  
Ptpn18 0.49 Cell communication  
Ptprc 0.45 Cell communication  
Ptpre 0.47 Cell communication  
Pycard 0.33 Apoptosis  
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Rab24 0.53 Cell communication  
Rab2b 0.54 Cell communication  
Rab7l1 0.44 Cell communication  
Rabac1 0.44 Transport  
Ramp1 0.25 Cell communication  
Ramp3 0.52 Cell communication  
Rasa3 0.42 Cell communication  
Rasgrp1 0.53 Cell communication  
Rbm5 0.46 Metabolism, nucleotide and nucleic acid metabolism 
Rgs2 0.39 Cell communication  
Rhoh 0.49 Cell communication  
Ric8a 0.50 Cell communication  
Rnf146 0.51 Metabolism, Protein metabolism  
Rnf44 0.47 Metabolism, Protein metabolism  
Rps6ka1 0.52 Cell communication  
Runx1 0.49 Metabolism, nucleotide and nucleic acid metabolism 
S100a4 0.41 Cell growth and/or maintenance 
S100a6 0.28 Cell communication  
Sdc1 0.40 Cell communication  
Sema4a 0.41 Cell communication  
Serinc1 0.42 Biological process unknown  
Serinc3 0.52 Biological process unknown  
Sf3b1 0.39 Metabolism, nucleotide and nucleic acid metabolism 
Sfrs5 0.52 Metabolism, nucleotide and nucleic acid metabolism 
Sh3bp5 0.53 Signal transduction  
Sh3kbp1 0.50 Signal transduction  
Sirt2 0.53 Cell communication  
Sla  0.51 Cell communication  
Slc12a6 0.55 Transport  
Slc2a3 0.51 Transport  
Slc4a7 0.55 Transport  
Slc6a6 0.54 Transport  
Slco4a1 0.52 Transport  
Smad4 0.50 Metabolism, nucleotide and nucleic acid metabolism 
Smpd1 0.47 Signal transduction  
Smpdl3a 0.43 Metabolism  
Snapap 0.49 Transport  
Sos2 0.52 Cell communication  
Sqstm1 0.47 Metabolism, Protein metabolism  
Ssbp3 0.37 Metabolism, DNA metabolism 
Sstr3 0.32 Cell communication  
Stat1 0.48 Metabolism, nucleotide and nucleic acid metabolism 
Stat3 0.48 Metabolism, nucleotide and nucleic acid metabolism 
Stk10 0.44 Cell communication  
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Gene Symbol Tactivated Biological Process 
Stk17b 0.43 Cell communication  
Stom 0.54 Cell communication  
Stxbp3 0.52 Transport  
Sv2b 0.34 Transport  
Sytl1 0.47 Transport, Vesicle docking  
Tacc2 0.42 Cell growth and/or maintenance 
Tapbp 0.54 Protein folding 
Tcp11l2 0.18 Biological process unknown  
Tegt 0.52 Apoptosis  
Tgoln2 0.46 Transport  
Tle4 0.54 Metabolism, nucleotide and nucleic acid metabolism 
Tloc1 0.47 Metabolism, Protein metabolism  
Tmem106b 0.51 Biological process unknown  
Tmem49 0.38 Apoptosis  
Tnfaip8l2 0.54 Biological process unknown  
Tnfrsf1b 0.50 Cell communication  
Tor1aip1 0.47 Biological process unknown  
Tpp1 0.46 Metabolism, Protein metabolism  
Tpst2 0.44 Energy pathways  
Tsc22d3 0.49 Regulation of gene expression, epigenetic 
Txnip 0.18 Cell communication  
Ubl3 0.38 Metabolism, Protein metabolism  
Wasl 0.52 Cell growth and/or maintenance 
Wdr23 0.48 Biological process unknown  
Xdh 0.39 Metabolism  
Xylt2 0.49 Metabolism  
Ypel5 0.35 Biological process unknown  
Zap70 0.54 Cell communication  
Zbp1 0.31 Metabolism, nucleotide and nucleic acid metabolism 
Zfand3 0.41 Metabolism, nucleotide and nucleic acid metabolism 
Zfp36 0.43 Metabolism, nucleotide and nucleic acid metabolism 
Zfp36l1 0.34 Metabolism, nucleotide and nucleic acid metabolism 
Zfp36l2 0.41 Metabolism, nucleotide and nucleic acid metabolism 
Znf292 0.44 Transcription  
Znrf1 0.49 Metabolism, Protein metabolism  
Zyx 0.38 Signal transduction  
Aaas 2.84 Cell communication  
Aatf 2.32 Apoptosis  
Abce1 2.47 Transport  
Acaca 2.60 Metabolism  
Acat2 4.07 Metabolism  
Acly 2.48 Metabolism  
Acsl3 2.15 Metabolims, Fatty acid metabolism 
Acy1 2.69 Metabolism  
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Gene Symbol Tactivated Biological Process 
Adam8 1.97 Metabolism, Protein metabolism  
Adk 3.23 Metabolism, nucleotide and nucleic acid metabolism 
Adsl 2.08 Metabolism  
Ahcy 4.53 Metabolism  
Ak2 3.00 Metabolism  
Aldh7a1 3.22 Metabolism  
Aloxe3 5.09 Metabolism  
Anapc5 2.30 Cell communication  
Anp32b 2.41 Biological process unknown  
Anp32e 2.04 Biological process unknown  
Anxa7 2.05 Transport  
Ap1s1 1.97 Transport  
Apex1 3.60 Metabolism, nucleotide and nucleic acid metabolism 
Appbp1 1.97 Cell communication  
Asf1a 2.13 Metabolism, Protein metabolism  
Asf1b 8.08 Metabolism, Protein metabolism  
Ash2l 2.19 Metabolism, nucleotide and nucleic acid metabolism 
Asns 3.02 Metabolism, Protein metabolism  
Aspm 5.31 Biological process unknown  
Atad3a 2.30 Metabolism  
Atp5b 2.46 Metabolism  
Aurka 4.70 Cell communication  
Aurkb 2.67 Cell communication  
Banf1 2.41 Biological process unknown  
Bcat1 3.86 Metabolism  
Bcs1l 2.12 Metabolism  
Bex1 2.21 Biological process unknown  
Birc5 3.78 Cell communication  
Blm 4.45 Metabolism, nucleotide and nucleic acid metabolism 
Bop1 2.56 Biological process unknown   
Bpnt1 2.34 Cell communication  
Bspry 3.39 Biological process unknown   
Bub1 9.65 Cell communication  
Bub1b 7.18 Cell communication  
Bxdc1 2.88 Biological process unknown  
Bxdc2 2.33 Biological process unknown  
Bysl 2.12 Cell growth and/or maintenance 
Bzw2 2.07 Metabolism, Protein metabolism  
C1qbp 3.33 Immune response  
Cacybp 3.32 Metabolism, Protein metabolism  
Cad 3.03 Metabolism  
Cand1 2.00 Metabolism, nucleotide and nucleic acid metabolism 
Cars 2.96 Metabolism  
Casp4 2.35 Apoptosis  
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Cbr1 1.96 Metabolism  
Cbx5 2.47 Metabolism, nucleotide and nucleic acid metabolism 
Ccdc5 2.54 Cell growth and/or maintenance 
Ccl2 1.98 Immune response  
Ccna2 13.85 Cell communication  
Ccnb1 10.06 Cell communication  
Ccnb2 8.44 Cell communication  
Ccne1 2.60 Cell communication  
Ccne2 2.15 Cell cycle  
Ccnf 2.52 Cell communication  
Cct2 2.35 Metabolism, Protein metabolism  
Cct4 2.17 Metabolism, Protein metabolism  
Cct5 2.33 Metabolism, Protein metabolism  
Cct7 2.07 Protein folding  
Cct8 3.38 Metabolism, Protein metabolism  
Cd200 2.20 Immune response  
Cd74 2.04 Immune response  
Cdc20 6.08 Cell cycle  
Cdca2 4.12 Biological process unknown  
Cdca4 2.00 Cell division, fate commitment  
Cdca7 4.95 Metabolism, nucleotide and nucleic acid metabolism 
Cdca8 6.33 Cell communication  
Cdkn1a 3.20 Cell cycle  
Cenpe 2.18 Metabolism, nucleotide and nucleic acid metabolism 
Chchd6 2.63 Biological process unknown  
Chek1 5.79 Cell communication  
Chtf18 2.41 Metabolism, nucleotide and nucleic acid metabolism 
Cit 2.47 Cell communication  
Ckap2 5.44 Cell growth and/or maintenance  
Ckap5 1.97 Cell cycle, Mitosis  
Clic4 2.05 Transport  
Clspn 2.32 Cell communication  
Cndp2 1.99 Metabolism, Protein metabolism  
Cops5 2.17 Metabolism, Protein metabolism  
Creld2 2.05 Cell communication  
Csda 2.45 Metabolism, nucleotide and nucleic acid metabolism 
Cse1l 1.99 Transport  
Csrp1 2.07 Cell communication  
Ctps 4.16 Metabolism  
Ctsz 1.95 Metabolism, Protein metabolism  
Cyb5b 2.52 Transport  
Cyc1 2.44 Metabolism  
Cycs 2.84 Metabolism  
Dars 2.22 Metabolism  
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Dazap1 2.29 Metabolism, nucleotide and nucleic acid metabolism 
Dbi 3.06 Metabolism  
Dcps 1.99 Metabolism  
Ddx1 2.43 Metabolism, nucleotide and nucleic acid metabolism 
Ddx11 2.69 Metabolism, nucleotide and nucleic acid metabolism 
Ddx18 2.00 Transport  
Ddx39 2.30 Metabolism, nucleotide and nucleic acid metabolism 
Ddx56 2.27 Metabolism, nucleotide and nucleic acid metabolism 
Depdc1b 2.93 Biological process unknown  
Dhcr24 2.62 Metabolism  
Dhcr7 3.31 Metabolism  
Dhfr 3.12 Metabolism, nucleotide and nucleic acid metabolism 
Dkc1 2.25 Metabolism, nucleotide and nucleic acid metabolism 
Dlg7 5.04 Cell cycle  
Dnajc9 2.56 Metabolism, Protein metabolism  
Dnd1 2.53 Metabolism, nucleotide and nucleic acid metabolism 
Dnmt1 3.42 Metabolism, nucleotide and nucleic acid metabolism 
Dph5 2.49 Biological process unknown  
Drg1 2.43 Cell growth and/or maintenance 
Dut 4.72 DNA replication 
E2f8 3.04 Cell cycle  
Ebna1bp2 3.71 Biological process unknown  
Echdc1 2.49 Biological process unknown  
Ect2 8.63 Cell communication  
Eef1d 2.01 Cell communication  
Eftud2 2.10 Metabolism, Protein metabolism  
Eif2a 2.68 Metabolism, Protein metabolism  
Eif2b3 2.54 Metabolism, Protein metabolism  
Eif2s1 2.33 Metabolism, Protein metabolism  
Eif2s2 2.49 Metabolism, Protein metabolism  
Eif3s6ip 2.55 Metabolism, Protein metabolism  
Eif3s7 2.14 Metabolism, Protein metabolism  
Eif3s8 2.41 Metabolism, Protein metabolism  
Eif3s9 2.42 Metabolism, Protein metabolism  
Eif4a1 2.55 Metabolism, Protein metabolism  
Eif4ebp1 2.18 Metabolism, Protein metabolism  
Eif5a 2.48 Metabolism, Protein metabolism  
Elovl6 2.45 Biological process unknown  
Emg1 3.42 Metabolism, Protein metabolism  
Eprs 2.53 Metabolism, Protein metabolism  
Erp29 1.97 Protein folding 
Esd 2.53 Metabolism  
Espl1 9.86 Metabolism, Protein metabolism  
Etf1 2.11 Metabolism, Protein metabolism  
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Ets1 0.55 Metabolism, nucleotide and nucleic acid metabolism 
Exo1 4.14 Metabolism, nucleotide and nucleic acid metabolism 
Exosc7 2.81 Metabolism, nucleotide and nucleic acid metabolism 
Exosc8 2.74 Metabolism, nucleotide and nucleic acid metabolism 
Fabp5 27.18 Transport  
Fads1 2.10 Metabolism  
Fancd2 4.00 Cell communication  
Fasn 3.65 Metabolism  
Fbl 3.76 Metabolism, nucleotide and nucleic acid metabolism 
Fbxo5 2.22 Cell communication  
Fdft1 3.61 Metabolism  
Fdps 5.10 Metabolism  
Fen1 4.01 Metabolism, nucleotide and nucleic acid metabolism 
Fkbp11 2.03 Metabolism  
Fkbp3 2.64 Metabolism  
Fkbp4 3.02 Metabolism  
Foxm1 2.24 Metabolism, nucleotide and nucleic acid metabolism 
Foxq1 2.01 Metabolism, nucleotide and nucleic acid metabolism 
Ftsj3 2.01 Biological process unknown  
Fubp1 1.97 Metabolism, nucleotide and nucleic acid metabolism 
Fxc1 2.28 Transport  
Fxn 2.54 Transport  
Fzr1 2.08 Cell communication  
Galk1 3.59 Metabolism  
Gars 2.91 Metabolism, Protein metabolism  
Gart 2.40 Metabolism, nucleotide and nucleic acid metabolism 
Gcsh 6.03 Metabolism  
Gfer 2.39 Cell communication  
Gmps 2.84 Metabolism  
Gnai1 2.76 Cell communication  
Gnl3 2.60 Cell cycle, Regulation of cell proliferation  
Gpd2 2.48 Metabolism  
Gpr19 2.32 Cell communication  
Gzmb 2.00 Metabolism, Protein metabolism  
Hat1 4.03 Metabolism  
Hdgf 2.54 Cell communication  
Hey1 2.43 Metabolism, nucleotide and nucleic acid metabolism 
Hirip3 3.33 Metabolism, nucleotide and nucleic acid metabolism 
Hmga1 2.21 Metabolism, nucleotide and nucleic acid metabolism 
Hmgcr 2.23 Metabolism  
Hmgcs1 4.85 Metabolism  
Hmgn1 3.66 Metabolism, nucleotide and nucleic acid metabolism 
Hmgn2 3.69 Metabolism, nucleotide and nucleic acid metabolism 
Hmgn3 2.39 Metabolism, nucleotide and nucleic acid metabolism 
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Hmmr 4.82 Cell communication  
Hnrpa1 3.73 Metabolism, nucleotide and nucleic acid metabolism 
Hnrpab 2.22 Metabolism, nucleotide and nucleic acid metabolism 
Hnrpm 2.13 Metabolism, nucleotide and nucleic acid metabolism 
Hsd17b12 3.31 Metabolism  
Hspa14 2.44 Biological process unknown  
Hspd1 3.54 Protein folding  
Hspe1 4.00 Metabolism, Protein metabolism  
Hsph1 2.22 Metabolism, Protein metabolism  
Idi1 6.70 Metabolism  
Ift74 2.01 Cell growth and/or maintenance 
Il17f 5.58 Immune response  
Ilf2 3.37 Metabolism, nucleotide and nucleic acid metabolism 
Impdh2 2.98 Metabolism  
Insig1 2.35 Metabolism, Lipid metabolism 
Josd3 2.17 Cell cycle  
Kdr 4.01 Cell communication  
Kif11 4.72 Cell growth and/or maintenance  
Kif15 7.22 Cell communication  
Kif22 8.07 Metabolism, nucleotide and nucleic acid metabolism 
Kif2c 5.31 Cell growth and/or maintenance  
Kpna2 4.76 Cell communication  
Kpnb1 2.73 Transport  
Lgals3 2.12 Metabolism, nucleotide and nucleic acid metabolism 
Lig1 3.86 Metabolism, nucleotide and nucleic acid metabolism 
Lmna 2.61 Cell growth and/or maintenance 
Lmnb1 3.36 Cell growth and/or maintenance  
Lrrc59 2.59 Biological process unknown  
Ltv1 2.61 Biological process unknown  
Mad2l2 2.10 Cell cycle  
Mccc2 2.09 Metabolism  
Mcm4 4.36 Metabolism, nucleotide and nucleic acid metabolism 
Mcm6 4.49 Metabolism, nucleotide and nucleic acid metabolism 
Mcm7 6.68 DNA replication 
Mesdc1 2.24 Biological process unknown  
Mki67ip 2.09 Metabolism, nucleotide and nucleic acid metabolism 
Mrpl12 3.07 Metabolism, nucleotide and nucleic acid metabolism 
Mrpl17 1.99 Metabolism, Protein metabolism  
Mrpl19 2.01 Metabolism, Protein metabolism  
Mrpl23 2.26 Metabolism, Protein metabolism  
Mrpl37 2.18 Metabolism, Protein metabolism  
Mrpl38 2.51 Metabolism, Protein metabolism  
Mrpl47 2.03 Metabolism, Protein metabolism  
Mrpl49 1.95 Metabolism, Protein metabolism  
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Mrps15 2.03 Metabolism, Protein metabolism  
Mrps18b 2.49 Metabolism, Protein metabolism  
Mrps25 2.02 Metabolism, Protein metabolism  
Msh2 2.07 Metabolism, nucleotide and nucleic acid metabolism 
Mt1a 2.74 Metabolism  
Mthfd1 5.31 Metabolism  
Mvd 4.12 Metabolism  
Mybbp1a 3.12 Metabolism, nucleotide and nucleic acid metabolism 
Myc 2.81 Metabolism, nucleotide and nucleic acid metabolism 
Myo1g 2.49 Cell growth and/or maintenance 
Nap1l1 2.34 Metabolism, nucleotide and nucleic acid metabolism 
Nars 2.67 Metabolism, Protein metabolism  
Nasp 4.98 Cell cycle  
Ncl 2.32 Metabolism, nucleotide and nucleic acid metabolism 
Ndufa11 2.11 Metabolism  
Nedd4 2.50 Metabolism, Protein metabolism  
Net1 4.38 Cell communication  
Nfil3 2.01 Metabolism, nucleotide and nucleic acid metabolism 
Nkg7 5.34 Biological process unknown  
Nme1 2.48 Metabolism  
Nme2 4.28 Signal transduction  
Nol5a 3.45 Metabolism, nucleotide and nucleic acid metabolism 
Nolc1 4.13 Metabolism, nucleotide and nucleic acid metabolism 
Npm1 2.23 Metabolism, Protein metabolism  
Nrm 1.96 Biological process unknown  
Nsdhl 2.20 Metabolism  
Nudc 3.48 Cell communication  
Nup107 2.34 Transport  
Nup155 3.24 Transport  
Nup35 2.38 Transport  
Nup88 2.13 Transport  
Nup93 3.37 Transport  
Oat 2.68 Metabolism  
Odc1 3.63 Metabolism  
Oprs1 2.09 Cell communication  
Orc6l 2.77 Metabolism, nucleotide and nucleic acid metabolism 
Pa2g4 4.01 Metabolism, nucleotide and nucleic acid metabolism 
Pabpc4 3.38 Metabolism, nucleotide and nucleic acid metabolism 
Paics 2.78 Metabolism  
Pbef1 2.35 Anti-apoptosis  
Pcca 2.74 Metabolism  
Pcna 3.32 DNA repair  
Pebp1 2.00 Cell communication  
Pfkp 1.95 Metabolism  
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Pgd 2.02 Metabolism  
Phb 3.40 Cell communication  
Phb2 2.29 Metabolism, nucleotide and nucleic acid metabolism 
Phgdh 5.03 Metabolism  
Pi4k2b 2.01 Cell communication  
Plk1 5.11 Cell communication  
Plscr1 2.93 Cell communication  
Pmvk 2.13 Metabolism  
Pola1 3.43 Metabolism, nucleotide and nucleic acid metabolism 
Pola2 3.44 Metabolism, nucleotide and nucleic acid metabolism 
Pold1 4.42 Metabolism, nucleotide and nucleic acid metabolism 
Pold2 2.50 Metabolism, nucleotide and nucleic acid metabolism 
Pole 2.93 Metabolism, nucleotide and nucleic acid metabolism 
Pole3 2.43 Metabolism, nucleotide and nucleic acid metabolism 
Polr2f 2.53 Metabolism, nucleotide and nucleic acid metabolism 
Ppat 1.98 Metabolism  
Ppid 2.55 Metabolism  
Ppp1r14b 2.26 Metabolism  
Ppp1r7 1.98 Metabolism, nucleotide and nucleic acid metabolism 
Ppp3cb 2.18 Cell communication  
Prdx1 2.71 Metabolism  
Prdx4 2.45 Metabolism  
Prim1 4.28 Metabolism, nucleotide and nucleic acid metabolism 
Prps1 3.89 Metabolism  
Psat1 19.58 Metabolism  
Psmb6 2.09 Metabolism, Protein metabolism  
Psmb7 2.20 Metabolism, Protein metabolism  
Psmc5 2.00 Metabolism, Protein metabolism  
Psmc6 2.62 Metabolism, Protein metabolism  
Psmd1 2.42 Metabolism, Protein metabolism  
Psmd12 2.14 Metabolism, Protein metabolism  
Psme3 2.05 Metabolism, Protein metabolism  
Psph 2.45 Metabolism  
Ptma 2.14 Cell cycle, Cell proliferation  
Ptpn5 3.71 Cell communication  
Pttg1 5.99 Metabolism, nucleotide and nucleic acid metabolism 
Qdpr 2.62 Metabolism  
Rab34 2.04 Cell communication  
Rae1 1.96 Metabolism, nucleotide and nucleic acid metabolism 
Ran 3.02 Cell communication  
Rangap1 2.46 Cell communication  
Rassf4 2.73 Biological process unknown  
Rbbp7 2.22 Metabolism, nucleotide and nucleic acid metabolism 
Rbm14 2.72 Metabolism, nucleotide and nucleic acid metabolism 
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Rexo2 2.38 Metabolism, nucleotide and nucleic acid metabolism 
Rfc3 3.17 DNA replication 
Rhebl1 2.66 Cell communication  
Rnf126 2.23 Metabolism, Protein metabolism  
Rnps1 2.42 Metabolism, nucleotide and nucleic acid metabolism 
Rpa2 2.19 Metabolism, nucleotide and nucleic acid metabolism 
Rrm1 4.53 Metabolism, nucleotide and nucleic acid metabolism 
Rrm2 16.7 Metabolism, nucleotide and nucleic acid metabolism 
Ruvbl1 4.06 Metabolism, nucleotide and nucleic acid metabolism 
Ruvbl2 3.35 Metabolism, nucleotide and nucleic acid metabolism 
Samm50 2.06 Biological process unknown  
Sc4mol 4.05 Metabolims, Fatty acid metabolism 
Scarb1 2.87 Cell communication  
Scye1 2.06 Immune response  
Sfrs2 2.37 Metabolism, nucleotide and nucleic acid metabolism 
Shmt1 2.75 Metabolism  
Shmt2 4.94 Metabolism  
Slc16a1 2.05 Transport  
Slc16a3 2.01 Transport  
Slc25a4 3.96 Transport  
Slc7a1 2.35 Transport  
Slc7a5 4.47 Transport  
Smagp 2.47 Cell adhesion 
Smn1 2.39 Metabolism, nucleotide and nucleic acid metabolism 
Sms 2.66 Metabolism  
Snrpa 4.95 Metabolism, nucleotide and nucleic acid metabolism 
Spag5 4.38 Cell growth and/or maintenance  
Sqle 2.85 Metabolism  
Srm 3.80 Metabolism  
Srpk1 2.42 Metabolism, nucleotide and nucleic acid metabolism 
Ssbp1 2.39 Metabolism, nucleotide and nucleic acid metabolism 
St13 2.47 Cell communication  
Stip1 2.16 Cell communication  
Stmn1 7.59 Cell growth and/or maintenance 
Stoml2 2.30 Transport  
Stra6 2.14 Biological process unknown  
Sympk 2.26 Cell growth and/or maintenance 
Syncrip 2.43 Metabolism, nucleotide and nucleic acid metabolism 
Taf9 2.44 Transcription  
Tardbp 2.56 Metabolism, nucleotide and nucleic acid metabolism 
Tars 2.81 Metabolism  
Tbl3 2.35 Biological process unknown  
Tbrg4 2.17 Cell communication  
Tcp1 3.69 Metabolism, Protein metabolism  
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Tdp1 2.01 DNA repair  
Tfpi 2.18 Metabolism, Protein metabolism  
Tfrc 7.14 Transport  
Thop1 4.88 Metabolism, Protein metabolism  
Timeless 3.38 Metabolism, nucleotide and nucleic acid metabolism 
Timm10 2.28 Metabolism, Protein metabolism  
Timm13 2.02 Transport  
Timm8a 3.52 Metabolism  
Tk1 6.64 Metabolism  
Tkt 2.61 Metabolism  
Tm7sf2 2.79 Metabolism  
Tmem147 1.97 Biological process unknown  
Tmem97 5.13 Cell cycle, Cell proliferation  
Tmpo 2.00 Metabolism, Nuclear organization and biogenesis  
Tnfrsf8 6.01 Cell communication  
Tnpo1 2.40 Transport  
Tomm40 2.28 Transport  
Tomm70a 2.12 Transport  
Top1mt 1.99 Metabolism, nucleotide and nucleic acid metabolism 
Top2a 7.33 Metabolism, nucleotide and nucleic acid metabolism 
Trap1 1.99 Metabolism, Protein metabolism  
Trnt1 2.08 Metabolism  
Troap 2.23 Cell adhesion 
Tuba4a 3.18 Cell growth and/or maintenance 
Tubb2c 4.95 Cell growth and/or maintenance 
Tubb6 2.37 Cell growth and/or maintenance 
Tubg1 2.50 Cell growth and/or maintenance 
Tusc3 2.30 Cell communication  
Txnl1 2.33 Metabolism  
Txnl2 2.90 Biological process unknown  
Txnrd1 2.13 Metabolism  
Tyms 2.71 Metabolism  
Ube2v2 2.08 Metabolism, Protein metabolism  
Uchl5 3.42 Metabolism, Protein metabolism  
Uhrf1 6.35 Metabolism, nucleotide and nucleic acid metabolism 
Umps 2.58 Metabolism  
Ung 3.04 DNA repair  
Usp1 1.96 Metabolism, Protein metabolism  
Usp10 1.98 Metabolism, Protein metabolism  
Utp14a 1.98 Biological process unknown  
Vars2 2.55 Metabolism  
Vdac1 3.07 Transport  
Vrk1 3.44 Cell communication  
Wdr12 2.05 Biological process unknown  
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Wdr18 2.57 Biological process unknown  
Wdr77 2.07 Biological process unknown  
Xpo1 4.09 Cell communication  
Yars 2.75 Metabolism  
Ywhae 2.05 Cell communication  
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Aaas 0.37 Cell communication 
Aamp 0.46 Cell adhesion 
Aatf 0.49 Apoptosis  
Abce1 0.46 Transport 
Abcf2 0.43 Immune response 
Abhd8 0.48 Biological process unknown  
Abi2 0.54 Cell communication 
Acaca 0.35 Metabolism 
Acat2 0.16 Metabolism 
Acly 0.45 Metabolism 
Acp6 0.51 Metabolism 
Acsl3 0.34 Metabolism, Fatty acid metabolism  
Acss2 0.42 Metabolism 
Acy1 0.36 Metabolism 
Adfp 0.37 Metabolism, Lipid storage 
Adk 0.41 Nucleotide and nucleic acid metabolism  
Adsl 0.49 Metabolism 
Ahctf1 0.53 Nucleotide and nucleic acid metabolism  
Ahcy 0.31 Metabolism 
Ahcyl1 0.46 Metabolism 
Ak3l1 0.20 Metabolism 
Akr7a2 0.45 Metabolism 
Aldh2 0.55 Metabolism 
Aldh7a1 0.21 Metabolism 
Aldoa 0.46 Metabolism 
Aldoc 0.47 Metabolism 
Aloxe3 0.16 Metabolism 
Amd1 0.54 Metabolism 
Ampd2 0.54 Metabolism 
Anapc5 0.49 Cell communication 
Anxa7 0.53 Transport 
Ap1s1 0.40 Transport 
Apex1 0.32 Nucleotide and nucleic acid metabolism 
Appbp1 0.45 Cell communication 
Arl2 0.50 Cell communication 
Armc9 0.53 Biological process unknown  
Asf1b 0.34 Metabolism, Protein metabolism  
Ash2l 0.47 Nucleotide and nucleic acid metabolism 
Asns 0.23 Metabolism, Protein metabolism  
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Aspm 0.34 Biological process unknown  
Atad3a 0.46 Metabolism 
Atp5g1 0.52 Metabolism 
Aurka 0.40 Cell communication 
Bat2 0.53 Biological process unknown  
Baz1b 0.50 Regulation of gene expression, epigenetic  
Bcat1 0.44 Metabolism 
Bckdk 0.38 Metabolism 
Bcr 0.49 Cell communication 
Bcs1l 0.51 Metabolism 
Bex1 0.26 Biological process unknown  
Birc5 0.50 Cell communication 
Blm 0.40 Nucleotide and nucleic acid metabolism 
Bnip3 0.22 Apoptosis  
Bola1 0.51 Biological process unknown  
Bop1 0.39 Biological process unknown  
Bpnt1 0.40 Cell communication 
Bsg 0.43 Cell communication 
Btbd14b 0.51 Biological process unknown  
Bub1 0.31 Cell communication 
Bub1b 0.32 Cell communication 
Bxdc1 0.43 Biological process unknown  
Bxdc2 0.47 Biological process unknown  
C1qbp 0.39 Immune response 
Cacybp 0.46 Metabolism, Protein metabolism  
Cad 0.39 Metabolism 
Calca 0.43 Metabolism, Regulation of physiological process  
Cand1 0.51 Nucleotide and nucleic acid metabolism 
Casp4 0.49 Apoptosis  
Cbr1 0.29 Metabolism 
Ccdc5 0.44 Cell growth and/or maintenance  
Ccna2 0.30 Cell communication 
Ccnb1 0.29 Cell communication 
Ccnb2 0.50 Cell communication 
Ccnd2 0.43 Cell communication 
Ccnf 0.49 Cell communication 
Ccng1 0.49 Cell cycle, Regulation of cell cycle 
Cct3 0.48 Metabolism, Protein metabolism  
Cct5 0.44 Metabolism, Protein metabolism  
Cct7 0.47 Protein folding 
Cct8 0.33 Metabolism, Protein metabolism  
Cd200 0.28 Immune response 
Cdc20 0.39 Cell cycle  
Cdca2 0.48 Biological process unknown  
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Cdca4 0.55 Cell division, Cell fate commitment  
Cdca7 0.25 Nucleotide and nucleic acid metabolism 
Cdca8 0.38 Cell communication 
Cdk2 0.52 Nucleotide and nucleic acid metabolism 
Cdk4 0.39 Cell communication 
Cdkn1a 0.55 Cell cycle, Regulation of cell cycle 
Cdkn2a 0.48 Cell communication 
Cep68 0.53 Biological process unknown  
Chchd4 0.55 Biological process unknown  
Chchd6 0.49 Biological process unknown  
Chek1 0.30 Cell communication 
Chtf18 0.53 Nucleotide and nucleic acid metabolism 
Ckap2 0.32 Cell growth and/or maintenance  
Clpb 0.46 Metabolism 
Cog7 0.55 Transport 
Cops4 0.53 Metabolism, Protein metabolism  
Cpsf2 0.53 Nucleotide and nucleic acid metabolism 
Cpsf6 0.52 Nucleotide and nucleic acid metabolism  
Cse1l 0.51 Transport 
Cst7 0.52 Metabolism, Protein metabolism  
Ctps 0.26 Metabolism 
Cttn 0.50 Cell growth and/or maintenance  
Cyb5b 0.52 Transport 
Cyc1 0.52 Metabolism 
Cycs 0.46 Metabolism 
Cyp2s1 0.50 Metabolism 
Dars 0.47 Metabolism 
Dazap1 0.53 Nucleotide and nucleic acid metabolism 
Dbi 0.47 Metabolism 
Ddb1 0.46 Nucleotide and nucleic acid metabolism 
Ddx1 0.40 Nucleotide and nucleic acid metabolism 
Ddx11 0.50 Nucleotide and nucleic acid metabolism 
Ddx18 0.55 Transport 
Ddx56 0.48 Nucleotide and nucleic acid metabolism 
Dhcr24 0.30 Metabolism 
Dhcr7 0.27 Metabolism 
Dkc1 0.48 Nucleotide and nucleic acid metabolism 
Dlg7 0.39 Cell cycle, Regulation of cell cycle 
Dnajc9 0.51 Metabolism, Protein metabolism  
Dnd1 0.54 Nucleotide and nucleic acid metabolism 
Dnmt1 0.42 Nucleotide and nucleic acid metabolism 
Dph5 0.54 Biological process unknown  
Drg1 0.39 Cell growth and/or maintenance  
Dut 0.51 DNA replication  
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Dync2li1 0.50 Cell growth and/or maintenance  
Ebna1bp2 0.41 Biological process unknown  
Echdc1 0.30 Biological process unknown  
Ect2 0.28 Cell communication 
Eftud2 0.50 Metabolism, Protein metabolism  
Egln3 0.42 Metabolism, Protein metabolism  
Eif2a 0.54 Metabolism, Protein metabolism  
Eif2b3 0.46 Metabolism, Protein metabolism  
Eif2s1 0.48 Metabolism, Protein metabolism  
Eif2s2 0.55 Metabolism, Protein metabolism  
Eif3s6ip 0.40 Metabolism, Protein metabolism  
Eif3s8 0.54 Metabolism, Protein metabolism  
Eif3s9 0.44 Metabolism, Protein metabolism  
Eif4ebp1 0.41 Metabolism, Protein metabolism  
Eif4g1 0.47 Metabolism, Protein metabolism  
Eif5a 0.46 Metabolism, Protein metabolism  
Elovl6 0.47 Biological process unknown  
Emg1 0.40 Metabolism, Protein metabolism  
Eml2 0.48 Cell growth and/or maintenance  
Enah 0.53 Cell growth and/or maintenance  
Eno1 0.38 Metabolism 
Eno2 0.30 Metabolism 
Epor 0.51 Cell communication 
Eprs 0.52 Metabolism, Protein metabolism  
Ero1l 0.52 Metabolism 
Erp29 0.55 Protein folding 
Espl1 0.27 Metabolism, Protein metabolism  
Exo1 0.37 Nucleotide and nucleic acid metabolism 
Exosc5 0.51 Nucleotide and nucleic acid metabolism 
Exosc7 0.38 Nucleotide and nucleic acid metabolism 
Exosc8 0.41 Nucleotide and nucleic acid metabolism 
Fabp5 0.16 Transport 
Fads1 0.54 Metabolism 
Fads2 0.50 Metabolism 
Fancd2 0.40 Cell communication 
Fasn 0.34 Metabolism 
Fdft1 0.53 Metabolism 
Fdps 0.16 Metabolism 
Fem1b 0.52 Apoptosis  
Fen1 0.42 Nucleotide and nucleic acid metabolism 
Fgf13 0.51 Cell communication 
Fkbp3 0.45 Metabolism 
Fkbp4 0.35 Metabolism 
Foxq1 0.48 Nucleotide and nucleic acid metabolism 
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Frap1 0.55 Cell communication 
Fubp1 0.49 Nucleotide and nucleic acid metabolism 
Fxc1 0.48 Cell adhesion 
Fxn 0.49 Transport 
Gadd45gip1 0.52 Cell communication 
Galk1 0.20 Metabolism 
Gars 0.52 Metabolism, Protein metabolism  
Gart 0.37 Nucleotide and nucleic acid metabolism 
Gbe1 0.46 Metabolism 
Gcat 0.43 Metabolism 
Gcsh 0.25 Metabolism 
Gemin6 0.55 Nucleotide and nucleic acid metabolism 
Gfer 0.41 Cell communication 
Gfi1 0.54 Nucleotide and nucleic acid metabolism 
Gmps 0.40 Metabolism 
Gnai1 0.37 Cell communication 
Gnl3 0.42 Cell cycle, Regulation of cell proliferation  
Gpc1 0.47 Cell adhesion 
Gpiap1 0.41 Transport 
Gsta4 0.43 Metabolism 
Gsto1 0.45 Metabolism 
Gtf2h4 0.52 Nucleotide and nucleic acid metabolism 
Gtpbp4  0.48 Cell adhesion 
Hat1 0.38 Metabolism 
Hdgf 0.49 Cell communication 
Hey1 0.43 Nucleotide and nucleic acid metabolism 
Higd1a 0.36 Biological process unknown  
Hirip3 0.39 Nucleotide and nucleic acid metabolism 
Hk2 0.50 Metabolism 
Hmbs 0.55 Metabolism 
Hmga1 0.37 Nucleotide and nucleic acid metabolism 
Hmgcr 0.54 cell migration 
Hmgcs1 0.26 Metabolism 
Hmgn1 0.45 Nucleotide and nucleic acid metabolism 
Hmgn3 0.48 Nucleotide and nucleic acid metabolism 
Hmmr 0.38 Cell communication 
Hs2st1 0.53 Metabolism 
Hsf2 0.35 Metabolism, Protein metabolism  
Hspa14 0.42 Biological process unknown  
Hspd1 0.42 Protein folding 
Hspe1 0.42 Metabolism, Protein metabolism  
Hsph1 0.54 Metabolism, Protein metabolism  
Idh1 0.45 Metabolism 
Idi1 0.26 Metabolism 
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Ier3 0.42 Anti-apoptosis 
Ift74 0.54 Cell growth and/or maintenance  
Il17f 0.45 Immune response 
Ilf2 0.46 Nucleotide and nucleic acid metabolism 
Immt 0.54 Cell growth and/or maintenance  
Impdh2 0.40 Metabolism 
Insig1 0.44 Metabolism, Lipid metabolism  
Jam3 0.48 Cell adhesion 
Josd3 0.51 Cell cycle, Regulation of cell cycle 
Kdr 0.28 Cell communication 
Kif11 0.49 Cell growth and/or maintenance  
Kif15 0.47 Cell communication 
Kif22 0.36 Nucleotide and nucleic acid metabolism 
Kif2c 0.40 Cell growth and/or maintenance  
Kifc1 0.44 Cell cycle, Microtubule-based process 
Kpna2 0.36 Cell communication 
Kpnb1 0.36 Transport 
Laptm4b 0.33 Cell cycle, Regulation of cell proliferation  
Ldha 0.51 Metabolism 
Lig1 0.51 Nucleotide and nucleic acid metabolism 
Lmnb1 0.52 Cell growth and/or maintenance  
Lrpprc 0.51 Nucleotide and nucleic acid metabolism 
Lrrc59 0.45 Biological process unknown  
Lss 0.51 Metabolism 
Luc7l 0.52 Biological process unknown  
Mad2l2 0.52 Cell cycle, Regulation of cell cycle 
Mcm4 0.35 Nucleotide and nucleic acid metabolism 
Mcm6 0.33 Nucleotide and nucleic acid metabolism 
Mcm7 0.32 DNA replication  
Mif 0.29 Cell communication 
Mina 0.54 Cell growth and/or maintenance  
Mki67ip 0.46 Nucleotide and nucleic acid metabolism 
Morf4l2 0.55 Nucleotide and nucleic acid metabolism 
Mrpl12 0.40 Nucleotide and nucleic acid metabolism 
Mrpl19 0.51 Metabolism, Protein metabolism  
Mrpl23 0.46 Metabolism, Protein metabolism  
Mrpl38 0.43 Metabolism, Protein metabolism  
Mrpl47 0.51 Metabolism, Protein metabolism  
Mrps18b 0.45 Metabolism, Protein metabolism  
Mrps25 0.51 Metabolism, Protein metabolism  
Mta1 0.39 Nucleotide and nucleic acid metabolism 
Mtf2 0.55 Nucleotide and nucleic acid metabolism 
Mthfd1 0.35 Metabolism 
Mtss1 0.54 Cell adhesion 
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Mvd 0.23 Metabolism 
Mybbp1a 0.37 Nucleotide and nucleic acid metabolism 
Myc 0.41 Nucleotide and nucleic acid metabolism 
Nars 0.50 Metabolism, Protein metabolism  
Nasp 0.46 Cell cycle, Regulation of cell cycle 
Ndufa11 0.46 Metabolism 
Nedd4 0.49 Metabolism, Protein metabolism  
Net1 0.43 Cell communication 
Nif3l1 0.54 Nucleotide and nucleic acid metabolism 
Nip7 0.55 Cell growth and/or maintenance  
Nme1 0.55 Metabolism 
Nme2 0.52 Signal transduction 
Nol5a 0.35 Nucleotide and nucleic acid metabolism 
Nol9 0.54 Biological process unknown  
Nolc1 0.44 Nucleotide and nucleic acid metabolism 
Nphp1 0.48 Cell adhesion 
Nsdhl 0.47 Metabolism 
Nt5dc2 0.50 Biological process unknown  
Nts 0.51 Cell communication 
Nudc 0.36 Cell communication 
Nup107 0.39 Transport 
Nup155 0.33 Transport 
Nup188 0.53 Biological process unknown  
Nup35 0.41 Transport 
Nup88 0.52 Transport 
Nup93 0.38 Transport 
Oat 0.39 Metabolism 
Oprs1 0.37 Cell communication 
Orc1l 0.30 Nucleotide and nucleic acid metabolism 
Orc6l 0.48 Nucleotide and nucleic acid metabolism 
P4ha1 0.26 Metabolism 
Pa2g4 0.41 Nucleotide and nucleic acid metabolism 
Pabpc4 0.42 Nucleotide and nucleic acid metabolism 
Paics 0.37 Metabolism 
Pbef1 0.42 Anti-apoptosis 
Pcca 0.36 Metabolism 
Pcgf6 0.49 Nucleotide and nucleic acid metabolism 
Pcyt2 0.52 Metabolism 
Pdk1 0.24 Metabolism 
Pdk3 0.53 Metabolism 
Pebp1 0.27 Cell communication 
Pfkl 0.28 Metabolism 
Pfkm 0.50 Metabolism 
Pfkp 0.45 Metabolism 
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Pgam1 0.54 Metabolism 
Pgd 0.34 Metabolism 
Pgk1 0.41 Metabolism 
Pgm1 0.36 Metabolism 
Phb 0.30 Cell communication 
Phb2 0.51 Nucleotide and nucleic acid metabolism 
Phgdh 0.35 Metabolism 
Phlda3 0.54 Cell communication 
Pi4k2b 0.45 Cell communication 
Pik3r2 0.50 Cell adhesion 
Pkig 0.34 Biological process unknown  
Plk1 0.35 Cell communication 
Plscr1 0.49 Cell communication 
Pmvk 0.54 Metabolism 
Pola1 0.51 Nucleotide and nucleic acid metabolism 
Pola2 0.39 Nucleotide and nucleic acid metabolism 
Pold1 0.30 Nucleotide and nucleic acid metabolism 
Pold2 0.28 Nucleotide and nucleic acid metabolism 
Pole 0.48 Nucleotide and nucleic acid metabolism 
Pole3 0.47 Nucleotide and nucleic acid metabolism 
Polr2f 0.46 Nucleotide and nucleic acid metabolism 
Ppan 0.55 Cell communication 
Ppat 0.36 Metabolism 
Ppid 0.48 Metabolism 
Ppif 0.53 Metabolism, Protein metabolism  
Ppp1r14b 0.34 Metabolism 
Ppp1r7 0.50 Nucleotide and nucleic acid metabolism 
Ppp2r1a 0.44 Cell communication 
Prdx1 0.36 Metabolism 
Prdx3 0.53 Metabolism 
Prim1 0.39 Nucleotide and nucleic acid metabolism 
Prps1 0.46 Metabolism 
Psat1 0.24 Metabolism 
Psmc3 0.53 Metabolism, Protein metabolism  
Psmc6 0.54 Metabolism, Protein metabolism  
Psmd1 0.51 Metabolism, Protein metabolism  
Psmd12 0.48 Metabolism, Protein metabolism  
Psmd2 0.49 Metabolism, Protein metabolism  
Ptpmt1 0.49 Cell communication 
Ptpn5 0.28 Cell communication 
Pttg1 0.39 Nucleotide and nucleic acid metabolism 
Pus1 0.54 Nucleotide and nucleic acid metabolism 
Pycrl 0.54 Metabolism 
Qdpr 0.52 Metabolism 
Appendix 2 
135 
Gene Symbol Tmigratory Biological Process 
Rab26 0.54 Cell communication 
Rab34 0.37 Cell communication 
Rad23b 0.37 Nucleotide and nucleic acid metabolism 
Rad50 0.54 Nucleotide and nucleic acid metabolism 
Rae1 0.50 Nucleotide and nucleic acid metabolism 
Ran 0.50 Cell communication 
Rangap1 0.41 Cell communication 
Rassf4 0.49 Biological process unknown  
Rbbp7 0.50 Nucleotide and nucleic acid metabolism 
Rbm13 0.54 Nucleotide and nucleic acid metabolism 
Rbm14 0.55 Nucleotide and nucleic acid metabolism 
Rbm17 0.53 Nucleotide and nucleic acid metabolism 
Rdbp 0.54 Nucleotide and nucleic acid metabolism 
Rfc3 0.53 DNA replication  
Rhebl1 0.42 Cell communication 
Rnaseh2a 0.54 Nucleotide and nucleic acid metabolism 
Rnf126 0.37 Metabolism, Protein metabolism  
Rnps1 0.41 Nucleotide and nucleic acid metabolism 
Rrm1 0.43 Nucleotide and nucleic acid metabolism 
Rrm2 0.39 Nucleotide and nucleic acid metabolism 
Rtcd1 0.46 Nucleotide and nucleic acid metabolism 
Ruvbl1 0.32 Nucleotide and nucleic acid metabolism 
Ruvbl2 0.25 Nucleotide and nucleic acid metabolism 
Sap18 0.54 Nucleotide and nucleic acid metabolism 
Sc4mol 0.18 Metabolism, Fatty acid metabolism  
Scarb1 0.32 Cell adhesion 
Scye1 0.54 Immune response 
Sf1 0.54 Nucleotide and nucleic acid metabolism 
Sf3a2 0.50 Metabolism, Protein metabolism  
Sfxn1 0.43 Transport 
Shmt1 0.38 Metabolism 
Shmt2 0.28 Metabolism 
Slc16a1 0.55 Transport 
Slc16a3 0.20 Transport 
Slc19a1 0.40 Transport 
Slc25a1 0.48 Transport 
Slc25a4 0.41 Transport 
Slc2a1 0.34 Transport 
Slc5a3 0.28 Transport 
Slc7a5 0.31 Transport 
Smagp 0.43 Cell adhesion 
Smn1 0.53 Nucleotide and nucleic acid metabolism 
Sms 0.46 Metabolism 
Snrpa 0.44 Nucleotide and nucleic acid metabolism 
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Spag5 0.51 Cell growth and/or maintenance  
Spr 0.40 Metabolism 
Sqle 0.25 Metabolism 
Srfbp1 0.53 Metabolism 
Srm 0.25 Metabolism 
Srpk1 0.42 Nucleotide and nucleic acid metabolism 
Ssbp1 0.44 Nucleotide and nucleic acid metabolism 
St13 0.31 Cell communication 
Stip1 0.43 Cell communication 
Stoml2 0.51 Transport 
Sympk 0.40 Cell adhesion 
Syncrip 0.41 Nucleotide and nucleic acid metabolism 
Tardbp 0.51 Nucleotide and nucleic acid metabolism 
Tars 0.42 Metabolism 
Tbl3 0.45 Biological process unknown  
Tcp1 0.38 Metabolism, Protein metabolism  
Tdp1 0.48 DNA repair  
Tfpi 0.34 Metabolism, Protein metabolism  
Tfrc 0.29 Transport 
Thop1 0.21 Metabolism, Protein metabolism  
Timeless 0.43 Nucleotide and nucleic acid metabolism 
Timm10 0.47 Metabolism, Protein metabolism  
Timm13 0.52 Transport 
Timm8a 0.42 Metabolism 
Timm9 0.55 Cell growth and/or maintenance  
Tk1 0.43 Metabolism 
Tkt 0.39 Metabolism 
Tm7sf2 0.34 Metabolism 
Tmem55a 0.50 Cell adhesion 
Tmem97 0.27 Cell division, proliferation  
Tnfrsf11b 0.44 Cell communication 
Tnfrsf4 0.38 Cell communication 
Tnfrsf8 0.15 Cell communication 
Tnpo1 0.45 Transport 
Tnpo3 0.54 Cell communication 
Tomm40 0.47 Transport 
Top1mt 0.51 Nucleotide and nucleic acid metabolism 
Top2a 0.53 Nucleotide and nucleic acid metabolism 
Tp53 0.41 Nucleotide and nucleic acid metabolism 
Tpi1 0.22 Metabolism 
Trap1 0.50 Metabolism, Protein metabolism  
Trim28 0.45 Nucleotide and nucleic acid metabolism 
Trnt1 0.52 Metabolism 
Tspan3 0.52 Cell adhesion 
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Tspan5 0.50 Biological process unknown  
Tuba4a 0.42 Cell growth and/or maintenance  
Tubb2c 0.38 Cell growth and/or maintenance  
Tubb6 0.49 Cell growth and/or maintenance  
Tubg1 0.46 Cell growth and/or maintenance  
Txnl1 0.53 Metabolism 
Txnl2 0.37 Biological process unknown  
Txnrd1 0.51 Metabolism 
Ubtf 0.55 Nucleotide and nucleic acid metabolism 
Uchl5 0.37 Metabolism, Protein metabolism  
Uhrf1 0.34 Nucleotide and nucleic acid metabolism 
Umps 0.40 Metabolism 
Ung 0.34 DNA repair  
Usp14 0.51 Metabolism, Protein metabolism  
Vars2 0.36 Metabolism 
Vdac1 0.42 Transport 
Vegfa 0.42 Cell communication 
Vegfb 0.51 Cell communication 
Vkorc1 0.37 Metabolism, Vitamin metabolism  
Vrk1 0.34 Cell communication 
Wdr18 0.40 Biological process unknown  
Wdr75 0.51 Cell communication 
Wdr77 0.50 Biological process unknown  
Xpo1 0.45 Cell communication 
Xrcc1 0.50 DNA repair  
Xylb 0.48 Metabolism 
Yars 0.46 Metabolism 
2-Mar 2.22 Metabolism, Protein metabolism  
9-Sep 2.03 Cell division, proliferation  
Abi1 2.07 Cell growth, Regulation of cell growth  
Acpl2 3.52 Metabolism 
Acss1 2.60 Biological process unknown  
Add3 4.42 Cell growth and/or maintenance  
Agpat2 2.16 Metabolism, Lipid metabolism  
Ahnak 4.45 Cell growth, cell differentiation, Muscle contraction  
Aif1 2.61 Cell communication 
Ap1s2 2.35 Transport 
App 2.06 Cell adhesion 
Arhgap4 2.02 Cell communication 
Arhgef18 3.77 Cell communication 
Arhgef3 2.86 Cell communication 
Arid4a 2.33 Nucleotide and nucleic acid metabolism 
Atp2a3 3.31 Transport, Ion transport  
Atp2b1 2.90 Transport 
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Axud1 3.11 Apoptosis  
Basp1 2.04 Nucleotide and nucleic acid metabolism 
Bcl9l 2.46 Biological process unknown  
Bin1 2.18 Cell communication 
Bin2 2.30 Cell communication 
Btg1 2.60 Cell growth and/or maintenance  
Btg2 4.92 Nucleotide and nucleic acid metabolism 
Ccl3 6.40 Immune response 
Ccl4 7.85 Immune response 
Ccl5 12.74 Cell communication 
Ccpg1 3.56 Biological process unknown  
Ccr2 4.33 Cell communication 
Ccr5 4.50 Cell communication 
Ccr6 2.93 Cell communication 
Cd14 2.17 Immune response 
Cd2 2.63 Cell adhesion 
Cd38 3.05 Metabolism 
Cd44 2.47 Cell adhesion 
Cd69 7.77 Immune response 
Cd83 1.99 Immune response 
Cd97 2.46 Cell adhesion 
Cdc25b 2.35 Cell communication 
Cdkn1b 2.31 Cell communication 
Ches1 1.99 Cell communication 
Chi3l1 3.43 Cell growth and/or maintenance  
Clk1 2.68 Signal transduction 
Clk4 2.28 Cell communication 
Cotl1 2.38 Cell growth and/or maintenance  
Cox7a2l 2.10 Metabolism 
Cpeb2 2.13 Nucleotide and nucleic acid metabolism 
Csf1r 2.02 Cell communication 
Ctse 3.06 Metabolism, Protein metabolism  
Ctsh 2.10 Metabolism, Protein metabolism  
Ctss 2.19 Metabolism, Protein metabolism  
Cxcl10 1.95 Cell migration 
Cxcl11 2.93 Cell communication 
Cxcl2 2.19 Immune response 
Cxcr4 2.92 Cell communication 
Cyb561d1 2.18 Biological process unknown  
Cybb 2.83 Metabolism 
Daam1 4.03 Cell communication 
Dap 2.99 Apoptosis  
Dgka 2.40 Cell communication 
Dnajb9 3.41 Metabolism, Protein metabolism  
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Dok2 2.73 Signal transduction  
Dusp1 4.80 Cell communication 
Dusp2 4.43 Cell communication 
Dusp5 5.66 Cell communication 
Dusp6 2.24 Cell communication 
Edg1 4.15 Cell adhesion 
Emp1 5.52 Cell growth and/or maintenance  
Evl 4.27 Cell adhesion 
Faah 2.89 Metabolism 
Faslg 2.12 Cell communication 
Fcgr2b 3.34 Signal transduction 
Fcgr3a 2.13 Immune response 
Fgl2 9.87 Cell growth and/or maintenance  
Fhl2 3.98 Nucleotide and nucleic acid metabolism 
Flna 2.72 Cell growth and/or maintenance  
Fn1 1.98 Cell adhesion 
Fos 12.19 Nucleotide and nucleic acid metabolism 
Foxp1 2.01 Regulation of gene expression, epigenetic  
Fxyd5 3.09 Transport, Regulation of cellular process 
Fyco1 2.40 Cell communication 
Fyn  2.30 Cell adhesion 
G0s2 2.11 Cell communication 
Gabbr1 2.25 Cell communication 
Gas7 2.24 Cell cycle  
Gbp2 4.11 Cell communication 
Gda 10.63 Metabolism 
Gimap4 3.36 Cell communication 
Gimap5 1.98 Apoptosis  
Gimap7 3.39 Cell communication 
Glipr1 3.91 Immune response 
Glul 2.54 Metabolism 
Gmfg 2.96 Cell communication 
Gna15 2.11 Cell communication 
Gpnmb 2.86 Biological process unknown  
Gpsm3 2.04 Cell communication 
Gsn 4.23 Cell adhesion 
Hbb 9.01 Transport 
Hbp1 2.15 Nucleotide and nucleic acid metabolism 
Hck 2.26 Cell communication 
Hcst 2.90 Cell communication 
Herc6 2.26 Metabolism, Protein metabolism  
Hpse 2.23 Metabolism 
Hsd11b1 2.10 Metabolism 
Ier2 4.65 Nucleotide and nucleic acid metabolism 
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Ifi44 2.09 Biological process unknown  
Ifit2 2.69 Cell growth and/or maintenance  
Ifng 3.52 Immune response 
Ifngr1 2.50 Immune response 
Igsf6 2.08 Immune response 
Il1b 6.19 Immune response 
Irak2 3.54 Cell communication 
Irf7 2.59 Nucleotide and nucleic acid metabolism 
Isg20 2.35 Nucleotide and nucleic acid metabolism 
Itgb1 5.61 Cell adhesion 
Itgb7 5.12 Cell adhesion 
Itm2b 2.02 Cell growth and/or maintenance  
Jun 4.00 Nucleotide and nucleic acid metabolism 
Klf10 2.13 Cell cycle, Regulation of cell growth  
Klf3 3.87 Nucleotide and nucleic acid metabolism 
Klf4 2.32 Nucleotide and nucleic acid metabolism 
Klf6 2.31 Nucleotide and nucleic acid metabolism 
Klf9 2.20 Nucleotide and nucleic acid metabolism 
Klrd1 8.07 Signal transduction  
Klrk1 2.00 Immune response 
Kpna1 2.34 Transport 
Kras 1.97 Signal transduction 
Lamp2 1.99 Cell adhesion 
Laptm5 2.16 Cell communication 
Lcp2 2.05 Cell communication 
Lgals1 11.73 Immune response 
Lgals3 2.75 Nucleotide and nucleic acid metabolism 
Lgals3bp 5.77 Immune response 
Lgals9 3.38 Apoptosis  
Litaf 2.08 Nucleotide and nucleic acid metabolism 
Lrg1 2.05 Biological process unknown  
Ltb 2.12 Immune response, Inflammatory response  
Lyz 15.94 Metabolism 
Maf 4.77 Regulation of gene expression, epigenetic  
Map3k8 2.20 Cell communication 
Mbp 2.57 Immune response 
Metrnl 2.12 Biological process unknown  
Mll5 2.58 cell growth, Regulation of cell growth  
Mx1 3.92 Cell communication 
Mx2 2.00 Immune response 
Myadm 5.25 Biological process unknown  
Napsa 2.89 Metabolism, Protein metabolism  
Ncald 2.02 Cell communication 
Nfkbia 2.63 Nucleotide and nucleic acid metabolism 
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Nr1d1 3.16 Cell communication 
Nr1d2 3.15 Nucleotide and nucleic acid metabolism 
Nr4a1 9.67 Cell communication 
Nr4a2 3.25 Cell communication 
Nr4a3 6.55 Nucleotide and nucleic acid metabolism 
Nrp1 2.45 Cell adhesion 
Nucb2 2.07 Cell communication 
Olfm1 3.03 Biological process unknown  
Pbxip1 2.28 Nucleotide and nucleic acid metabolism 
Pcsk3 2.17 Cell migration 
Pctk2 2.34 Cell communication 
Pde4b 4.95 Signal transduction 
Pdlim2 2.00 Cell adhesion 
Per1 2.18 Nucleotide and nucleic acid metabolism 
Phyhd1 2.28 Metabolism 
Pip5k2a 2.07 Cell communication 
Pitpnm1 1.98 Metabolism, Lipid metabolism  
Plaur 3.09 Cell communication 
Plek 2.16 Cell communication 
Ppapdc2 2.07 Immune response, Innate immune response  
Ppp1r9b 1.96 Cell communication 
Prf1 2.70 Transport 
Psap 2.03 Cell communication 
Pten 2.54 Cell communication 
Ptpn18 2.49 Cell communication 
Pycard 4.92 Apoptosis  
Rab7l1 3.33 Cell communication 
Ramp1 2.07 Cell communication 
Ramp2 2.84 Cell communication 
Rasa3 5.55 Cell communication 
Rgs1 4.25 Cell communication 
Rgs10 2.96 Cell communication 
Rgs2 6.78 Cell communication 
Rhoh 2.22 Cell communication 
Rnf167 2.18 Metabolism, Protein metabolism  
Rxra 2.33 Cell communication 
S100a10 3.26 Cell communication 
S100a11 8.36 Cell communication 
S100a4 4.70 Cell growth and/or maintenance  
S100a6 5.90 Cell communication 
S100a8 6.13 Cell communication 
S100a9 13.68 Cell communication 
Sell 2.44 Cell adhesion 
Sema4b 2.45 Biological process unknown  
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Sepp1 2.46 Cell adhesion 
Serinc1 2.18 Biological process unknown  
Sfxn3 2.67 Biological process unknown  
Sgk 2.71 Cell communication 
Sh3bp5 2.07 Signal transduction 
Slc28a2 2.05 Transport 
Slc2a3 3.16 Transport 
Slc35b2 3.32 Transport 
Smpdl3a 2.24 Metabolism 
Snf1lk 2.34 Cell communication 
Sorl1 2.26 Cell communication 
Sqstm1 2.12 Metabolism, Protein metabolism  
Ssbp3 2.04 Metabolism, DNA metabolism  
Stk17b 2.78 Cell communication 
Stk38 2.11 Cell communication 
Sv2b 2.73 Transport 
Sytl1 2.34 transport, Vesicle docking  
Tacc2 3.64 Cell growth and/or maintenance  
Tcp11l2 4.69 Biological process unknown  
Tgfbi 2.51 Cell adhesion 
Tnf 2.48 Cell communication 
Tnfrsf1b 3.11 Cell communication 
Tob1 2.66 Cell communication 
Tpst2 3.23 Energy pathways 
Tsc22d3 5.77 Regulation of gene expression, epigenetic  
Txk 3.16 Cell communication 
Txnip 3.15 Cell communication 
Tyrobp 2.69 Cell communication 
Ubl3 2.03 Metabolism, Protein metabolism  
Vamp3 2.51 Transport 
Vcam1 2.42 Cell adhesion 
Vcl 1.96 Cell adhesion 
Vim 2.36 Cell growth and/or maintenance  
Wsb1 2.10 Cell communication 
Xdh 5.11 Metabolism 
Ypel5 3.11 Biological process unknown  
Zbp1 6.44 Nucleotide and nucleic acid metabolism 
Zfp36 4.39 Nucleotide and nucleic acid metabolism 
Zfp36l1 2.65 Nucleotide and nucleic acid metabolism 
Zfp36l2 3.90 Nucleotide and nucleic acid metabolism 
Zyx 2.58 Cell adhesion 
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Aamp 0.40 Cell adhesion 
Abcf1 0.39 Protein folding 
Abhd4 0.47 Biological process unknown  
Abhd8 0.24 Biological process unknown  
Ablim2 0.27 Cell growth and/or maintenance 
Acin1 0.26 Nucleotide and nucleic acid metabolism 
Acp1 0.46 Metabolism 
Acrbp 0.54 Biological process unknown  
Acsl5 0.51 Metabolism 
Actb 0.40 Cell communication 
Actn1 0.53 Cell adhesion 
Actr2 0.29 Cell communication 
Acvr1 0.54 Cell communication 
Adarb1 0.54 Nucleotide and nucleic acid metabolism 
Adss 0.39 Metabolism 
Ak2 0.51 Metabolism 
Ak3l1 0.51 Metabolism 
Ak7 0.49 Metabolism 
Akr1a1 0.36 Metabolism 
Akr1d1 0.46 Metabolism 
Als2cr4 0.50 Biological process unknown  
Amfr 0.51 Protein folding 
Angel2 0.48 Biological process unknown  
Anxa3 0.38 Cell communication 
Ap1s2 0.38 Transport 
Ap2m1 0.52 Transport 
Apeh 0.48 Metabolism 
Aph1a 0.47 Signal transduction 
Arcn1 0.48 Transport 
Arf4 0.50 Transport 
Arid2 0.23 Nucleotide and nucleic acid metabolism 
Arid5a 0.50 Nucleotide and nucleic acid metabolism 
Arl2bp 0.51 Cell communication 
Arsk 0.49 Metabolism 
Ascc3l1 0.49 Nucleotide and nucleic acid metabolism 
Aspm 0.50 Biological process unknown  
Atg3 0.39 Biological process unknown  
Atg4b 0.26 Biological process unknown, Proteolysis and peptidolysis 
Atp1b3 0.51 Transport 
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Atp5f1 0.40 Metabolism 
Atp6v0b 0.44 Transport 
Atp6v1f 0.41 Metabolism 
Atp6v1g1 0.41 Metabolism 
Atrn 0.52 Immune response 
Atxn10 0.37 Biological process unknown  
Aurkaip1 0.38 Signal transduction 
Avp 0.51 Cell communication,Regulation of biological process 
Axl  0.53 Cell migration 
Bcan 0.54 Cell adhesion 
Bin3 0.41 Cell communication 
Bloc1s2 0.55 Biological process unknown  
Bmp2 0.55 Cell communication 
Bmpr2 0.32 Cell communication 
Bop1 0.35 Biological process unknown  
Brd7 0.23 Cell cycle 
Btbd14a 0.53 Biological process unknown  
C1qbp 0.44 Immune response 
Cacnb1 0.45 Transport 
Cacnb3 0.23 Transport 
Calr 0.44 Protein folding 
Capza2 0.38 Cell adhesion 
Capzb 0.25 Cell communication 
Cbfb 0.47 Nucleotide and nucleic acid metabolism 
Ccnl2 0.47 Nucleotide and nucleic acid metabolism 
Ccnt2 0.35 Nucleotide and nucleic acid metabolism 
Ccrl2 0.44 Cell communication 
Cct5 0.53 Protein folding 
Cd44 0.44 Cell adhesion 
Cd81 0.41 Metabolism 
Cdc16 0.41 Cell communication 
Cdc2l5 0.46 Cell communication 
Cdc5l 0.44 Cell communication 
Cdyl2 0.44 Nucleotide and nucleic acid metabolism 
Cetn1 0.52 Cell communication 
Churc1 0.35 Nucleotide and nucleic acid metabolism 
Clk1 0.30 Signal transduction 
Clk4 0.34 Cell communication 
Cltc 0.37 Cell communication 
Cmklr1 0.52 Cell communication 
Cndp1 0.44 Protein folding 
Cog6 0.44 Transport 
Col12a1 0.44 Cell adhesion 
Col15a1 0.37 Cell adhesion 
Appendix 2 
145 
Gene Symbol Teffector Biological Process 
Commd3 0.24 Biological process unknown  
Commd9 0.44 Biological process unknown  
Comp 0.53 Cell adhesion 
Cops3 0.45 Cell communication 
Cops6 0.48 Cell communication 
Cops8 0.39 Signal transduction 
Cpne8 0.37 Transport 
Crhr1 0.55 Cell communication 
Crim1 0.48 Cell communication 
Csad 0.40 Metabolism 
Cse1l 0.27 Transport 
Csrp3 0.51 Cell communication 
Ctnnal1 0.50 Apoptosis 
Cul3 0.30 Protein folding 
Cul4b 0.54 Protein folding 
Cuta 0.42 Biological process unknown  
Cyb561d2 0.30 Protein folding 
Cyp2u1 0.44 Metabolism 
Dars 0.52 Metabolism 
Dars2 0.50 Biological process unknown  
Dclk3 0.55 Cell communication 
Dctn3 0.45 Cell communication 
Ddb1 0.43 Nucleotide and nucleic acid metabolism 
Ddhd1 0.34 Metabolism 
Dhrs1 0.49 Metabolism 
Dhx15 0.30 Nucleotide and nucleic acid metabolism 
Dhx16 0.38 Nucleotide and nucleic acid metabolism 
Diap1 0.53 Cell migration 
Dicer1 0.49 Regulation of gene expression, epigenetic, Gene silencing 
Dmn 0.50 Cell communication 
Dnpep 0.33 Protein folding 
Dom3z 0.45 Biological process unknown  
Dscr6 0.49 Biological process unknown  
Dst 0.39 Cell communication 
Dtx4 0.29 Signal transduction 
Dync1h1 0.49 Metabolism 
Dynll2 0.51 Cell communication 
Ebp 0.42 Metabolism 
Eea1 0.51 Transport 
Egr2 0.53 Nucleotide and nucleic acid metabolism 
Eif3s3 0.49 Protein folding 
Eif3s6ip 0.51 Protein folding 
Eif5 0.43 Protein folding 
Eps15 0.25 Cell communication 
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Ercc1 0.46 Nucleotide and nucleic acid metabolism 
Etv1 0.48 Nucleotide and nucleic acid metabolism 
Exoc5 0.42 Transport 
Exosc9 0.55 Nucleotide and nucleic acid metabolism 
Ezh1 0.33 Nucleotide and nucleic acid metabolism 
Fbxl11 0.18 Protein folding 
Fbxo7 0.41 Protein folding 
Fem1a 0.54 Cell communication 
Fgd2 0.41 Cell communication 
Fibp 0.34 Cell communication 
Fignl1 0.47 Biological process unknown  
Fkbp1a 0.44 Cell communication 
Folr2 0.48 Cell communication 
Foxp4 0.42 Nucleotide and nucleic acid metabolism 
Gab1 0.36 Cell communication 
Galnt1 0.38 Metabolism 
Gba2 0.29 Metabolism 
Ghsr 0.54 Cell communication 
Gja5 0.49 Transport 
Glo1 0.34 Metabolism 
Glt8d1 0.50 Biological process unknown  
Gnb2 0.38 Cell communication 
Gng5 0.50 Cell communication 
Gnl3l 0.52 Biological process unknown  
Golga7 0.36 Transport 
Golph4 0.46 Cell communication 
Gorasp1 0.21 Cell communication 
Gpr20 0.51 Cell communication 
Gpr88 0.26 Cell communication 
Gps1 0.43 Cell communication 
Gramd3 0.34 Biological process unknown  
Grinl1a 0.44 Biological process unknown  
Grip2 0.44 Biological process unknown  
Gstk1 0.53 Metabolism 
Gtpbp3 0.48 Nucleotide and nucleic acid metabolism 
H3f3b 0.40 Nucleotide and nucleic acid metabolism 
Hapln2 0.24 Cell adhesion 
Hbs1l 0.52 Protein folding 
Hdac2 0.48 Nucleotide and nucleic acid metabolism 
Hdlbp 0.35 Transport 
Hk1 0.39 Metabolism 
Hnrpk 0.49 Nucleotide and nucleic acid metabolism 
Hnrpl 0.48 Nucleotide and nucleic acid metabolism 
Homer1 0.21 Cell communication 
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Hoxd3 0.43 Nucleotide and nucleic acid metabolism 
Igfals 0.38 Cell adhesion 
Il1b 0.52 Immune response 
Ilk 0.34 Cell adhesion 
Impa1 0.52 Metabolism 
Impad1 0.39 Metabolism 
Inpp1 0.30 Cell communication 
Inpp5e 0.53 Metabolism 
Jtb 0.52 Biological process unknown  
Kcnh7 0.32 Transport 
Kcnk3 0.53 transport, Ion transport 
Khdrbs1 0.52 Nucleotide and nucleic acid metabolism 
Klc1 0.19 Signal transduction 
Klf5 0.54 Nucleotide and nucleic acid metabolism 
Klhl7 0.23 Biological process unknown  
Lamp1 0.36 Biological process unknown  
Lbp 0.44 Immune response 
Lemd2 0.35 Biological process unknown  
Letm2 0.33 Biological process unknown  
Lgals8 0.39 Signal transduction 
Lims1 0.51 Cell adhesion 
Lrrc23 0.47 Biological process unknown  
Magi3 0.46 Cell communication 
Mak10 0.54 Cell communication 
Man2b1 0.32 Metabolism 
Map2k2 0.39 Cell adhesion 
Mapk12 0.54 Cell adhesion 
Mapk8ip3 0.52 Signal transduction 
Mat2a 0.54 Metabolism 
Mbtps1 0.44 Protein folding 
Mecp2 0.48 Nucleotide and nucleic acid metabolism 
Mecr 0.50 Metabolism 
Mef2d 0.44 Nucleotide and nucleic acid metabolism 
Men1 0.45 Regulation of gene expression, epigenetic 
Metap2 0.43 Protein folding 
Mkks 0.48 Protein folding 
Mkrn2 0.55 Nucleotide and nucleic acid metabolism 
Mll 0.52 Nucleotide and nucleic acid metabolism 
Mog 0.43 Immune response 
Morf4l1 0.29 Regulation of gene expression, epigenetic 
Mrpl12 0.39 Nucleotide and nucleic acid metabolism 
Mrpl37 0.45 Protein folding 
mrpl9 0.40 Protein folding 
Mtrr 0.46 Metabolism 
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Mvk 0.46 Metabolism 
Mylk2 0.45 Cell adhesion 
Myod1 0.41 Nucleotide and nucleic acid metabolism 
Myst2 0.50 Nucleotide and nucleic acid metabolism 
Nanp 0.43 Metabolism 
Napa  0.29 Transport 
Narfl 0.24 Biological process unknown  
Nck2 0.54 Cell migration 
Ncl 0.43 Nucleotide and nucleic acid metabolism 
Ncor1 0.31 Nucleotide and nucleic acid metabolism 
Nde1 0.47 Cell communication 
Ndfip1 0.47 Cell communication 
Nedd4l 0.39 Protein folding 
Nedd8 0.38 Protein folding 
Nfx1 0.46 Regulation of gene expression, epigenetic 
Nicn1 0.47 Biological process unknown  
Nmt2 0.38 Metabolism 
Nmur2 0.54 Cell communication 
Nono 0.34 Nucleotide and nucleic acid metabolism 
Notch2 0.54 Cell communication 
Npc2 0.42 Metabolism 
Npm1 0.44 Protein folding 
Nrbf2 0.44 Nucleotide and nucleic acid metabolism 
Nsdhl 0.51 Metabolism 
Nsfl1c 0.41 Cell communication 
Ntn1 0.55 Cell communication 
Nudt4 0.44 Biological process unknown  
Numa1 0.31 Cell communication 
Nup155 0.50 Transport 
Nup98 0.39 Transport 
Ocln 0.54 Cell adhesion 
Odf4 0.35 Biological process unknown  
Orc6l 0.53 Nucleotide and nucleic acid metabolism 
Paics 0.55 Metabolism 
Pak1 0.53 Cell adhesion 
Pcbp2 0.26 Nucleotide and nucleic acid metabolism 
Pcnx 0.37 Biological process unknown  
Pdap1 0.35 Cell communication 
Pdia3 0.44 Protein folding 
Pfkfb2 0.53 Metabolism 
Pgam5 0.52 Metabolism 
Pigl 0.54 Metabolism 
Pitpna 0.44 Transport 
Plau 0.46 Protein folding 
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Plekha3 0.33 Cell communication 
Plekhc1 0.54 Cell communication 
Plxnc1 0.53 Cell adhesion 
Poll 0.33 Nucleotide and nucleic acid metabolism 
Polr3k 0.21 Nucleotide and nucleic acid metabolism 
Ppia 0.43 Protein folding 
Ppm1b 0.45 Signal transduction 
Ppp2ca 0.24 Cell communication 
Ppp5c 0.47 Cell communication 
Prl 0.54 Cell communication 
Prpf18 0.38 Nucleotide and nucleic acid metabolism 
Prpf19 0.51 Nucleotide and nucleic acid metabolism 
Psma1 0.38 Protein folding 
Psma2 0.32 Protein folding 
Psmb1 0.47 Protein folding 
Psmb2 0.49 Protein folding 
Psmb3 0.47 Protein folding 
Psmb4 0.44 Protein folding 
Psmb6 0.44 Protein folding 
Psmc1 0.45 Protein folding 
Psmc4 0.37 Protein folding 
Psmd2 0.48 Protein folding 
Psmd9 0.49 Protein folding 
Ptch1 0.30 Cell communication 
Ptpn1 0.50 Cell communication 
Pum2 0.39 Protein folding 
Rab11a 0.45 Cell communication 
Rab15 0.44 Cell communication 
Rabac1 0.48 Transport 
Rad50 0.48 Nucleotide and nucleic acid metabolism 
Rap1b 0.45 Cell adhesion 
Rapgef1 0.33 Cell adhesion 
Rax 0.43 Nucleotide and nucleic acid metabolism 
Rbbp7 0.45 Nucleotide and nucleic acid metabolism 
Rbm5 0.48 Nucleotide and nucleic acid metabolism 
Rgs1 0.47 Cell communication 
Rheb 0.32 Cell communication 
Rhoa 0.29 Cell adhesion 
Rhobtb2 0.23 Cell communication 
Ric8a 0.35 Cell communication 
Rnf12 0.43 Regulation of gene expression, epigenetic 
Rnf25 0.51 Protein folding 
Rnmt 0.40 Nucleotide and nucleic acid metabolism 
Rom1 0.42 Cell adhesion 
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Rpl15 0.48 Protein folding 
Rpl17 0.48 Protein folding 
Rpl21 0.41 Protein folding 
Rpl23 0.44 Protein folding 
Rpl24 0.52 Protein folding 
Rpl28 0.51 Protein folding 
Rpl30 0.41 Protein folding 
Rpl35a 0.40 Protein folding 
Rpl36a 0.39 Protein folding 
Rpl37 0.27 Protein folding 
Rpl4 0.46 Protein folding 
Rpl5 0.31 Protein folding 
Rpl7 0.43 Protein folding 
Rpn1 0.54 Protein folding 
Rpn2 0.46 Protein folding 
Rps15a 0.39 Protein folding 
Rps21 0.41 Protein folding 
Rps5 0.44 Protein folding 
Ryr3 0.53 Transport 
Scyl1 0.36 Nucleotide and nucleic acid metabolism 
Sdcbp 0.41 Cell communication 
Serinc3 0.43 Biological process unknown  
Sf1 0.50 Nucleotide and nucleic acid metabolism 
Sh2d4a 0.47 Cell communication 
Skiv2l 0.32 Nucleotide and nucleic acid metabolism 
Slc12a3 0.50 Transport 
Slc29a1 0.45 Transport 
Slc38a6 0.32 Transport 
Slc3a2 0.38 Transport 
Slc9a3r2 0.28 Cell communication 
Smap1l 0.47 Cell communication 
Son 0.41 Nucleotide and nucleic acid metabolism 
Sparcl1 0.54 Cell communication 
Spred1 0.54 Cell communication 
Sprn 0.51 Biological process unknown  
St13 0.43 Cell communication 
Stip1 0.35 Cell communication 
Stoml2 0.45 Transport 
Sub1 0.37 Nucleotide and nucleic acid metabolism 
Sumo1 0.26 Cell cycle 
Surf1 0.36 Metabolism 
Surf4 0.29 Transport 
Tax1bp1 0.33 Cell communication 
Tceb1 0.46 Nucleotide and nucleic acid metabolism 
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Tceb2 0.36 Nucleotide and nucleic acid metabolism 
Tdrd3 0.51 Nucleotide and nucleic acid metabolism 
Thrap4 0.32 Nucleotide and nucleic acid metabolism 
Timm13 0.40 Transport 
Timm23 0.25 Protein folding 
Tm2d2 0.42 Signal transduction 
Tmed10 0.49 Transport 
Tmed2 0.36 Transport 
Tmed5 0.45 Biological process unknown  
Tmem39b 0.38 Biological process unknown  
Tmem66 0.36 Biological process unknown  
Tomm20 0.34 Transport 
Tpst2 0.38 Energy pathways 
Trpm7 0.53 Transport 
Tsc22d1 0.40 Cell growth , Regulation of cell growth 
Tsnax 0.37 Nucleotide and nucleic acid metabolism 
Tsta3 0.43 Cell adhesion 
Tubb4 0.47 Cell communication 
Txn2 0.39 Metabolism 
Txnrd1 0.29 Metabolism 
Uba52 0.42 Protein folding 
Ube1c 0.53 Protein folding 
Ube2g1 0.41 Protein folding 
Ube2n 0.33 Protein folding 
Unc50 0.48 Nucleotide and nucleic acid metabolism 
Usf1 0.45 Nucleotide and nucleic acid metabolism 
Usf2 0.40 Nucleotide and nucleic acid metabolism 
Usp19 0.29 Protein folding 
Usp48 0.33 Protein folding 
Vamp3 0.34 Transport 
Vamp5 0.39 Transport 
Vapa 0.45 Transport, Vesicle docking 
Vps4a 0.30 Cell communication 
Vwa1 0.49 Cell adhesion 
Wdr44 0.48 Cell migration 
Wdr45 0.42 Biological process unknown  
Wsb2 0.51 Protein folding 
Wwp1 0.51 Protein folding 
Ywhab 0.41 Signal transduction  
Ywhae 0.35 Cell communication 
Zan 0.51 Cell adhesion 
Zdhhc13 0.54 Biological process unknown  
Zfand3 0.43 Nucleotide and nucleic acid metabolism 
Zfp91 0.39 metabolism, RNA metabolism 
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9-Sep 1.98 Cell communication 
A2m 2.11 Protein folding 
Acadm 2.74 Metabolism 
Acads 1.96 Metabolism 
Acadvl 2.39 Energy pathways 
Accn1 2.01 Transport 
Acly 4.16 Metabolism 
Aco2 2.09 Metabolism 
Acp5 2.37 Metabolism 
Acsl1 2.00 Metabolism 
Acsl6 2.00 Metabolism 
Actn3 2.67 Cell adhesion 
Adrm1 1.97 Cell adhesion 
Afp 2.06 Transport 
Ahcy 2.00 Metabolism 
Akap11 2.14 Cell communication 
Alad 2.15 Metabolism 
Alb 5.03 Transport 
Aldh2 2.03 Metabolism 
Amacr 2.13 Metabolism 
Anapc2 3.93 Cell communication 
Ankrd1 3.41 Nucleotide and nucleic acid metabolism 
Anxa2 2.05 Siganl transduction, Regulation of enzyme activity 
Ap2b1 1.98 Biological process unknown  
Ap3d1 3.01 Transport 
Apc2 1.96 Cell communication 
Apcs 3.08 Protein folding 
Api5 4.46 Apoptosis 
Apip 6.18 Apoptosis 
Apoa1bp 2.53 Biological process unknown  
Arf1 10.00 Signal transduction 
Arf5 2.10 Cell communication 
Arfgap1 2.50 metabolism, Lipid metabolism 
Atp1b1 3.58 Transport 
Atp2b1 2.00 Transport 
Atp5g1 3.49 Metabolism 
Atp5g3 2.64 Metabolism 
Atp6v0e1 2.37 Transport 
Aurkb 2.29 Cell communication 
B4galt3 4.12 Metabolism 
Bak1 2.07 Apoptosis 
Bbs1 3.55 Biological process unknown  
Bcap31 3.94 Transport 
Becn1 10.45 Cell communication 
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Bgn 3.01 Cell communication 
Bmp15 3.00 Cell communication 
Btg1 2.21 Cell communication 
Btg3 1.96 Cell cycle 
Ca2 2.91 Metabolism 
Cacna1a 2.24 Transport 
Cand1 2.09 Nucleotide and nucleic acid metabolism 
Capns1 15.57 Cell adhesion 
Ccdc43 2.39 Biological process unknown  
Cd36 2.92 Cell adhesion 
Cd59 2.76 Immune response 
Cd63 1.98 Cell communication 
Cdc37 6.61 Protein folding 
Cdc42 4.08 Cell adhesion 
Cdk5rap3 2.09 Cell cycle 
Cdo1 2.17 Metabolism 
Ceacam12 2.15 Cell adhesion 
Cfi 2.01 Immune response 
Chgb 2.04 Cell communication 
Cib1 2.58 Cell adhesion 
Cited2 2.02 Nucleotide and nucleic acid metabolism 
Ckm 2.09 Metabolism 
Clns1a 2.27 Transport 
Clu 2.21 Immune response 
Cnot7 2.10 Nucleotide and nucleic acid metabolism 
Copb1 4.15 Transport 
Copb2 17.59 Transport 
Cox4i1 2.20 Metabolism 
Cox6a2 2.72 Metabolism 
Cox6c 2.37 Metabolism 
Cox7a2 2.02 Metabolism 
Crip2 2.09 Nucleotide and nucleic acid metabolism 
Cryba4 2.16 Cell communication 
Crym 2.81 Cell migration, Osmoregulation 
Csn2 2.04 Transport 
Ctps2 3.52 Nucleotide and nucleic acid metabolism 
Ctsb 2.15 Protein folding 
Cubn 2.62 Transport 
Cxcr4 8.29 Cell communication 
Cyp2e1 3.51 Metabolism 
Dad1 3.92 Apoptosis 
Dazap2 8.49 Nucleotide and nucleic acid metabolism 
Dctn1 2.00 Transport 
Decr1 1.99 Metabolism 
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Des 2.54 Cell communication 
Dnaja1 1.96 Protein folding 
Dnajc8 3.10 Protein folding 
Dpep1 3.43 Protein folding 
Dtnbp1 3.30 Cell communication 
Dusp5 1.98 Cell communication 
Eif2b2 2.65 Protein folding 
Eif4g2 5.95 Protein folding 
Ell2 2.09 Nucleotide and nucleic acid metabolism 
Eno1 3.01 Metabolism 
Exoc7 2.20 Biological process unknown  
F2r 2.15 Cell communication 
Fasn 2.01 Metabolism 
Fbxw8 3.25 Protein folding 
Fdxr 2.64 Metabolism 
Fez1 2.10 Biological process unknown  
Flot2 3.10 Cell adhesion 
Fth1 2.05 Transport 
Gabrr1 1.95 Transport 
Gap43 3.00 Cell communication 
Gata2 2.11 Nucleotide and nucleic acid metabolism 
Gatm 2.30 Metabolism 
Gdi1 3.33 Cell communication 
Gdi2 6.56 Transport 
Gfra1 2.05 Signal transduction 
Gls 2.36 Metabolism 
Glul 2.33 Metabolism 
Gnb2l1 2.20 Cell communication 
Gng11 2.70 Cell communication 
Got1 2.04 Metabolism 
Gpx1 2.29 Anti-apoptosis 
Gys2 2.26 Metabolism 
H1f0 2.31 Nucleotide and nucleic acid metabolism 
Hadhb 2.04 Metabolism 
Hdgf 2.70 Cell communication 
Herpud1 2.17 Biological process unknown  
Hmgcs1 4.76 Metabolism 
Hspb1 2.33 Protein folding 
Ifitm2 5.62 Cell communication 
Ifnb1 1.96 Immune response 
Ifrd1 1.97 Signal transduction 
Igf2r 2.75 Cell communication 
Il2rb 2.24 Immune response 
Insig1 1.97 Metabolism, Lipid metabolism 
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Itpr3 2.15 Cell communication 
Kdr 2.27 Cell communication 
Kpna2 2.27 Cell communication 
Laptm5 2.72 Cell communication 
Ldha 2.27 Metabolism 
Lig1 2.44 Nucleotide and nucleic acid metabolism 
Lmo4 2.05 Nucleotide and nucleic acid metabolism 
Lox 2.21 Metabolism 
Lxn 2.31 Metabolism 
Lypla1 2.21 Metabolism 
Lypla2 9.77 Metabolism 
Maf 2.37 Regulation of gene expression, epigenetic 
Map2k1 2.05 Cell adhesion 
Map3k12 2.19 Cell communication 
Mapk14 2.06 Cell communication 
Mapt 1.97 Cell communication 
Mb 2.03 Transport 
Mdk 2.48 Cell communication 
Mfge8 4.75 Cell adhesion 
Mgp 2.49 Transport 
Mif 2.29 Cell communication 
Mllt10 2.18 Nucleotide and nucleic acid metabolism 
Mlycd 3.54 Metabolism 
Mmp10 2.17 Protein folding 
Mpg 2.35 DNA repair 
mrpl11 3.16 Protein folding 
Myl3 2.21 Cell communication 
Nat1 2.20 Metabolism 
Ncoa2 2.04 Nucleotide and nucleic acid metabolism 
Ncstn 3.36 Cell communication 
Ndel1 2.20 Cell communication 
Nme2 2.01 Signal transduction 
Nolc1 2.21 Nucleotide and nucleic acid metabolism 
Nppa 2.76 Cell communication 
Nppb 3.27 Cell communication 
Nudt22 3.08 Biological process unknown  
Nup54 2.09 Transport 
Orm1 2.13 Immune response 
Osbpl2 2.86 Transport, Vesicle-mediated transport 
P4hb 2.01 Protein folding 
Palm 1.95 Biological process unknown  
Pam 2.13 Protein folding 
Pcdh21 2.01 Cell adhesion 
Pcna 2.61 DNA repair 
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Pcsk3 1.98 Cell migration 
Pecr 2.21 Metabolism 
Pfn1 2.25 Cell communication 
Pga5 1.96 Protein folding 
Phb 2.98 Cell communication 
Phb2 10.63 Nucleotide and nucleic acid metabolism 
Phkg2 2.02 Metabolism 
Pim3 2.95 Cell communication 
Pitpnb 2.56 Transport 
Pitx2 2.05 Cell migration 
Ppm2c 2.23 Cell communication 
Ppp1cc 3.00 Cell communication 
Ppp3r2 2.59 Cell communication 
Prap1 2.12 Biological process unknown  
Prdm2 6.59 Nucleotide and nucleic acid metabolism 
Prdx1 2.10 Metabolism 
Prdx2 2.00 Metabolism 
Prdx3 2.95 Metabolism 
Prdx5 2.28 Metabolism 
Prpf8 9.33 Nucleotide and nucleic acid metabolism 
Psmb7 2.10 Protein folding 
Psme1 1.95 Protein folding 
Ptbp1 1.95 Nucleotide and nucleic acid metabolism 
Ptdss1 3.04 Metabolism 
Ptpns1 2.12 Cell adhesion 
Qdpr 2.08 Metabolism 
Ralgds 1.95 Cell communication 
Ran 2.80 Cell communication 
Rara 2.10 Signal transduction 
Rcn2 3.32 Cell communication 
Rgs2 3.10 Cell communication 
Rhoq 2.22 Cell communication 
Rpl10 2.52 Protein folding 
Rpl10a 2.19 Protein folding 
Rpl13a 2.05 Protein folding 
Rpl18 6.32 Protein folding 
Rpl19 2.73 Protein folding 
Rpl27 2.39 Protein folding 
Rpl29 5.47 Protein folding 
Rpl6 2.55 Protein folding 
Rps17 2.05 Protein folding 
Rps27 2.09 Nucleotide and nucleic acid metabolism 
Rps27a 2.25 Protein folding 
Rps3a 2.12 Protein folding 
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Rps6 2.81 Protein folding 
Rpsa 2.35 Cell adhesion 
Sar1a 6.43 Cell communication 
Scamp4 2.01 Transport 
Scn10a 2.00 Transport 
Sdc1 2.45 Cell adhesion 
Sdc4 2.11 Cell adhesion 
Sdha 2.37 Metabolism 
Selenbp1 2.97 Protein folding 
Sepw1 2.57 Metabolism 
Shox2 2.39 Nucleotide and nucleic acid metabolism 
Slc22a8 2.29 Transport 
Slc2a4 2.00 Transport 
Slc30a1 2.06 Transport 
Slc34a2 2.08 Transport 
Slc6a4 2.66 Transport 
Slc6a8 2.83 Transport 
Slc8a2 4.11 Transport 
Snca 2.03 Protein folding 
Snx1 1.95 Cell communication 
Sod1 2.34 Metabolism 
Sparc 2.83 Cell communication 
Spp1 2.68 Cell adhesion 
Statip1 3.42 Cell communication 
Stmn1 3.20 Cell communication 
Stx1a 2.84 Cell communication 
Suclg1 2.04 Metabolism 
Sult4a1 2.16 Metabolism 
Syk 2.14 Cell adhesion 
Syn3 2.03 transport, Neurotransmitter transport 
Synj2bp 2.40 Transport, Mitochondrial transport 
Tagln 2.56 Biological process unknown, Muscle development 
Tcea1 4.34 Transcription 
Tdg 1.97 DNA repair 
Thrap3 2.75 Nucleotide and nucleic acid metabolism 
Timp1 5.27 Cell communication 
Tm9sf4 5.14 Biological process unknown  
Tmpo 2.42 Metabolism, Nuclear organization and biogenesis 
Tnfrsf1a 2.20 Cell communication 
Tomm22 3.61 Transport 
Tp53 2.53 Nucleotide and nucleic acid metabolism 
Tpi1 2.22 Metabolism 
Trmt1 2.77 Nucleotide and nucleic acid metabolism 
Tsn 3.02 Nucleotide and nucleic acid metabolism 
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Ttr 3.95 Transport 
Tusc3 2.35 Cell communication 
Txnrd2 2.46 Cell communication 
Ube2d3 13.21 Protein folding 
Ube2e2 3.15 Protein folding 
Ugdh 2.72 Metabolism 
Ung 2.43 DNA repair 
Vcp 14.4 Metabolism 
Vgf 2.44 Cell communication 
Vim 3.75 Cell communication 
Vsnl1 1.96 Cell communication 
Wdr5 3.85 Cell communication 
Ythdf1 2.85 Biological process unknown  
Ywhah 2.43 Cell communication 
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Description of different T cells used in the dissertation. 
 
TMBP-GFP Myelin basic protein (MBP) –specific T cells retrovirally transduced with  
  green fluorescent protein (GFP) 
 
TMBP-KLF4 Myelin basic protein (MBP) –specific T cells retrovirally transduced with  
   full length cDNA for Krüppel like factor 4 (KLF4) and green fluorescent  
  protein (GFP) 
 
TMBP-EMP1 Myelin basic protein (MBP) –specific T cells retrovirally transduced with  
   full length cDNA for Epithelial membrane protein 1 (EMP1) and green  
  fluorescent protein (GFP) 
 
TOVA-GFP Ovalbumin (OVA) –specific T cells retrovirally transduced with   
  green fluorescent protein (GFP) 
 
TOVA-KLF4 Ovalbumin (OVA) –specific T cells retrovirally transduced with   
   full length cDNA for Krüppel like factor 4 (KLF4) and green fluorescent  
  protein (GFP) 
 
Tblast  Freshly activated GFP labeled MBP-specific T cells 48 hours post antigen  
  presenting cell (APC) mediated restimulation in vitro. 
 
Tresting  Resting GFP labeled MBP-specific T cells 7 days post APC mediated  
  restimulation in vitro. 
 
Tspleen  Ex vivo FACS sorted GFP labeled MBP-specific T cells from spleen 3.5  
  days post adoptive transfer of Tblast cells. 
 
TCNS   Ex vivo FACS sorted GFP labeled MBP-specific T cells from CNS 3.5  
  days post adoptive transfer of Tblast cells. 
 
Tactivated Activated T cell transcriptome obtained by dividing gene expression  
  values of Tblast by Tresting 
 
Tmigratory CNS Migratory T cell transcriptome obtained by dividing gene expression 
  values of Tspleen by Tblast 
 
Teffector  CNS effector T cell transcriptome obtained by dividing gene expression  
  values  of TCNS by Tblast 
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